Release Notes for 2025-10-30: Number of new affinity data: 72609 Number of compounds (ligands) new to BindingDB: 28210 Number of Targets new to BindingDB: 1730 New Targets: (Q9NQV7): 2 inhibitors 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (Q9NUQ2): 1 inhibitors 1-phosphatidylinositol 3-phosphate 5-kinase [S696N,L932S,Q995L,T998S,S1033A,Q1183K]/Early endosome antigen 1 (Q9Y2I7[1-2098,S696N,L932L,Q995L,T998S,S1033A,Q1183K],Q15075): 74 inhibitors 1-phosphatidylinositol 3-phosphate 5-kinase [S696N,L932S,Q995L,T998S,S1033A,Q1183K]/TAR DNA-binding protein 43 (Q9Y2I7[1-2098,S696N,L932L,Q995L,T998S,S1033A,Q1183K],Q13148): 23 inhibitors 10 kDa heat shock protein, mitochondrial (P61604): 2 inhibitors 116 kDa U5 small nuclear ribonucleoprotein component (Q15029): 3 inhibitors 14-3-3 protein epsilon (P62258): 2 inhibitors 182 kDa tankyrase-1-binding protein (Q9C0C2): 1 inhibitors 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial (Q16698): 2 inhibitors 2-hydroxyacyl-CoA lyase 2 (A1L0T0): 1 inhibitors 2-oxoglutarate dehydrogenase complex component E1 (Q02218): 2 inhibitors 26S proteasome non-ATPase regulatory subunit 1 (Q99460): 2 inhibitors 26S proteasome non-ATPase regulatory subunit 12 (O00232): 2 inhibitors 26S proteasome non-ATPase regulatory subunit 13 (Q9UNM6): 1 inhibitors 26S proteasome non-ATPase regulatory subunit 2 (Q13200): 2 inhibitors 26S proteasome non-ATPase regulatory subunit 3 (O43242): 2 inhibitors 26S proteasome non-ATPase regulatory subunit 5 (Q16401): 1 inhibitors 26S proteasome non-ATPase regulatory subunit 6 (Q15008): 1 inhibitors 26S proteasome non-ATPase regulatory subunit 7 (P51665): 2 inhibitors 26S proteasome non-ATPase regulatory subunit 8 (P48556): 2 inhibitors 26S proteasome non-ATPase regulatory subunit 9 (O00233): 1 inhibitors 26S proteasome regulatory subunit 10B (P62333): 2 inhibitors 26S proteasome regulatory subunit 4 (P62191): 2 inhibitors 26S proteasome regulatory subunit 6A (P17980): 2 inhibitors 26S proteasome regulatory subunit 7 (P35998): 2 inhibitors 26S proteasome regulatory subunit 8 (P62195): 2 inhibitors 28 kDa heat- and acid-stable phosphoprotein (Q13442): 1 inhibitors 28S rRNA (cytosine(4447)-C(5))-methyltransferase (P46087): 2 inhibitors 28S rRNA (cytosine-C(5))-methyltransferase (Q96P11): 1 inhibitors 28S rRNA (uridine-N(3))-methyltransferase (Q5T280): 1 inhibitors 3-ketoacyl-CoA thiolase, mitochondrial (P42765): 1 inhibitors 3-mercaptopyruvate sulfurtransferase (P25325): 1 inhibitors 45 kDa calcium-binding protein (Q9BRK5): 1 inhibitors 5-azacytidine-induced protein 2 (Q9H6S1): 2 inhibitors 5-phosphohydroxy-L-lysine phospho-lyase (Q8IUZ5): 1 inhibitors A disintegrin and metalloproteinase with thrombospondin motifs 7 (Q9UKP4): 49 inhibitors A-kinase anchor protein 8-like (Q9ULX6): 1 inhibitors ADP-ribosylation factor 4 (P18085): 1 inhibitors ADP-ribosylation factor 5 (P84085): 1 inhibitors ADP-ribosylation factor-like protein 1 (P40616): 3 inhibitors ADP/ATP translocase 1 (P12235): 2 inhibitors ADP/ATP translocase 2 (P05141): 3 inhibitors ADP/ATP translocase 3 (P12236): 3 inhibitors AF4/FMR2 family member 1 (P51825): 2 inhibitors AF4/FMR2 family member 2 (P51816): 1 inhibitors AF4/FMR2 family member 4 (Q9UHB7): 2 inhibitors AH receptor-interacting protein (O00170): 5 inhibitors AP-1 complex subunit gamma-1 (O43747): 2 inhibitors AP-1 complex subunit mu-1 (Q9BXS5): 3 inhibitors AP-1 complex subunit sigma-1A (P61966): 1 inhibitors AP-2 complex subunit alpha-1 (O95782): 2 inhibitors AP-2 complex subunit alpha-2 (O94973): 1 inhibitors AP-2 complex subunit beta (P63010): 2 inhibitors AP-2 complex subunit mu (Q96CW1): 2 inhibitors AP-3 complex subunit beta-1 (O00203): 3 inhibitors AP-3 complex subunit delta-1 (O14617): 1 inhibitors AP-3 complex subunit mu-1 (Q9Y2T2): 1 inhibitors AP-3 complex subunit sigma-1 (Q92572): 2 inhibitors AP-5 complex subunit zeta-1 (O43299): 1 inhibitors AT-rich interactive domain-containing protein 1A (O14497): 1 inhibitors AT-rich interactive domain-containing protein 2 (Q68CP9): 1 inhibitors ATP synthase F(0) complex subunit 8 (P03928): 1 inhibitors ATP synthase F(0) complex subunit a (P00846): 2 inhibitors ATP synthase F(0) complex subunit e, mitochondrial (P56385): 2 inhibitors ATP synthase F(0) complex subunit f, mitochondrial (P56134): 2 inhibitors ATP synthase F(0) complex subunit g, mitochondrial (O75964): 2 inhibitors ATP synthase F(0) complex subunit k, mitochondrial (Q96IX5): 2 inhibitors ATP synthase F(1) complex subunit alpha, mitochondrial (P25705): 2 inhibitors ATP synthase F(1) complex subunit beta, mitochondrial (P06576): 2 inhibitors ATP synthase F(1) complex subunit delta, mitochondrial (P30049): 2 inhibitors ATP synthase F(1) complex subunit gamma, mitochondrial (P36542): 2 inhibitors ATP synthase peripheral stalk subunit OSCP, mitochondrial (P48047): 2 inhibitors ATP synthase peripheral stalk subunit b, mitochondrial (P24539): 2 inhibitors ATP synthase peripheral stalk subunit d, mitochondrial (O75947): 2 inhibitors ATP-binding cassette sub-family D member 3 (P28288): 2 inhibitors ATP-binding cassette sub-family E member 1 (P61221): 2 inhibitors ATP-binding cassette sub-family F member 1 (Q8NE71): 2 inhibitors ATP-binding cassette sub-family F member 2 (Q9UG63): 1 inhibitors ATP-dependent 6-phosphofructokinase, platelet type (Q01813): 2 inhibitors ATP-dependent DNA/RNA helicase DHX36 (Q9H2U1): 2 inhibitors ATP-dependent RNA helicase DDX18 (Q9NVP1): 2 inhibitors ATP-dependent RNA helicase DDX24 (Q9GZR7): 2 inhibitors ATP-dependent RNA helicase DDX42 (Q86XP3): 1 inhibitors ATPase GET3 (O43681): 1 inhibitors ATPase family AAA domain-containing protein 3A (Q9NVI7): 2 inhibitors ATPase family AAA domain-containing protein 3B (Q5T9A4): 2 inhibitors ATPase family AAA domain-containing protein 5 (Q96QE3): 1 inhibitors AarF domain-containing protein kinase 1 (Q86TW2): 2 inhibitors Abasic site processing protein HMCES (Q96FZ2): 1 inhibitors Acidic fibroblast growth factor intracellular-binding protein (O43427): 2 inhibitors Acidic leucine-rich nuclear phosphoprotein 32 family member A (P39687): 2 inhibitors Acidic leucine-rich nuclear phosphoprotein 32 family member B (Q92688): 3 inhibitors Actin, alpha cardiac muscle 1 (P68032): 1 inhibitors Actin-binding protein WASF2 (Q9Y6W5): 1 inhibitors Actin-like protein 6A (O96019): 3 inhibitors Actin-related protein 2/3 complex subunit 1B (O15143): 3 inhibitors Actin-related protein 2/3 complex subunit 2 (O15144): 1 inhibitors Actin-related protein 2/3 complex subunit 3 (O15145): 2 inhibitors Actin-related protein 2/3 complex subunit 4 (P59998): 2 inhibitors Actin-related protein 2/3 complex subunit 5 (O15511): 2 inhibitors Actin-related protein 2/3 complex subunit 5-like protein (Q9BPX5): 1 inhibitors Actin-related protein 3 (P61158): 1 inhibitors Actin-related protein 5 (Q9H9F9): 1 inhibitors Actin-related protein 8 (Q9H981): 1 inhibitors Activated RNA polymerase II transcriptional coactivator p15 (P53999): 2 inhibitors Activator of 90 kDa heat shock protein ATPase homolog 1 (O95433): 2 inhibitors Acyl-CoA dehydrogenase family member 10 (Q6JQN1): 2 inhibitors Acyl-CoA dehydrogenase family member 11 (Q709F0): 2 inhibitors Acyl-CoA-binding protein (P07108): 1 inhibitors Acylglycerol kinase, mitochondrial (Q53H12): 2 inhibitors Adenine phosphoribosyltransferase (P07741): 1 inhibitors Adenylosuccinate lyase (P30566): 1 inhibitors Adenylyl cyclase-associated protein 1 (Q01518): 1 inhibitors Adhesion G protein-coupled receptor E5 (P48960): 1 inhibitors Adipocyte plasma membrane-associated protein (Q9HDC9): 1 inhibitors Aflatoxin B1 aldehyde reductase member 2 (O43488): 1 inhibitors Aladin (Q9NRG9): 2 inhibitors Aldehyde dehydrogenase family 16 member A1 (Q8IZ83): 1 inhibitors Aldo-keto reductase family 1 member D1 (P51857): 1 inhibitors Alkyldihydroxyacetonephosphate synthase, peroxisomal (O00116): 2 inhibitors Alpha-actinin-1 (P12814): 1 inhibitors Alpha-actinin-4 (O43707): 3 inhibitors Alpha-aminoadipic semialdehyde dehydrogenase (P49419): 1 inhibitors Alpha-internexin (Q16352): 2 inhibitors Alpha-soluble NSF attachment protein (P54920): 1 inhibitors Alpha-taxilin (P40222): 1 inhibitors Amino acid transporter heavy chain SLC3A2 (P08195): 2 inhibitors Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 (Q12904): 2 inhibitors Anamorsin (Q6FI81): 2 inhibitors Anaphase-promoting complex subunit 7 (Q9UJX3): 1 inhibitors Ankyrin repeat domain-containing protein 54 (Q6NXT1): 1 inhibitors Annexin A1 (P04083): 2 inhibitors Annexin A11 (P50995): 1 inhibitors Annexin A2 (P07355): 1 inhibitors Annexin A3 (P12429): 1 inhibitors Annexin A4 (P09525): 1 inhibitors Annexin A5 (P08758): 1 inhibitors Annexin A6 (P08133): 2 inhibitors Annexin A7 (P20073): 2 inhibitors Antigen peptide transporter 1 (Q03518): 1 inhibitors Antigen peptide transporter 2 (Q03519): 2 inhibitors Apoptosis inhibitor 5 (Q9BZZ5): 1 inhibitors Apoptosis regulator Bcl-2 [D111A] (P10415[D111A]): 76 inhibitors Apoptosis regulator Bcl-2 [F104I] (P10415[F104I]): 85 inhibitors Apoptosis-associated speck-like protein containing a CARD (Q9ULZ3): 1 inhibitors Apoptosis-inducing factor 1, mitochondrial (O95831): 2 inhibitors Apoptotic chromatin condensation inducer in the nucleus (Q9UKV3): 2 inhibitors Arfaptin-2 (P53365): 1 inhibitors Arginine and glutamate-rich protein 1 (Q9NWB6): 1 inhibitors Arginine/serine-rich protein PNISR (Q8TF01): 1 inhibitors Argininosuccinate synthase (P00966): 2 inhibitors Aryl-hydrocarbon-interacting protein-like 1 (Q9NZN9): 1 inhibitors Asparagine--tRNA ligase, cytoplasmic (O43776): 2 inhibitors Aspartate--tRNA ligase, cytoplasmic (P14868): 2 inhibitors Ataxin-10 (Q9UBB4): 3 inhibitors Ataxin-2-like protein (Q8WWM7): 2 inhibitors Atlastin-3 (Q6DD88): 2 inhibitors Autophagy-related protein 13 (O75143): 1 inhibitors B-cell antigen receptor complex-associated protein beta chain (P40259): 1 inhibitors B-cell receptor-associated protein 31 (P51572): 3 inhibitors BAG family molecular chaperone regulator 2 (O95816): 2 inhibitors BH3-interacting domain death agonist (P55957): 1 inhibitors BOS complex subunit NCLN (Q969V3): 1 inhibitors BRCA2 and CDKN1A-interacting protein (Q9P287): 1 inhibitors BRD4-interacting chromatin-remodeling complex-associated protein (Q9NZM4): 1 inhibitors BRI3-binding protein (Q8WY22): 1 inhibitors BRO1 domain-containing protein BROX (Q5VW32): 1 inhibitors BUB3-interacting and GLEBS motif-containing protein ZNF207 (O43670): 4 inhibitors Band 4.1-like protein 2 (O43491): 2 inhibitors Basigin (P35613): 1 inhibitors Bax inhibitor 1 (P55061): 1 inhibitors Bcl-2-associated transcription factor 1 (Q9NYF8): 2 inhibitors Bcl-2-like protein 13 (Q9BXK5): 1 inhibitors Benzodiazepine central (Q9H3P7): 1 inhibitors Beta-catenin-like protein 1 (Q8WYA6): 1 inhibitors Beta/gamma crystallin domain-containing protein 1 (Q9Y4K1): 1 inhibitors Biogenesis of lysosome-related organelles complex 1 subunit 5 (Q8TDH9): 1 inhibitors Biorientation of chromosomes in cell division protein 1-like 1 (Q8NFC6): 1 inhibitors BolA-like protein 2 (Q9H3K6): 2 inhibitors Bone marrow stromal antigen 2 (Q10589): 2 inhibitors Brefeldin A-inhibited guanine nucleotide-exchange protein 1 (Q9Y6D6): 2 inhibitors Bystin (Q13895): 1 inhibitors C2 domain-containing protein 5 (Q86YS7): 2 inhibitors C5a anaphylatoxin chemotactic receptor 2 (Q9P296): 2 inhibitors CCAAT/enhancer-binding protein zeta (Q03701): 1 inhibitors CCHC-type zinc finger nucleic acid binding protein (P62633): 1 inhibitors CCR4-NOT transcription complex subunit 1 (A5YKK6): 2 inhibitors CCR4-NOT transcription complex subunit 9 (Q92600): 1 inhibitors CD2 antigen cytoplasmic tail-binding protein 2 (O95400): 1 inhibitors CD59 glycoprotein (P13987): 1 inhibitors CDK5 and ABL1 enzyme substrate 1 (Q8TDN4): 2 inhibitors CDP-diacylglycerol--inositol 3-phosphatidyltransferase (O14735): 2 inhibitors CGG triplet repeat-binding protein 1 (Q9UFW8): 1 inhibitors CLIP-associating protein 1 (Q7Z460): 1 inhibitors CMP-sialic acid transporter (P78382): 1 inhibitors COP9 signalosome complex subunit 1 (Q13098): 1 inhibitors COP9 signalosome complex subunit 2 (P61201): 2 inhibitors COP9 signalosome complex subunit 3 (Q9UNS2): 1 inhibitors COP9 signalosome complex subunit 4 (Q9BT78): 1 inhibitors COP9 signalosome complex subunit 6 (Q7L5N1): 1 inhibitors COP9 signalosome complex subunit 8 (Q99627): 1 inhibitors CUGBP Elav-like family member 2 (O95319): 1 inhibitors CYFIP-related Rac1 interactor B (Q9NUQ9): 2 inhibitors Calcineurin B homologous protein 1 (Q99653): 1 inhibitors Calcium homeostasis endoplasmic reticulum protein (Q8IWX8): 1 inhibitors Calcium load-activated calcium channel (Q9UM00): 2 inhibitors Calcium uniporter protein, mitochondrial (Q8NE86): 1 inhibitors Calcium-binding and coiled-coil domain-containing protein 2 (Q13137): 1 inhibitors Calcium-binding protein 39 (Q9Y376): 2 inhibitors Calcium-regulated heat-stable protein 1 (Q9Y2V2): 1 inhibitors Calcium-transporting ATPase type 2C member 1 (P98194): 1 inhibitors Calcyclin-binding protein (Q9HB71): 2 inhibitors Caldesmon (Q05682): 1 inhibitors Calponin-2 (Q99439): 2 inhibitors Calreticulin (P27797): 2 inhibitors Calumenin (O43852): 2 inhibitors Cancer-related nucleoside-triphosphatase (Q9BSD7): 2 inhibitors CapZ-interacting protein (Q6JBY9): 1 inhibitors Caprin-1 (Q14444): 1 inhibitors Carbonyl reductase [NADPH] 3 (O75828): 1 inhibitors Carboxymethylenebutenolidase homolog (Q96DG6): 2 inhibitors Caspase recruitment domain-containing protein 19 (Q96LW7): 1 inhibitors Catenin alpha-1 (P35221): 1 inhibitors Catenin delta-1 (O60716): 1 inhibitors Cell cycle and apoptosis regulator protein 2 (Q8N163): 2 inhibitors Cell division cycle 5-like protein (Q99459): 2 inhibitors Cell division cycle protein 16 homolog (Q13042): 1 inhibitors Cell division cycle protein 23 homolog (Q9UJX2): 2 inhibitors Cell division cycle-associated protein 2 (Q69YH5): 1 inhibitors Cell growth-regulating nucleolar protein (Q9NX58): 1 inhibitors Centromere protein E (A0A8P0P634): 2 inhibitors Centromere/kinetochore protein zw10 homolog (O43264): 2 inhibitors Centrosomal protein of 170 kDa (Q5SW79): 1 inhibitors Centrosome and spindle pole-associated protein 1 (Q1MSJ5): 1 inhibitors Cerebellar degeneration-related protein 2 (Q01850): 2 inhibitors Ceroid-lipofuscinosis neuronal protein 6 (Q9NWW5): 2 inhibitors Charged multivesicular body protein 1a (Q9HD42): 1 inhibitors Charged multivesicular body protein 4b (Q9H444): 1 inhibitors Chemerin-like receptor 2 (P46091): 1 inhibitors Chitinase-3-like protein 2 (Q15782): 5 inhibitors Chitobiosyldiphosphodolichol beta-mannosyltransferase (Q9BT22): 2 inhibitors Chloride intracellular channel protein 4 (Q9Y696): 2 inhibitors Choline transporter-like protein 1 (Q8WWI5): 1 inhibitors Chromatin assembly factor 1 subunit B (Q13112): 1 inhibitors Chromatin-remodeling ATPase INO80 (Q9ULG1): 1 inhibitors Chromodomain-helicase-DNA-binding protein 1-like (Q86WJ1): 1 inhibitors Chromodomain-helicase-DNA-binding protein 3 (Q12873): 1 inhibitors Chromodomain-helicase-DNA-binding protein 4 (Q14839): 3 inhibitors Chromodomain-helicase-DNA-binding protein 8 (Q9HCK8): 1 inhibitors Chromodomain-helicase-DNA-binding protein 9 (Q3L8U1): 1 inhibitors Chromosome alignment-maintaining phosphoprotein 1 (Q96JM3): 1 inhibitors Chromosome-associated kinesin KIF4A (O95239): 1 inhibitors Cilia- and flagella-associated protein 20 (Q9Y6A4): 1 inhibitors Cilia- and flagella-associated protein 410 (O43822): 2 inhibitors Citrate synthase, mitochondrial (O75390): 2 inhibitors Claspin (Q9HAW4): 1 inhibitors Clathrin interactor 1 (Q14677): 1 inhibitors Clathrin light chain A (P09496): 2 inhibitors Clathrin light chain B (P09497): 1 inhibitors Cleavage and polyadenylation specificity factor subunit 1 (Q10570): 2 inhibitors Cleavage and polyadenylation specificity factor subunit 3 (Q9UKF6): 1 inhibitors Cleavage and polyadenylation specificity factor subunit 4 (O95639): 1 inhibitors Cleavage and polyadenylation specificity factor subunit 5 (O43809): 1 inhibitors Cleavage and polyadenylation specificity factor subunit 6 (Q16630): 2 inhibitors Cleavage and polyadenylation specificity factor subunit 7 (Q8N684): 2 inhibitors Coatomer subunit alpha (P53621): 2 inhibitors Coatomer subunit beta (P53618): 3 inhibitors Coatomer subunit delta (P48444): 2 inhibitors Coatomer subunit epsilon (O14579): 2 inhibitors Coatomer subunit gamma-1 (Q9Y678): 3 inhibitors Coatomer subunit gamma-2 (Q9UBF2): 2 inhibitors Cofilin-1 (P23528): 3 inhibitors Coiled-coil domain-containing protein 22 (O60826): 2 inhibitors Coilin (P38432): 1 inhibitors Cold shock domain-containing protein E1 (O75534): 2 inhibitors Collagen alpha-1(XIV) chain (Q05707): 1 inhibitors Complement component 1 Q subcomponent-binding protein, mitochondrial (Q07021): 1 inhibitors Complex I assembly factor ACAD9, mitochondrial (Q9H845): 1 inhibitors Condensin complex subunit 1 (Q15021): 1 inhibitors Condensin complex subunit 2 (Q15003): 1 inhibitors Condensin-2 complex subunit D3 (P42695): 1 inhibitors Conserved oligomeric Golgi complex subunit 1 (Q8WTW3): 2 inhibitors Conserved oligomeric Golgi complex subunit 2 (Q14746): 1 inhibitors Conserved oligomeric Golgi complex subunit 3 (Q96JB2): 1 inhibitors Conserved oligomeric Golgi complex subunit 4 (Q9H9E3): 2 inhibitors Conserved oligomeric Golgi complex subunit 5 (Q9UP83): 1 inhibitors Conserved oligomeric Golgi complex subunit 6 (Q9Y2V7): 2 inhibitors Conserved oligomeric Golgi complex subunit 7 (P83436): 2 inhibitors Conserved oligomeric Golgi complex subunit 8 (Q96MW5): 2 inhibitors Constitutive coactivator of PPAR-gamma-like protein 1 (Q9NZB2): 2 inhibitors Contactin-1 (Q12860): 1 inhibitors Copine-4 (Q96A23): 1 inhibitors Coronin-1A (P31146): 3 inhibitors Coronin-1C (Q9ULV4): 1 inhibitors Corrinoid adenosyltransferase MMAB (Q96EY8): 1 inhibitors Creatine kinase U-type, mitochondrial (P12532): 1 inhibitors Crk-like protein (P47941): 6 inhibitors Cullin-1 (Q13616): 2 inhibitors Cullin-2 (Q13617): 1 inhibitors Cullin-3 (Q13618): 2 inhibitors Cullin-4A/DNA damage-binding protein 1 (P22629[25-183,Y67F],Q13619): 73 inhibitors Cullin-4B (Q13620): 1 inhibitors Cullin-5 (Q93034): 1 inhibitors Cullin-associated NEDD8-dissociated protein 1 (Q86VP6): 2 inhibitors Cyclin-H (P51946): 2 inhibitors Cyclin-I (Q14094): 1 inhibitors Cyclin-L2 (Q96S94): 1 inhibitors Cyclin-T2 (O60583): 2 inhibitors Cyclin-dependent kinases regulatory subunit 1 (P61024): 1 inhibitors Cyclin-dependent kinases regulatory subunit 2 (P33552): 1 inhibitors Cystatin-B (P04080): 2 inhibitors Cysteine--tRNA ligase, cytoplasmic (P49589): 2 inhibitors Cytochrome b-245 light chain (P13498): 1 inhibitors Cytochrome b-c1 complex subunit 1, mitochondrial (P31930): 2 inhibitors Cytochrome b-c1 complex subunit 2, mitochondrial (P22695): 2 inhibitors Cytochrome c oxidase assembly protein COX14 (Q96I36): 1 inhibitors Cytochrome c oxidase subunit 3 (P00414): 1 inhibitors Cytochrome c oxidase subunit 4 isoform 1, mitochondrial (P13073): 1 inhibitors Cytochrome c oxidase subunit 5A, mitochondrial (P20674): 2 inhibitors Cytochrome c oxidase subunit 5B, mitochondrial (P10606): 2 inhibitors Cytochrome c oxidase subunit 6A1, mitochondrial (P12074): 1 inhibitors Cytochrome c oxidase subunit 6B1 (P14854): 1 inhibitors Cytochrome c oxidase subunit 6C (P09669): 2 inhibitors Cytochrome c1, heme protein, mitochondrial (P08574): 2 inhibitors Cytoplasmic FMR1-interacting protein 1 (Q7L576): 3 inhibitors Cytoplasmic FMR1-interacting protein 2 (Q96F07): 1 inhibitors Cytoplasmic dynein 1 intermediate chain 2 (Q13409): 1 inhibitors Cytoplasmic dynein 1 light intermediate chain 1 (Q9Y6G9): 2 inhibitors Cytoplasmic dynein 1 light intermediate chain 2 (O43237): 1 inhibitors Cytoskeleton-associated protein 4 (Q07065): 2 inhibitors Cytosolic acyl coenzyme A thioester hydrolase (O00154): 1 inhibitors Cytospin-A (Q69YQ0): 1 inhibitors Cytotoxic granule associated RNA binding protein TIA1 (P31483): 1 inhibitors D-aminoacyl-tRNA deacylase 1 (Q8TEA8): 1 inhibitors D-dopachrome decarboxylase (P30046): 6 inhibitors DAZ-associated protein 1 (Q96EP5): 2 inhibitors DDB1- and CUL4-associated factor 7 (P61962): 2 inhibitors DDRGK domain-containing protein 1 (Q96HY6): 1 inhibitors DNA dC->dU-editing enzyme APOBEC-3C (Q9NRW3): 2 inhibitors DNA mismatch repair protein Msh2 (P43246): 2 inhibitors DNA mismatch repair protein Msh6 (P52701): 3 inhibitors DNA polymerase delta subunit 2 (P49005): 1 inhibitors DNA polymerase delta subunit 3 (Q15054): 1 inhibitors DNA polymerase epsilon subunit 3 (Q9NRF9): 1 inhibitors DNA repair protein RAD50 (Q92878): 3 inhibitors DNA replication licensing factor MCM2 (P49736): 2 inhibitors DNA replication licensing factor MCM3 (P25205): 3 inhibitors DNA replication licensing factor MCM4 (P33991): 2 inhibitors DNA replication licensing factor MCM5 (P33992): 3 inhibitors DNA replication licensing factor MCM6 (Q14566): 2 inhibitors DNA replication licensing factor MCM7 (P33993): 2 inhibitors DNA-binding protein SATB2 (Q9UPW6): 1 inhibitors DNA-directed RNA polymerase I subunit RPA34 (O15446): 1 inhibitors DNA-directed RNA polymerase I subunit RPA49 (Q9GZS1): 1 inhibitors DNA-directed RNA polymerase II subunit RPB2 (P30876): 2 inhibitors DNA-directed RNA polymerases I and III subunit RPAC1 (O15160): 2 inhibitors DNA-directed RNA polymerases I, II, and III subunit RPABC1 (P19388): 1 inhibitors DNA-directed RNA polymerases I, II, and III subunit RPABC3 (P52434): 1 inhibitors Dachshund homolog 1 (Q9UI36): 1 inhibitors Death domain-associated protein 6 (Q9UER7): 1 inhibitors Dedicator of cytokinesis protein 11 (Q5JSL3): 1 inhibitors Delta(14)-sterol reductase LBR (Q14739): 2 inhibitors Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial (Q13011): 1 inhibitors Delta-1-pyrroline-5-carboxylate synthase (P54886): 2 inhibitors Density-regulated protein (O43583): 2 inhibitors Deoxycytidylate deaminase (P32321): 1 inhibitors Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 (Q9Y3Z3): 2 inhibitors Deoxyribose-phosphate aldolase (Q9Y315): 2 inhibitors Derlin-1 (Q9BUN8): 2 inhibitors Dermcidin (P81605): 1 inhibitors Desmocollin-1 (Q08554): 1 inhibitors Desmoglein-1 (Q02413): 2 inhibitors Desmoplakin (P15924): 2 inhibitors Destrin (P60981): 2 inhibitors Developmentally-regulated GTP-binding protein 1 (Q9Y295): 2 inhibitors Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (P36957): 1 inhibitors Dihydropyrimidinase-related protein 2 (Q16555): 1 inhibitors Dihydropyrimidinase-related protein 3 (Q14195): 2 inhibitors Dimethyladenosine transferase (Q9UNQ2): 1 inhibitors Dimethyladenosine transferase 2, mitochondrial (Q9H5Q4): 1 inhibitors DnaJ homolog subfamily A member 2 (O60884): 1 inhibitors DnaJ homolog subfamily A member 3, mitochondrial (Q96EY1): 2 inhibitors DnaJ homolog subfamily B member 11 (Q9UBS4): 1 inhibitors DnaJ homolog subfamily B member 12 (Q9NXW2): 1 inhibitors DnaJ homolog subfamily C member 10 (Q8IXB1): 3 inhibitors DnaJ homolog subfamily C member 13 (O75165): 1 inhibitors DnaJ homolog subfamily C member 5 (Q9H3Z4): 1 inhibitors DnaJ homolog subfamily C member 7 (Q99615): 4 inhibitors DnaJ homolog subfamily C member 9 (Q8WXX5): 1 inhibitors Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase (Q92685): 1 inhibitors Dolichol-phosphate mannosyltransferase subunit 1 (O60762): 2 inhibitors Dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (Q9BVK2): 2 inhibitors Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 (P04844): 3 inhibitors Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 (P61803): 2 inhibitors Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit KCP2 (Q8N6L1): 2 inhibitors Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit MAGT1 (Q9H0U3): 2 inhibitors Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A (P46977): 2 inhibitors Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3B (Q8TCJ2): 1 inhibitors Double-stranded RNA-binding protein Staufen homolog 1 (O95793): 2 inhibitors Double-stranded RNA-specific adenosine deaminase (P55265): 2 inhibitors Drebrin (Q16643): 1 inhibitors Drebrin-like protein (Q9UJU6): 2 inhibitors Dual specificity protein phosphatase CDC14B (O60729): 9 inhibitors Dynactin subunit 1 (Q14203): 1 inhibitors Dynactin subunit 3 (O75935): 1 inhibitors Dynamin-like GTPase OPA1, mitochondrial (O60313): 2 inhibitors Dynein axonemal heavy chain 12 (Q6ZR08): 1 inhibitors Dynein light chain 1, cytoplasmic (P63167): 3 inhibitors E3 SUMO-protein ligase PIAS4 (Q8N2W9): 1 inhibitors E3 SUMO-protein ligase RanBP2 (P49792): 1 inhibitors E3 UFM1-protein ligase 1 (O94874): 1 inhibitors E3 ubiquitin-protein ligase CBL (P22681): 24 inhibitors E3 ubiquitin-protein ligase CBL-C [47-435] (Q9ULV8[47-435]): 197 inhibitors E3 ubiquitin-protein ligase CHIP (Q9UNE7): 3 inhibitors E3 ubiquitin-protein ligase HUWE1 (Q7Z6Z7): 1 inhibitors E3 ubiquitin-protein ligase Itchy homolog (Q96J02): 1 inhibitors E3 ubiquitin-protein ligase MYCBP2 (O75592): 1 inhibitors E3 ubiquitin-protein ligase RAD18 (Q9NS91): 1 inhibitors E3 ubiquitin-protein ligase RBX1 (P62877): 1 inhibitors E3 ubiquitin-protein ligase RNF10 (Q8N5U6): 1 inhibitors E3 ubiquitin-protein ligase RNF213 (Q63HN8): 2 inhibitors E3 ubiquitin-protein ligase RNF5 (Q99942): 1 inhibitors E3 ubiquitin-protein ligase SHPRH (Q149N8): 1 inhibitors E3 ubiquitin-protein ligase TRIM4 (Q9C037): 1 inhibitors E3 ubiquitin-protein ligase UBR1 (Q8IWV7): 33 inhibitors E3 ubiquitin-protein ligase UBR2 (Q8IWV8): 33 inhibitors E3 ubiquitin-protein ligase UBR4 (Q5T4S7): 2 inhibitors E3 ubiquitin-protein ligase ZFP91 (Q96JP5): 1 inhibitors E3 ubiquitin-protein ligase listerin (O94822): 2 inhibitors E3 ubiquitin-protein ligase makorin-3 (Q13064): 1 inhibitors E3 ubiquitin-protein ligase pellino homolog 1 (Q96FA3): 40 inhibitors E3 ubiquitin-protein ligase synoviolin (Q86TM6): 2 inhibitors E3 ubiquitin/ISG15 ligase TRIM25 (Q14258): 3 inhibitors EF-hand domain-containing protein D2 (Q96C19): 2 inhibitors EKC/KEOPS complex subunit LAGE3 (Q14657): 1 inhibitors EKC/KEOPS complex subunit TPRKB (Q9Y3C4): 2 inhibitors ER lumen protein-retaining receptor 1 (P24390): 2 inhibitors ER lumen protein-retaining receptor 2 (P33947): 2 inhibitors ER membrane protein complex subunit 1 (Q8N766): 1 inhibitors ER membrane protein complex subunit 2 (Q15006): 1 inhibitors ER membrane protein complex subunit 3 (Q9P0I2): 1 inhibitors ER membrane protein complex subunit 5 (Q8N4V1): 1 inhibitors ETS domain-containing protein Elk-3 (P41970): 2 inhibitors Early endosome antigen 1 (Q15075): 1 inhibitors Electrogenic aspartate/glutamate antiporter SLC25A13, mitochondrial (Q9UJS0): 1 inhibitors Electron transfer flavoprotein subunit alpha, mitochondrial (P13804): 1 inhibitors Electron transfer flavoprotein subunit beta (P38117): 1 inhibitors Elongation factor 1-beta (P24534): 1 inhibitors Elongation factor 1-delta (P29692): 3 inhibitors Elongation factor 1-gamma (P26641): 3 inhibitors Elongation factor 2 (P13639): 3 inhibitors Elongation factor G, mitochondrial (Q96RP9): 1 inhibitors Elongation factor Tu, mitochondrial (P49411): 2 inhibitors Elongator complex protein 1 (O95163): 1 inhibitors Elongin-B (Q15370): 1 inhibitors Emerin (P50402): 2 inhibitors Endonuclease domain-containing 1 protein (O94919): 1 inhibitors Endoplasmic reticulum junction formation protein lunapark (Q9C0E8): 2 inhibitors Endoplasmic reticulum metallopeptidase 1 (Q7Z2K6): 1 inhibitors Endoplasmic reticulum resident protein 29 (P30040): 1 inhibitors Endoplasmic reticulum resident protein 44 (Q9BS26): 1 inhibitors Endoplasmic reticulum-Golgi intermediate compartment protein 1 (Q969X5): 1 inhibitors Endothelial differentiation-related factor 1 (O60869): 1 inhibitors Engulfment and cell motility protein 1 (Q92556): 1 inhibitors Enhancer of rudimentary homolog (P84090): 3 inhibitors Enoyl-CoA delta isomerase 1, mitochondrial (P42126): 2 inhibitors Enoyl-CoA hydratase, mitochondrial (P30084): 1 inhibitors Ensconsin (Q14244): 1 inhibitors Epithelial cell adhesion molecule (P16422): 1 inhibitors Equilibrative nucleobase transporter 1 (Q8NBI5): 2 inhibitors Ergosterol biosynthetic protein 28 homolog (Q9UKR5): 1 inhibitors Erlin-2 (O94905): 2 inhibitors Ethanolaminephosphotransferase 1 (Q9C0D9): 2 inhibitors Etoposide-induced protein 2.4 homolog (O14681): 1 inhibitors Eukaryotic peptide chain release factor GTP-binding subunit ERF3B (Q8IYD1): 1 inhibitors Eukaryotic peptide chain release factor subunit 1 (P62495): 1 inhibitors Eukaryotic translation elongation factor 1 epsilon-1 (O43324): 3 inhibitors Eukaryotic translation initiation factor 2 subunit 2 (P20042): 1 inhibitors Eukaryotic translation initiation factor 2A (Q9BY44): 2 inhibitors Eukaryotic translation initiation factor 3 subunit A (Q14152): 3 inhibitors Eukaryotic translation initiation factor 3 subunit B (P55884): 2 inhibitors Eukaryotic translation initiation factor 3 subunit C (Q99613): 1 inhibitors Eukaryotic translation initiation factor 3 subunit D (O15371): 2 inhibitors Eukaryotic translation initiation factor 3 subunit E (P60228): 3 inhibitors Eukaryotic translation initiation factor 3 subunit F (O00303): 1 inhibitors Eukaryotic translation initiation factor 3 subunit G (O75821): 2 inhibitors Eukaryotic translation initiation factor 3 subunit H (O15372): 2 inhibitors Eukaryotic translation initiation factor 3 subunit I (Q13347): 2 inhibitors Eukaryotic translation initiation factor 3 subunit J (O75822): 2 inhibitors Eukaryotic translation initiation factor 3 subunit K (Q9UBQ5): 1 inhibitors Eukaryotic translation initiation factor 3 subunit L (Q9Y262): 3 inhibitors Eukaryotic translation initiation factor 3 subunit M (Q7L2H7): 2 inhibitors Eukaryotic translation initiation factor 4B (P23588): 2 inhibitors Eukaryotic translation initiation factor 5B (O60841): 3 inhibitors Eukaryotic translation initiation factor 6 (P56537): 2 inhibitors Exocyst complex component 1 (Q9NV70): 2 inhibitors Exocyst complex component 3 (O60645): 1 inhibitors Exocyst complex component 4 (Q96A65): 2 inhibitors Exosome RNA helicase MTR4 (P42285): 3 inhibitors Exosome complex component 10 (Q01780): 2 inhibitors Exosome complex component RRP41 (Q9NPD3): 2 inhibitors Exosome complex component RRP45 (Q06265): 2 inhibitors Exosome complex component RRP46 (Q9NQT4): 1 inhibitors Exosome complex exonuclease RRP44 (Q9Y2L1): 1 inhibitors Exportin-2 (P55060): 3 inhibitors Exportin-4 (Q9C0E2): 1 inhibitors Exportin-5 (Q9HAV4): 2 inhibitors Exportin-6 (Q96QU8): 1 inhibitors Exportin-7 (Q9UIA9): 2 inhibitors Exportin-T (O43592): 3 inhibitors Extended synaptotagmin-1 (Q9BSJ8): 2 inhibitors Extended synaptotagmin-2 (A0FGR8): 2 inhibitors F-actin-capping protein subunit alpha-1 (P52907): 3 inhibitors F-actin-capping protein subunit alpha-2 (P47755): 2 inhibitors F-actin-capping protein subunit beta (P47756): 3 inhibitors F-box-like/WD repeat-containing protein TBL1XR1 (Q9BZK7): 1 inhibitors FACT complex subunit SPT16 (Q9Y5B9): 3 inhibitors FACT complex subunit SSRP1 (Q08945): 3 inhibitors FAD synthase (Q8NFF5): 1 inhibitors FAST kinase domain-containing protein 1, mitochondrial (Q53R41): 1 inhibitors FAST kinase domain-containing protein 4 (Q969Z0): 1 inhibitors FAST kinase domain-containing protein 5, mitochondrial (Q7L8L6): 1 inhibitors FUN14 domain-containing protein 1 (Q8IVP5): 1 inhibitors FYN-binding protein 1 (O15117): 1 inhibitors Fanconi anemia group D2 protein (Q9BXW9): 2 inhibitors Fanconi anemia group I protein (Q9NVI1): 2 inhibitors Far upstream element-binding protein 2 (Q92945): 2 inhibitors Far upstream element-binding protein 3 (Q96I24): 1 inhibitors Fatty acyl-CoA reductase 1 (Q8WVX9): 2 inhibitors Ferritin heavy chain (P02794): 2 inhibitors Ferroptosis suppressor protein 1 (Q9BRQ8): 1 inhibitors Filaggrin-2 (Q5D862): 1 inhibitors Filamin-A (P21333): 3 inhibitors Filamin-B (O75369): 1 inhibitors Flotillin-1 (O75955): 1 inhibitors Forkhead box protein K1 (P85037): 1 inhibitors Formin-like protein 1 (O95466): 2 inhibitors Fructosamine-3-kinase (Q9H479): 2 inhibitors Fumarate hydratase, mitochondrial (P07954): 1 inhibitors Fumarylacetoacetase (P16930): 1 inhibitors G patch domain-containing protein 8 (Q9UKJ3): 1 inhibitors G-patch domain and KOW motifs-containing protein (Q92917): 1 inhibitors G/T mismatch-specific thymine DNA glycosylase (Q13569): 1 inhibitors G2/mitotic-specific cyclin-B2 (O95067): 2 inhibitors GDNF family receptor alpha-1 (P56159): 16 inhibitors GDNF family receptor alpha-2 (O00451): 16 inhibitors GDNF family receptor alpha-3 (O60609): 16 inhibitors GDP-mannose 4,6 dehydratase (O60547): 3 inhibitors GEL complex subunit OPTI (Q9BUV8): 1 inhibitors GH3 domain-containing protein (Q8N2G8): 1 inhibitors GPI ethanolamine phosphate transferase 3, catalytic subunit (Q8TEQ8): 1 inhibitors GPI-anchor transamidase (Q92643): 2 inhibitors GPI-anchor transamidase component GPAA1 (O43292): 2 inhibitors GPI-anchor transamidase component PIGS (Q96S52): 2 inhibitors GPI-anchor transamidase component PIGT (Q969N2): 1 inhibitors GSK3B-interacting protein (Q9P0R6): 2 inhibitors GTP-binding nuclear protein Ran (P62826): 3 inhibitors GTP-binding protein 10 (A4D1E9): 1 inhibitors GTP-binding protein 4 (Q9BZE4): 2 inhibitors GTPase Era, mitochondrial (O75616): 1 inhibitors GTPase KRas [G12C]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase (P01116[G12C],P15056,P62937): 46 inhibitors GTPase KRas [G12D]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase (P01116[G12D],P15056,P62937): 46 inhibitors GTPase KRas [G12V]/Serine/threonine-protein kinase B-raf/Peptidyl-prolyl cis-trans isomerase (P01116[G12V],P15056,P62937): 46 inhibitors GTPase-activating protein and VPS9 domain-containing protein 1 (Q14C86): 2 inhibitors Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 (O94766): 6 inhibitors Galectin-3-binding protein (Q08380): 2 inhibitors Galectin-9C (Q6DKI2): 3 inhibitors Gamma-aminobutyric acid receptor subunit beta-2 (P47870): 1 inhibitors Gamma-aminobutyric acid receptor subunit delta (O14764): 30 inhibitors Gamma-aminobutyric acid receptor-associated protein-like 1 (Q9H0R8): 1 inhibitors Gamma-aminobutyric acid receptor-associated protein-like 2 (P60520): 1 inhibitors Gamma-glutamylcyclotransferase (O75223): 1 inhibitors Gamma-tubulin complex component 2 (Q9BSJ2): 3 inhibitors Gamma-tubulin complex component 3 (Q96CW5): 3 inhibitors Gamma-tubulin complex component 4 (Q9UGJ1): 1 inhibitors Gem-associated protein 5 (Q8TEQ6): 3 inhibitors General transcription and DNA repair factor IIH helicase subunit XPD (P18074): 2 inhibitors General transcription factor 3C polypeptide 1 (Q12789): 1 inhibitors General transcription factor 3C polypeptide 2 (Q8WUA4): 1 inhibitors General transcription factor 3C polypeptide 3 (Q9Y5Q9): 1 inhibitors General transcription factor 3C polypeptide 4 (Q9UKN8): 1 inhibitors General transcription factor 3C polypeptide 5 (Q9Y5Q8): 1 inhibitors General transcription factor II-I (P78347): 3 inhibitors General transcription factor IIF subunit 1 (P35269): 1 inhibitors General transcription factor IIF subunit 2 (P13984): 2 inhibitors General vesicular transport factor p115 (O60763): 1 inhibitors Glia maturation factor gamma (O60234): 2 inhibitors Glucosamine-6-phosphate deaminase 1 (P46926): 1 inhibitors Glucosidase 2 subunit beta (P14314): 1 inhibitors Glutamate-rich WD repeat-containing protein 1 (Q9BQ67): 1 inhibitors Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial (P0DPI2): 1 inhibitors Glutaredoxin-3 (O76003): 1 inhibitors Glutathione S-transferase 3, mitochondrial (O14880): 1 inhibitors Glutathione S-transferase LANCL1 (O43813): 1 inhibitors Glutathione synthetase (P48637): 1 inhibitors Glycerol-3-phosphate phosphatase (A6NDG6): 1 inhibitors Glycerophosphocholine cholinephosphodiesterase ENPP6 (Q6UWR7): 38 inhibitors Glyoxylate reductase/hydroxypyruvate reductase (Q9UBQ7): 1 inhibitors Glypican-3 (P51654): 5 inhibitors Golgi apparatus protein 1 (Q92896): 2 inhibitors Golgi integral membrane protein 4 (O00461): 1 inhibitors Golgin subfamily A member 2 (Q08379): 1 inhibitors Golgin subfamily A member 3 (Q08378): 1 inhibitors Growth hormone-inducible transmembrane protein (Q9H3K2): 2 inhibitors Guanine nucleotide exchange factor DBS (O15068): 6 inhibitors Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (P62873): 1 inhibitors Guanine nucleotide-binding protein G(i) subunit alpha-2 (P04899): 3 inhibitors Guanine nucleotide-binding protein subunit beta-like protein 1 (Q9BYB4): 1 inhibitors H-2 class II histocompatibility antigen gamma chain (P04441): 6 inhibitors H/ACA ribonucleoprotein complex non-core subunit NAF1 (Q96HR8): 1 inhibitors H/ACA ribonucleoprotein complex subunit 1 (Q9NY12): 1 inhibitors H/ACA ribonucleoprotein complex subunit 2 (Q9NX24): 1 inhibitors H/ACA ribonucleoprotein complex subunit 3 (Q9NPE3): 1 inhibitors H/ACA ribonucleoprotein complex subunit DKC1 (O60832): 3 inhibitors HBS1-like protein (Q9Y450): 1 inhibitors HCLS1-associated protein X-1 (O00165): 1 inhibitors HEAT repeat-containing protein 1 (Q9H583): 2 inhibitors HEAT repeat-containing protein 6 (Q6AI08): 1 inhibitors HIG1 domain family member 1A, mitochondrial (Q9Y241): 1 inhibitors HIRA-interacting protein 3 (Q9BW71): 1 inhibitors HLA class I histocompatibility antigen, B alpha chain (P01889): 1 inhibitors HLA class I histocompatibility antigen, C alpha chain (P10321): 2 inhibitors Haloacid dehalogenase-like hydrolase domain-containing 5 (Q9BXW7): 1 inhibitors Heat shock 70 kDa protein 4 (P34932): 2 inhibitors Heat shock 70 kDa protein 4L (O95757): 1 inhibitors Heat shock protein 105 kDa (Q92598): 3 inhibitors Hematopoietic lineage cell-specific protein (P14317): 2 inhibitors Heme A synthase COX15 (Q7KZN9): 1 inhibitors Hemoglobin subunit gamma-1 (P69891): 1 inhibitors Hemoglobin subunit gamma-2 (P69892): 1 inhibitors Hemoglobin subunit zeta (P02008): 1 inhibitors Hepatoma-derived growth factor (P51858): 2 inhibitors Hepatoma-derived growth factor-related protein 3 (Q9Y3E1): 1 inhibitors Heterogeneous nuclear ribonucleoprotein A/B (Q99729): 2 inhibitors Heterogeneous nuclear ribonucleoprotein A0 (Q13151): 2 inhibitors Heterogeneous nuclear ribonucleoprotein A3 (P51991): 2 inhibitors Heterogeneous nuclear ribonucleoprotein D-like (O14979): 1 inhibitors Heterogeneous nuclear ribonucleoprotein D0 (Q14103): 2 inhibitors Heterogeneous nuclear ribonucleoprotein F (P52597): 3 inhibitors Heterogeneous nuclear ribonucleoprotein H (P31943): 3 inhibitors Heterogeneous nuclear ribonucleoprotein H3 (P31942): 2 inhibitors Heterogeneous nuclear ribonucleoprotein K (P61978): 3 inhibitors Heterogeneous nuclear ribonucleoprotein L (P14866): 3 inhibitors Heterogeneous nuclear ribonucleoprotein L-like (Q8WVV9): 2 inhibitors Heterogeneous nuclear ribonucleoprotein M (P52272): 2 inhibitors Heterogeneous nuclear ribonucleoprotein Q (O60506): 2 inhibitors Heterogeneous nuclear ribonucleoprotein R (O43390): 2 inhibitors Heterogeneous nuclear ribonucleoprotein U (Q00839): 3 inhibitors Heterogeneous nuclear ribonucleoprotein U-like protein 1 (Q9BUJ2): 3 inhibitors Heterogeneous nuclear ribonucleoprotein U-like protein 2 (Q1KMD3): 2 inhibitors Heterogeneous nuclear ribonucleoproteins A2/B1 (P22626): 2 inhibitors Heterogeneous nuclear ribonucleoproteins C1/C2 (P07910): 2 inhibitors Hexokinase HKDC1 (Q2TB90): 1 inhibitors High affinity cationic amino acid transporter 1 (P30825): 2 inhibitors High mobility group protein B2 (P26583): 3 inhibitors High mobility group protein B3 (O15347): 1 inhibitors High mobility group protein HMG-I/HMG-Y (P17096): 1 inhibitors Histone H1.10 (Q92522): 2 inhibitors Histone H1.2 (P16403): 3 inhibitors Histone H1.3 (P16402): 1 inhibitors Histone H1.4 (P10412): 2 inhibitors Histone H1.5 (P16401): 2 inhibitors Histone H2A type 1-D (P20671): 1 inhibitors Histone H2A type 2-B (Q8IUE6): 1 inhibitors Histone H2A.Z (P0C0S5): 1 inhibitors Histone H2B type 1-A (Q96A08): 1 inhibitors Histone H3 (P84243): 1 inhibitors Histone deacetylase complex subunit SAP18 (O00422): 1 inhibitors Histone-binding protein RBBP4 (Q09028): 2 inhibitors Histone-binding protein RBBP7 (Q16576): 2 inhibitors Histone-lysine N-methyltransferase PRDM7 (Q9NQW5): 1 inhibitors Histone-lysine N-methyltransferase PRDM9 (Q9NQV7): 6 inhibitors Histone-lysine N-methyltransferase SETD1A (O15047): 1 inhibitors Holocytochrome c-type synthase (P53701): 2 inhibitors Hornerin (Q86YZ3): 1 inhibitors Host cell factor 1 (P51610): 3 inhibitors Hsp70-binding protein 1 (Q9NZL4): 1 inhibitors Huntingtin-interacting protein K (Q9NX55): 1 inhibitors Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (Q16836): 1 inhibitors Hydroxysteroid dehydrogenase-like protein 2 (Q6YN16): 1 inhibitors Hypoxia up-regulated protein 1 (Q9Y4L1): 2 inhibitors INO80 complex subunit C (Q6PI98): 1 inhibitors Importin subunit alpha-3 (O00629): 1 inhibitors Importin subunit alpha-4 (O00505): 1 inhibitors Importin subunit alpha-5 (P52294): 1 inhibitors Importin subunit alpha-7 (O60684): 1 inhibitors Importin subunit beta-1 (Q14974): 3 inhibitors Importin-11 (Q9UI26): 1 inhibitors Importin-4 (Q8TEX9): 3 inhibitors Importin-5 (O00410): 3 inhibitors Importin-7 (O95373): 2 inhibitors Importin-8 (O15397): 2 inhibitors Importin-9 (Q96P70): 2 inhibitors Inducible T-cell costimulator (Q9Y6W8): 2 inhibitors Inner centromere protein (Q9NQS7): 2 inhibitors Insulin-like growth factor 2 mRNA-binding protein 2 (Q9Y6M1): 5 inhibitors Insulin-like growth factor 2 mRNA-binding protein 3 (O00425): 1 inhibitors Integral membrane protein GPR180 (Q86V85): 1 inhibitors Integrator complex subunit 6 (Q9UL03): 1 inhibitors Integrator complex subunit 8 (Q75QN2): 1 inhibitors Integrator complex subunit 9 (Q9NV88): 1 inhibitors Integrin alpha-6 (P23229): 2 inhibitors Integrin beta-2 (P29965): 1 inhibitors Integrin beta-4 (P16144): 2 inhibitors Integrin beta-6 (P18564): 1 inhibitors Integrin-linked kinase-associated serine/threonine phosphatase 2C (Q9H0C8): 1 inhibitors Interferon regulatory factor 2-binding protein 2 (Q7Z5L9): 1 inhibitors Interferon-induced, double-stranded RNA-activated protein kinase /Eukaryotic translation initiation factor 2-alpha kinase 3 [536-1116]/Small ubiquitin-related modifier 1/eIF-2-alpha kinase GCN2 (P19525{252-551],A0A7P0TAL9[536-1116],Q9BY44,Q9P2K8[584-1019],P63165): 171 inhibitors Interleukin enhancer-binding factor 2 (Q12905): 2 inhibitors Inverted formin-2 (Q27J81): 1 inhibitors Iron-sulfur clusters transporter ABCB7, mitochondrial (O75027): 2 inhibitors Isochorismatase domain-containing protein 1 (Q96CN7): 1 inhibitors Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial (P50213): 2 inhibitors Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial (O43837): 1 inhibitors Isoleucine--tRNA ligase, mitochondrial (Q9NSE4): 1 inhibitors Junction plakoglobin (P14923): 2 inhibitors KH domain-containing, RNA-binding, signal transduction-associated protein 1 (Q07666): 3 inhibitors Katanin p60 ATPase-containing subunit A-like 2 (Q8IYT4): 2 inhibitors Katanin p60 ATPase-containing subunit A1 (O75449): 4 inhibitors Kelch-like protein 12 (Q53G59): 1 inhibitors Kelch-like protein 20 (Q9Y2M5): 1 inhibitors Kelch-like protein 3 (Q9UH77): 2 inhibitors Kelch-like protein 6 (Q8WZ60): 1 inhibitors Keratin, type I cytoskeletal 18 (P05783): 2 inhibitors Ketosamine-3-kinase (Q9HA64): 3 inhibitors Kinectin (Q86UP2): 2 inhibitors Kinesin-like protein KIF18B (Q86Y91): 1 inhibitors Kinesin-like protein KIF2A (O00139): 1 inhibitors Kinetochore-associated protein 1 (P50748): 2 inhibitors Kunitz-type protease inhibitor 2 (O43291): 1 inhibitors L-2,3-diaminopropanoate--citrate ligase (Q2G1M9): 22 inhibitors L-aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase (Q9NRN7): 1 inhibitors L-xylulose reductase (Q7Z4W1): 1 inhibitors LIM and SH3 domain protein 1 (Q14847): 2 inhibitors LIM and senescent cell antigen-like-containing domain protein 1 (P48059): 1 inhibitors LIM domain and actin-binding protein 1 (Q9UHB6): 1 inhibitors La-related protein 1 (Q6PKG0): 2 inhibitors Lamin-B1 (P20700): 3 inhibitors Lamin-B2 (Q03252): 2 inhibitors Lamina-associated polypeptide 2, isoform alpha (P42166): 3 inhibitors Lamina-associated polypeptide 2, isoforms beta/gamma (P42167): 1 inhibitors Large proline-rich protein BAG6 (P46379): 1 inhibitors Large ribosomal subunit protein P1 (P05386): 2 inhibitors Large ribosomal subunit protein P2 (P05387): 1 inhibitors Large ribosomal subunit protein bL12m (P52815): 2 inhibitors Large ribosomal subunit protein bL19m (P49406): 1 inhibitors Large ribosomal subunit protein bL21m (Q7Z2W9): 1 inhibitors Large ribosomal subunit protein bL9m (Q9BYD2): 1 inhibitors Large ribosomal subunit protein eL13 (P26373): 2 inhibitors Large ribosomal subunit protein eL14 (P50914): 2 inhibitors Large ribosomal subunit protein eL15 (P61313): 2 inhibitors Large ribosomal subunit protein eL18 (Q07020): 1 inhibitors Large ribosomal subunit protein eL19 (P84098): 1 inhibitors Large ribosomal subunit protein eL20 (Q02543): 2 inhibitors Large ribosomal subunit protein eL21 (P46778): 2 inhibitors Large ribosomal subunit protein eL22 (P35268): 3 inhibitors Large ribosomal subunit protein eL24 (P83731): 2 inhibitors Large ribosomal subunit protein eL27 (P61353): 2 inhibitors Large ribosomal subunit protein eL28 (P46779): 1 inhibitors Large ribosomal subunit protein eL30 (P62888): 2 inhibitors Large ribosomal subunit protein eL31 (P62899): 2 inhibitors Large ribosomal subunit protein eL33 (P18077): 2 inhibitors Large ribosomal subunit protein eL34 (P49207): 1 inhibitors Large ribosomal subunit protein eL36 (Q9Y3U8): 2 inhibitors Large ribosomal subunit protein eL38 (P63173): 2 inhibitors Large ribosomal subunit protein eL43 (P61513): 1 inhibitors Large ribosomal subunit protein eL6 (Q02878): 1 inhibitors Large ribosomal subunit protein eL8 (P62424): 2 inhibitors Large ribosomal subunit protein mL37 (Q9BZE1): 1 inhibitors Large ribosomal subunit protein mL38 (Q96DV4): 1 inhibitors Large ribosomal subunit protein mL66 (Q9NVS2): 1 inhibitors Large ribosomal subunit protein uL1 (P62906): 2 inhibitors Large ribosomal subunit protein uL11 (P30050): 2 inhibitors Large ribosomal subunit protein uL11m (Q9Y3B7): 1 inhibitors Large ribosomal subunit protein uL13 (P40429): 1 inhibitors Large ribosomal subunit protein uL14 (P62829): 2 inhibitors Large ribosomal subunit protein uL16 (P27635): 2 inhibitors Large ribosomal subunit protein uL18 (P46777): 2 inhibitors Large ribosomal subunit protein uL2 (P62917): 2 inhibitors Large ribosomal subunit protein uL22 (P18621): 2 inhibitors Large ribosomal subunit protein uL23 (P62750): 2 inhibitors Large ribosomal subunit protein uL24 (P61254): 2 inhibitors Large ribosomal subunit protein uL29 (P42766): 2 inhibitors Large ribosomal subunit protein uL3 (P39023): 2 inhibitors Large ribosomal subunit protein uL30 (P18124): 2 inhibitors Large ribosomal subunit protein uL4 (P36578): 2 inhibitors Large ribosomal subunit protein uL5 (P62913): 2 inhibitors Large ribosomal subunit protein uL6 (P32969): 2 inhibitors Large subunit GTPase 1 homolog (Q9H089): 1 inhibitors Leucine zipper protein 1 (Q86V48): 1 inhibitors Leucine-rich PPR motif-containing protein, mitochondrial (P42704): 2 inhibitors Leucine-rich repeat and WD repeat-containing protein 1 (Q9UFC0): 1 inhibitors Leucine-rich repeat flightless-interacting protein 1 (Q32MZ4): 2 inhibitors Leucine-rich repeat-containing G-protein coupled receptor 4 (Q9BXB1): 1 inhibitors Leucine-rich repeat-containing protein 40 (Q9H9A6): 1 inhibitors Leucine-rich repeat-containing protein 47 (Q8N1G4): 2 inhibitors Leucine-rich repeat-containing protein 59 (Q96AG4): 3 inhibitors Leukocyte elastase inhibitor (P30740): 1 inhibitors Leukocyte receptor cluster member 8 (Q96PV6): 1 inhibitors Leupaxin (O60711): 1 inhibitors Lipid droplet-regulating VLDL assembly factor AUP1 (Q9Y679): 1 inhibitors Lipid scramblase CLPTM1L (Q96KA5): 1 inhibitors Lipopolysaccharide-responsive and beige-like anchor protein (P50851): 2 inhibitors Lupus La protein (P05455): 3 inhibitors Lymphoid-specific helicase (Q9NRZ9): 1 inhibitors Lysophosphatidylcholine acyltransferase 1 (Q8NF37): 1 inhibitors Lysophospholipid acyltransferase 5 (Q6P1A2): 1 inhibitors Lysosome-associated membrane glycoprotein 1 (P11279): 1 inhibitors Lysosome-associated membrane glycoprotein 2 (P13473): 2 inhibitors M-phase phosphoprotein 6 (Q99547): 1 inhibitors MAP7 domain-containing protein 3 (Q8IWC1): 1 inhibitors MICOS complex subunit MIC13 (Q5XKP0): 1 inhibitors MICOS complex subunit MIC19 (Q9NX63): 2 inhibitors MICOS complex subunit MIC25 (Q9BRQ6): 1 inhibitors MICOS complex subunit MIC60 (Q16891): 2 inhibitors MMS19 nucleotide excision repair protein homolog (Q96T76): 2 inhibitors Macoilin (Q8N5G2): 1 inhibitors Macrophage-capping protein (P40121): 1 inhibitors Macrosialin (P34810): 1 inhibitors Major facilitator superfamily domain-containing protein 10 (Q14728): 1 inhibitors Male-specific lethal 1 homolog (Q68DK7): 1 inhibitors Malectin (Q14165): 2 inhibitors Mammalian ependymin-related protein 1 (Q9UM22): 2 inhibitors Man(5)GlcNAc(2)-PP-dolichol translocation protein RFT1 (Q96AA3): 1 inhibitors Mannose-P-dolichol utilization defect 1 protein (O75352): 1 inhibitors Matrin-3 (P43243): 3 inhibitors Mechanosensitive cation channel TMEM63A (O94886): 1 inhibitors Mediator of RNA polymerase II transcription subunit 12 (Q93074): 1 inhibitors Mediator of RNA polymerase II transcription subunit 16 (Q9Y2X0): 1 inhibitors Medium-chain specific acyl-CoA dehydrogenase, mitochondrial (P11310): 1 inhibitors Meiosis-specific nuclear structural protein 1 (Q8NEH6): 1 inhibitors Melanin-concentrating hormone receptor 1 [70-422] (Q99705[70-422]): 33 inhibitors Membrane-associated progesterone receptor component 2 (O15173): 1 inhibitors Membrane-bound acylglycerophosphatidylinositol O-acyltransferase MBOAT7 (Q96N66): 2 inhibitors Membrane-bound glycerophospholipid O-acyltransferase 1 (Q6ZNC8): 1 inhibitors Metal cation symporter ZIP14 (Q15043): 2 inhibitors Metastasis-associated protein MTA1 (Q13330): 1 inhibitors Metaxin-1 (Q13505): 1 inhibitors Metaxin-2 (O75431): 2 inhibitors Methionine adenosyltransferase 2 subunit beta (Q9NZL9): 1 inhibitors Methionine-R-sulfoxide reductase B3 (Q8IXL7): 1 inhibitors Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial (Q9HCC0): 2 inhibitors Methylosome subunit pICln (P54105): 1 inhibitors Methylsterol monooxygenase 1 (Q15800): 1 inhibitors Microfibrillar-associated protein 1 (P55081): 1 inhibitors Microspherule protein 1 (Q96EZ8): 1 inhibitors Microtubule cross-linking factor 3 (Q5TF21): 2 inhibitors Microtubule-actin cross-linking factor 1, isoforms 1/2/3/4/5 (Q9UPN3): 2 inhibitors Microtubule-associated protein 1 light chain 3 gamma (Q9BXW4): 1 inhibitors Microtubule-associated protein 1B (P46821): 2 inhibitors Microtubule-associated protein 4 (P27816): 2 inhibitors Microtubule-associated protein RP/EB family member 1 (Q15691): 1 inhibitors Microtubule-associated protein RP/EB family member 2 (Q15555): 2 inhibitors Midasin (Q9NU22): 3 inhibitors Mini-chromosome maintenance complex-binding protein (Q9BTE3): 1 inhibitors Mitochondrial 2-oxoglutarate/malate carrier protein (Q02978): 2 inhibitors Mitochondrial Rho GTPase 2 (Q8IXI1): 2 inhibitors Mitochondrial antiviral-signaling protein (Q7Z434): 2 inhibitors Mitochondrial carrier homolog 2 (Q9Y6C9): 2 inhibitors Mitochondrial fission 1 protein (Q9Y3D6): 1 inhibitors Mitochondrial import inner membrane translocase subunit TIM44 (O43615): 2 inhibitors Mitochondrial import inner membrane translocase subunit TIM50 (Q3ZCQ8): 2 inhibitors Mitochondrial import inner membrane translocase subunit Tim13 (Q9Y5L4): 1 inhibitors Mitochondrial import inner membrane translocase subunit Tim9 (Q9Y5J7): 1 inhibitors Mitochondrial import receptor subunit TOM22 homolog (Q9NS69): 1 inhibitors Mitochondrial import receptor subunit TOM34 (Q15785): 3 inhibitors Mitochondrial import receptor subunit TOM40 homolog (O96008): 1 inhibitors Mitochondrial import receptor subunit TOM70 (O94826): 4 inhibitors Mitochondrial inner membrane protein OXA1L (Q15070): 1 inhibitors Mitochondrial proton/calcium exchanger protein (O95202): 1 inhibitors Mitochondrial-processing peptidase subunit beta (O75439): 2 inhibitors Mitotic checkpoint protein BUB3 (O43684): 2 inhibitors Mitotic deacetylase-associated SANT domain protein (Q6PJG2): 1 inhibitors Moesin (P26038): 2 inhibitors Monofunctional C1-tetrahydrofolate synthase, mitochondrial (Q6UB35): 2 inhibitors Mortality factor 4-like protein 1 (Q9UBU8): 1 inhibitors Mothers against decapentaplegic homolog 4 (Q13485): 1 inhibitors Msx2-interacting protein (Q96T58): 1 inhibitors Myb-binding protein 1A (Q9BQG0): 1 inhibitors Myeloid-associated differentiation marker (Q96S97): 1 inhibitors Myosin light chain 4 (P12829): 1 inhibitors Myosin light polypeptide 6 (P60660): 2 inhibitors Myosin regulatory light chain 12A (P19105): 1 inhibitors Myotrophin (P58546): 1 inhibitors Myristoylated alanine-rich C-kinase substrate (P29966): 1 inhibitors N(6)-adenosine-methyltransferase catalytic subunit METTL3 (Q8C3P7): 1 inhibitors N-acetylneuraminate-9-phosphate synthase (Q9NR45): 2 inhibitors N-alpha-acetyltransferase 10 (P41227): 1 inhibitors N-alpha-acetyltransferase 15, NatA auxiliary subunit (Q9BXJ9): 2 inhibitors NAD(P) transhydrogenase, mitochondrial (Q13423): 2 inhibitors NAD-dependent protein lipoamidase sirtuin-4, mitochondrial (Q9Y6E7): 18 inhibitors NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2 (Q8N183): 1 inhibitors NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 4 (Q9P032): 2 inhibitors NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial (O95299): 1 inhibitors NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 (Q9P0J0): 2 inhibitors NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 (Q16718): 2 inhibitors NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 (O96000): 2 inhibitors NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial (O43674): 1 inhibitors NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 (O95139): 1 inhibitors NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 (P17568): 1 inhibitors NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial (O95169): 1 inhibitors NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial (P19404): 1 inhibitors NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial (O75306): 2 inhibitors NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial (O75489): 2 inhibitors NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial (O75380): 1 inhibitors NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial (O75251): 2 inhibitors NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial (P28331): 2 inhibitors NBAS subunit of NRZ tethering complex (A2RRP1): 2 inhibitors NF-X1-type zinc finger protein NFXL1 (Q6ZNB6): 1 inhibitors NHP2-like protein 1 (P55769): 2 inhibitors NSFL1 cofactor p47 (Q9UNZ2): 1 inhibitors Nardilysin (O43847): 2 inhibitors Nascent polypeptide-associated complex subunit alpha (Q13765): 1 inhibitors Natural cytotoxicity triggering receptor 1 (O76036): 1 inhibitors Nck-associated protein 1 (Q9Y2A7): 1 inhibitors Nck-associated protein 1-like (P55160): 3 inhibitors Nestin (P48681): 2 inhibitors Neuroblast differentiation-associated protein AHNAK (Q09666): 2 inhibitors Neurochondrin (Q9UBB6): 2 inhibitors Neurofilament medium polypeptide (P07197): 1 inhibitors Neuromodulin (P17677): 1 inhibitors Neuronal migration protein doublecortin (O43602): 2 inhibitors Neurosecretory protein VGF (O15240): 2 inhibitors Nicastrin (Q92542): 1 inhibitors Nicotinate phosphoribosyltransferase (Q6XQN6): 1 inhibitors Non-POU domain-containing octamer-binding protein (Q15233): 2 inhibitors Non-selective voltage-gated ion channel VDAC1 (P21796): 2 inhibitors Non-selective voltage-gated ion channel VDAC3 (Q9Y277): 2 inhibitors Non-structural protein 4b (F5B4I0): 32 inhibitors Nuclear RNA export factor 1 (Q9UBU9): 1 inhibitors Nuclear autoantigenic sperm protein (P49321): 2 inhibitors Nuclear cap-binding protein subunit 1 (Q09161): 3 inhibitors Nuclear cap-binding protein subunit 2 (P52298): 1 inhibitors Nuclear factor of activated T-cells, cytoplasmic 3 (Q12968): 1 inhibitors Nuclear factor related to kappa-B-binding protein (Q6P4R8): 1 inhibitors Nuclear hormone receptor isoform A (A0A0K0EQJ4): 13 inhibitors Nuclear migration protein nudC (Q9Y266): 2 inhibitors Nuclear mitotic apparatus protein 1 (Q14980): 3 inhibitors Nuclear pore complex protein Nup155 (O75694): 3 inhibitors Nuclear pore complex protein Nup160 (Q12769): 2 inhibitors Nuclear pore complex protein Nup205 (Q92621): 3 inhibitors Nuclear pore complex protein Nup50 (Q9UKX7): 1 inhibitors Nuclear pore complex protein Nup93 (Q8N1F7): 3 inhibitors Nuclear pore membrane glycoprotein 210 (Q8TEM1): 2 inhibitors Nuclear protein AMMECR1 (Q9Y4X0): 1 inhibitors Nuclear transport factor 2 (P61970): 2 inhibitors Nucleobindin-2 (P80303): 1 inhibitors Nucleolar MIF4G domain-containing protein 1 (Q5C9Z4): 1 inhibitors Nucleolar and coiled-body phosphoprotein 1 (Q14978): 3 inhibitors Nucleolar complex protein 2 homolog (Q9Y3T9): 2 inhibitors Nucleolar complex protein 4 homolog (Q9BVI4): 1 inhibitors Nucleolar protein 56 (O00567): 2 inhibitors Nucleolar protein 58 (Q9Y2X3): 1 inhibitors Nucleolar transcription factor 1 (P17480): 1 inhibitors Nucleolin (P19338): 2 inhibitors Nucleolysin TIAR (Q01085): 2 inhibitors Nucleoporin NDC1 (Q9BTX1): 1 inhibitors Nucleoporin NUP188 (Q5SRE5): 1 inhibitors Nucleoside diphosphate kinase A (P15531): 3 inhibitors Nucleosome assembly protein 1-like 1 (P55209): 2 inhibitors Nucleosome assembly protein 1-like 4 (Q99733): 1 inhibitors Nucleus accumbens-associated protein 1 (Q96RE7): 1 inhibitors OCIA domain-containing protein 1 (Q9NX40): 1 inhibitors OCIA domain-containing protein 2 (Q56VL3): 1 inhibitors ORM1-like protein 3 (Q8N138): 2 inhibitors Obg-like ATPase 1 (Q9NTK5): 1 inhibitors Olfactory receptor 10J3 (Q5JRS4): 1 inhibitors Oligosaccharyltransferase complex subunit OSTC (Q9NRP0): 2 inhibitors Omega-amidase NIT2 (Q9NQR4): 1 inhibitors Opioid growth factor receptor (Q9NZT2): 1 inhibitors Origin recognition complex subunit 3 (Q9UBD5): 1 inhibitors Origin recognition complex subunit 5 (O43913): 1 inhibitors Oxysterol-binding protein-related protein 3 (Q9H4L5): 1 inhibitors Oxysterol-binding protein-related protein 8 (Q9BZF1): 2 inhibitors P-type sodium-transporting ATPase4 (A0A143ZZK9): 2 inhibitors PAN2-PAN3 deadenylation complex subunit PAN3 (Q58A45): 1 inhibitors PAT complex subunit CCDC47 (Q96A33): 2 inhibitors PAX3- and PAX7-binding protein 1 (Q9Y5B6): 1 inhibitors PCI domain-containing protein 2 (Q5JVF3): 3 inhibitors PDZ and LIM domain protein 5 (Q96HC4): 1 inhibitors PEST proteolytic signal-containing nuclear protein (Q8WW12): 1 inhibitors PHD finger protein 20 (Q9BVI0): 1 inhibitors PHD finger protein 20-like protein 1 (A8MW92): 1 inhibitors PHD finger protein 6 (Q8IWS0): 1 inhibitors PHD finger-like domain-containing protein 5A (Q7RTV0): 1 inhibitors PITH domain-containing protein 1 (Q9GZP4): 1 inhibitors POTE ankyrin domain family member E (Q6S8J3): 2 inhibitors PWWP domain-containing protein 2B (Q6NUJ5): 1 inhibitors Paired amphipathic helix protein Sin3a (Q96ST3): 2 inhibitors Palmitoyl-protein thioesterase ABHD10, mitochondrial (Q9NUJ1): 3 inhibitors Palmitoyltransferase ZDHHC7 (Q9NXF8): 2 inhibitors Palmitoyltransferase ZDHHC9 (Q9Y397): 2 inhibitors Parafibromin (Q6P1J9): 1 inhibitors Paraspeckle component 1 (Q8WXF1): 2 inhibitors Parathymosin (P20962): 1 inhibitors Partner of Y14 and mago (Q9BRP8): 1 inhibitors Peflin (Q9UBV8): 3 inhibitors Peptidyl-prolyl cis-trans isomerase E (Q9UNP9): 1 inhibitors Peptidyl-prolyl cis-trans isomerase FKBP8 (Q14318): 3 inhibitors Peptidyl-prolyl cis-trans isomerase-like 4 (Q8WUA2): 1 inhibitors Perilipin-3 (O60664): 1 inhibitors Peripherin (P41219): 2 inhibitors Periphilin-1 (Q8NEY8): 1 inhibitors Peroxiredoxin-2 (P32119): 4 inhibitors Peroxiredoxin-4 (Q13162): 4 inhibitors Peroxiredoxin-5, mitochondrial (P30044): 2 inhibitors Peroxiredoxin-6 (P30041): 4 inhibitors Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] (Q9NUI1): 1 inhibitors Peroxisomal acyl-coenzyme A oxidase 3 (O15254): 2 inhibitors Peroxisomal biogenesis factor 3 (P56589): 1 inhibitors Peroxisomal membrane protein 4 (Q9Y6I8): 1 inhibitors Peroxisomal membrane protein PMP34 (O43808): 1 inhibitors Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Q9UBK2): 1 inhibitors Peroxisome proliferator-activated receptor gamma/Nuclear receptor corepressor 1/Retinoic acid receptor RXR-alpha (P37231,P19793,O75376): 7 inhibitors Pescadillo homolog (O00541): 1 inhibitors Phenylalanine--tRNA ligase beta subunit (Q9NSD9): 2 inhibitors Phosphatidate cytidylyltransferase 2 (O95674): 1 inhibitors Phosphatidylethanolamine-binding protein 1 (P30086): 1 inhibitors Phosphatidylinositol 3-kinase regulatory subunit gamma (Q92569): 5 inhibitors Phosphatidylinositol 4-kinase type 2-beta (Q8TCG2): 1 inhibitors Phosphatidylinositol transfer protein beta isoform (P48739): 2 inhibitors Phosphatidylinositol-3-phosphatase SAC1 (Q9NTJ5): 1 inhibitors Phosphatidylinositol-3-phosphate phosphatase MTMR1 (Q13613): 1 inhibitors Phosphatidylinositol-binding clathrin assembly protein (Q13492): 1 inhibitors Phosphatidylserine synthase 1 (P48651): 2 inhibitors Phosphatidylserine synthase 2 (Q9BVG9): 1 inhibitors Phosphoenolpyruvate carboxykinase [GTP], mitochondrial (Q16822): 2 inhibitors Phosphoheptose isomerase (Q93UJ2): 12 inhibitors Phosphopentomutase (Q96G03): 2 inhibitors Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (Q9NWQ8): 2 inhibitors Phosphoribosylformylglycinamidine synthase (O15067): 1 inhibitors Phosphorylase b kinase regulatory subunit alpha, liver isoform (P46019): 1 inhibitors Phosphorylase b kinase regulatory subunit beta (Q93100): 2 inhibitors Phosphorylated adapter RNA export protein (Q9H814): 1 inhibitors Phosphoserine aminotransferase (Q9Y617): 2 inhibitors Phosphoserine phosphatase (P78330): 1 inhibitors Pinin (Q9H307): 1 inhibitors Plastin-2 (P13796): 2 inhibitors Platelet-activating factor acetylhydrolase IB subunit alpha1 (Q15102): 1 inhibitors Pleckstrin homology domain-containing family G member 3 (A1L390): 1 inhibitors Poly(U)-binding-splicing factor PUF60 (Q9UHX1): 2 inhibitors Poly(rC)-binding protein 1 (Q15365): 3 inhibitors Poly(rC)-binding protein 2 (Q15366): 1 inhibitors Polyadenylate-binding protein 4 (Q13310): 2 inhibitors Polyadenylate-binding protein-interacting protein 1 (Q9H074): 2 inhibitors Polyphenol oxidase 4 (C7FF05): 237 inhibitors Polypyrimidine tract-binding protein 1 (P26599): 3 inhibitors Polypyrimidine tract-binding protein 3 (O95758): 1 inhibitors Potassium channel subfamily K member 13 (Q8R1P5): 20 inhibitors Pre-mRNA-processing factor 40 homolog A (O75400): 3 inhibitors Pre-mRNA-processing factor 6 (O94906): 3 inhibitors Pre-mRNA-processing-splicing factor 8 (Q6P2Q9): 3 inhibitors Pre-mRNA-splicing factor CWC22 homolog (Q9HCG8): 1 inhibitors Pre-mRNA-splicing factor RBM22 (Q9NW64): 1 inhibitors Pre-mRNA-splicing factor SPF27 (O75934): 2 inhibitors Prefoldin subunit 1 (O60925): 1 inhibitors Prefoldin subunit 2 (Q9UHV9): 2 inhibitors Prefoldin subunit 6 (O15212): 1 inhibitors Prelamin-A/C (P02545): 3 inhibitors Probable ATP-dependent RNA helicase DDX20 (Q9UHI6): 2 inhibitors Probable ATP-dependent RNA helicase DDX41 (Q9UJV9): 1 inhibitors Probable G-protein coupled receptor 132 (Q9UNW8): 1 inhibitors Probable arginine--tRNA ligase, mitochondrial (Q5T160): 1 inhibitors Probable helicase with zinc finger domain (P42694): 1 inhibitors Probable rRNA-processing protein EBP2 (Q99848): 2 inhibitors Procollagen galactosyltransferase 1 (Q8NBJ5): 1 inhibitors Profilin-1 (P07737): 2 inhibitors Profilin-2 (P35080): 1 inhibitors Programmed cell death 6-interacting protein (Q8WUM4): 3 inhibitors Programmed cell death protein 10 (Q9BUL8): 1 inhibitors Programmed cell death protein 2-like (Q9BRP1): 2 inhibitors Programmed cell death protein 5 (O14737): 1 inhibitors Programmed cell death protein 6 (O75340): 2 inhibitors Prohibitin 1 (P35232): 2 inhibitors Proliferation marker protein Ki-67 (P46013): 3 inhibitors Proliferation-associated protein 2G4 (Q9UQ80): 2 inhibitors Proline-, glutamic acid- and leucine-rich protein 1 (Q8IZL8): 1 inhibitors Proline-rich protein 12 (Q9ULL5): 1 inhibitors Proline-serine-threonine phosphatase-interacting protein 2 (Q9H939): 1 inhibitors Propionyl-CoA carboxylase alpha chain, mitochondrial (P05165): 2 inhibitors Prospero homeobox protein 1 (Q92786): 1 inhibitors Prostaglandin E synthase 3 (Q15185): 1 inhibitors Proteasome activator complex subunit 1 (Q06323): 3 inhibitors Proteasome activator complex subunit 2 (Q9UL46): 3 inhibitors Proteasome activator complex subunit 3 (P61289): 2 inhibitors Proteasome activator complex subunit 4 (Q14997): 1 inhibitors Proteasome adapter and scaffold protein ECM29 (Q5VYK3): 2 inhibitors Proteasome subunit alpha type-3 (P25788): 2 inhibitors Proteasome subunit alpha type-4 (P25789): 3 inhibitors Proteasome subunit alpha type-5 (P28066): 2 inhibitors Proteasome subunit alpha type-7 (O14818): 2 inhibitors Proteasome subunit beta type-3 (P49720): 1 inhibitors Protein 4.1 (P11171): 1 inhibitors Protein Aster-A (Q96CP6): 17 inhibitors Protein CDV3 homolog (Q9UKY7): 1 inhibitors Protein CIP2A (Q8TCG1): 1 inhibitors Protein CutA (O60888): 1 inhibitors Protein DEK (P35659): 1 inhibitors Protein ERGIC-53 (P49257): 1 inhibitors Protein FAM136A (Q96C01): 2 inhibitors Protein FAM162A (Q96A26): 1 inhibitors Protein FAM222B (Q8WU58): 1 inhibitors Protein FAM83A (Q86UY5): 1 inhibitors Protein FAM83B (Q5T0W9): 2 inhibitors Protein FAM83E (Q2M2I3): 2 inhibitors Protein FRG1 (Q14331): 1 inhibitors Protein HIRA (P54198): 1 inhibitors Protein IWS1 homolog (Q96ST2): 1 inhibitors Protein LSM12 (Q3MHD2): 2 inhibitors Protein LSM14 homolog A (Q8ND56): 2 inhibitors Protein LYRIC (Q86UE4): 2 inhibitors Protein MAL2 (Q969L2): 2 inhibitors Protein MON2 homolog (Q7Z3U7): 2 inhibitors Protein Niban 2 (Q96TA1): 1 inhibitors Protein NipSnap homolog 1 (Q9BPW8): 1 inhibitors Protein NipSnap homolog 3A (Q9UFN0): 1 inhibitors Protein PBDC1 (Q9BVG4): 2 inhibitors Protein PML (P29590): 1 inhibitors Protein POF1B (Q8WVV4): 1 inhibitors Protein PRRC2A (P48634): 1 inhibitors Protein PRRC2C (Q9Y520): 2 inhibitors Protein RCC2 (Q9P258): 3 inhibitors Protein RER1 (O15258): 2 inhibitors Protein RRP5 homolog (Q14690): 2 inhibitors Protein S100-A10 (P60903): 1 inhibitors Protein S100-A11 (P31949): 2 inhibitors Protein S100-A6 (P06703): 2 inhibitors Protein S100-A8 (P05109): 1 inhibitors Protein S100-P (P25815): 1 inhibitors Protein SAAL1 (Q96ER3): 1 inhibitors Protein SCO2 homolog, mitochondrial (O43819): 1 inhibitors Protein SDA1 homolog (Q9NVU7): 2 inhibitors Protein SEC13 homolog (P55735): 1 inhibitors Protein SET (Q01105): 1 inhibitors Protein SGT1 homolog (Q9Y2Z0): 2 inhibitors Protein SON (P18583): 1 inhibitors Protein Shroom3 (Q8TF72): 1 inhibitors Protein THEM6 (Q8WUY1): 2 inhibitors Protein VAC14 homolog (Q08AM6): 2 inhibitors Protein Wiz (O95785): 1 inhibitors Protein YIF1A (O95070): 1 inhibitors Protein YIPF5 (Q969M3): 2 inhibitors Protein canopy homolog 2 (Q9Y2B0): 1 inhibitors Protein canopy homolog 3 (Q9BT09): 1 inhibitors Protein cereblon/CUL4A/AR (P10275): 90 inhibitors Protein cholesin (Q9BRJ6): 2 inhibitors Protein diaphanous homolog 1 (O60610): 2 inhibitors Protein disulfide-isomerase A5 (Q14554): 1 inhibitors Protein kinase C and casein kinase substrate in neurons protein 2 (Q9UNF0): 1 inhibitors Protein pelota homolog (Q9BRX2): 1 inhibitors Protein phosphatase 1 regulatory subunit 12A (O14974): 1 inhibitors Protein phosphatase 1 regulatory subunit 1B (Q9UD71): 1 inhibitors Protein phosphatase 1 regulatory subunit 7 (Q15435): 1 inhibitors Protein phosphatase 1F (P49593): 1 inhibitors Protein prenyltransferase alpha subunit repeat-containing protein 1 (Q7Z6K3): 1 inhibitors Protein salvador homolog 1 (Q9H4B6): 2 inhibitors Protein transport protein Sec16A (O15027): 2 inhibitors Protein transport protein Sec23A (Q15436): 2 inhibitors Protein transport protein Sec23B (Q15437): 2 inhibitors Protein transport protein Sec24C (P53992): 2 inhibitors Protein transport protein Sec61 subunit alpha isoform 1 (P61619): 2 inhibitors Protein transport protein Sec61 subunit beta (P60468): 2 inhibitors Protein transport protein Sec61 subunit gamma (P60059): 1 inhibitors Protein unc-119 homolog A (Q13432): 2 inhibitors Protein unc-93 homolog B1 (Q9H1C4): 1 inhibitors Protein-lysine N-trimethyltransferase SMYD5 (Q6GMV2): 1 inhibitors Proteolipid protein 2 (Q04941): 1 inhibitors Prothymosin alpha (P06454): 2 inhibitors Proto-oncogene c-Rel (Q04864): 1 inhibitors Proton-coupled zinc antiporter SLC30A5 (Q8TAD4): 1 inhibitors Pseudouridylate synthase 1 homolog (Q9Y606): 1 inhibitors Pumilio homolog 1 (Q14671): 1 inhibitors Pumilio homolog 2 (Q8TB72): 1 inhibitors Putative E3 ubiquitin-protein ligase UBR7 (Q8N806): 1 inhibitors Putative RNA-binding protein Luc7-like 2 (Q9Y383): 3 inhibitors Putative divalent cation/proton antiporter TMEM165 (Q9HC07): 2 inhibitors Putative heat shock protein HSP 90-beta 2 (Q58FF8): 2 inhibitors Putative lipid scramblase CLPTM1 (O96005): 1 inhibitors Putative protein-lysine deacylase ABHD14B (Q96IU4): 1 inhibitors Putative uncharacterized protein ZNF436-AS1 (Q8NC38): 1 inhibitors Pyridoxal phosphate homeostasis protein (O94903): 1 inhibitors Pyruvate carboxylase (A0A0H3JRU9): 21 inhibitors Pyruvate carboxylase, mitochondrial (P11498): 29 inhibitors Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrial (P29803): 1 inhibitors Pyruvate dehydrogenase complex component E3-binding protein (O00330): 1 inhibitors Queuine tRNA-ribosyltransferase accessory subunit 2 (Q9H974): 1 inhibitors RNA N(6)-adenosine-methyltransferase METTL16 (Q86W50): 8 inhibitors RNA cytidine acetyltransferase (Q9H0A0): 2 inhibitors RNA cytosine C(5)-methyltransferase NSUN2 (Q08J23): 3 inhibitors RNA polymerase II elongation factor ELL (P55199): 1 inhibitors RNA polymerase II-associated factor 1 homolog (Q8N7H5): 1 inhibitors RNA polymerase II-associated protein 1 (Q9BWH6): 1 inhibitors RNA polymerase-associated protein CTR9 homolog (Q6PD62): 2 inhibitors RNA polymerase-associated protein LEO1 (Q8WVC0): 1 inhibitors RNA polymerase-associated protein RTF1 homolog (Q92541): 1 inhibitors RNA transcription, translation and transport factor protein (Q9Y224): 1 inhibitors RNA-binding motif protein, X chromosome (P38159): 1 inhibitors RNA-binding protein 12 (Q9NTZ6): 1 inhibitors RNA-binding protein 14 (Q96PK6): 1 inhibitors RNA-binding protein 15 (Q96T37): 1 inhibitors RNA-binding protein 25 (P49756): 2 inhibitors RNA-binding protein 26 (Q5T8P6): 1 inhibitors RNA-binding protein 28 (Q9NW13): 2 inhibitors RNA-binding protein 3 (P98179): 2 inhibitors RNA-binding protein 39 (Q14498): 2 inhibitors RNA-binding protein EWS (Q01844): 3 inhibitors RNA-binding protein FUS (P35637): 2 inhibitors RNA-binding protein Musashi homolog 2 (Q96DH6): 1 inhibitors RNA-binding protein RO60 (P10155): 2 inhibitors RRP12-like protein (Q5JTH9): 1 inhibitors RRP15-like protein (Q9Y3B9): 1 inhibitors Rab GDP dissociation inhibitor alpha (P31150): 1 inhibitors Rab GDP dissociation inhibitor beta (P50395): 2 inhibitors Rab-like protein 3 (Q5HYI8): 2 inhibitors Rab-like protein 6 (Q3YEC7): 1 inhibitors Radixin (P35241): 1 inhibitors Raftlin (Q14699): 1 inhibitors Ragulator complex protein LAMTOR3 (Q9UHA4): 1 inhibitors Ran-specific GTPase-activating protein (P43487): 2 inhibitors Rapamycin-insensitive companion of mTOR (Q6R327): 1 inhibitors Ras GTPase-activating protein-binding protein 1 (Q13283): 1 inhibitors Ras GTPase-activating protein-binding protein 2 (Q9UN86): 1 inhibitors Ras GTPase-activating-like protein IQGAP1 (P46940): 3 inhibitors Ras association domain-containing protein 2 (P50749): 2 inhibitors Ras association domain-containing protein 5 (Q8WWW0): 2 inhibitors Ras suppressor protein 1 (Q15404): 1 inhibitors Ras-related protein Rab-10 (P61026): 2 inhibitors Ras-related protein Rab-14 (P61106): 2 inhibitors Ras-related protein Rab-1A (P62820): 1 inhibitors Ras-related protein Rab-27A (P51159): 1 inhibitors Ras-related protein Rab-35 (Q15286): 1 inhibitors Ras-related protein Rab-39A (Q14964): 1 inhibitors Ras-related protein Rab-5B (P61020): 2 inhibitors Ras-related protein Rab-5C (P51148): 2 inhibitors Ras-related protein Rab-8A (P61006): 2 inhibitors Ras-related protein Ral-A (P11233): 1 inhibitors Ras-related protein Rap-2c (Q9Y3L5): 1 inhibitors Receptor activity-modifying protein 3 (Q9JJ73): 17 inhibitors Receptor for retinol uptake STRA6 (Q9BX79): 1 inhibitors Recombining binding protein suppressor of hairless (Q06330): 1 inhibitors Regulation of nuclear pre-mRNA domain-containing protein 2 (Q5VT52): 1 inhibitors Regulator of chromosome condensation (P18754): 1 inhibitors Regulator of nonsense transcripts 1 (Q92900): 1 inhibitors Replicase polyprotein 1a [P3395H] (P0DTC1[P3395H]): 3 inhibitors Replicase polyprotein 1ab [E3429V] (P0DTD1[E3429V]): 3 inhibitors Replication factor C subunit 1 (P35251): 2 inhibitors Replication factor C subunit 2 (P35250): 1 inhibitors Replication factor C subunit 3 (P40938): 3 inhibitors Replication factor C subunit 4 (P35249): 2 inhibitors Replication factor C subunit 5 (P40937): 2 inhibitors Replication protein A 14 kDa subunit (P35244): 1 inhibitors Replication termination factor 2 (Q9BY42): 1 inhibitors Reticulocalbin-1 (Q15293): 1 inhibitors Reticulon-3 (O95197): 2 inhibitors Retinoblastoma-binding protein 5 (Q15291): 2 inhibitors Retinol-binding protein 1 (P09455): 7 inhibitors Rho GDP-dissociation inhibitor 1 (P52565): 1 inhibitors Rho GDP-dissociation inhibitor 2 (P52566): 2 inhibitors Rho guanine nucleotide exchange factor 2 (Q92974): 3 inhibitors Rho guanine nucleotide exchange factor 6 (Q15052): 1 inhibitors Rhox homeobox family member 2 (Q9BQY4): 1 inhibitors Ribonuclease P protein subunit p30 (P78346): 1 inhibitors Ribonucleases P/MRP protein subunit POP1 (Q99575): 1 inhibitors Ribonucleoprotein PTB-binding 1 (Q8IY67): 1 inhibitors Ribonucleoside-diphosphate reductase large subunit/subunit M2[1-330] (P31350[1-330],P23921): 16 inhibitors Ribosomal RNA processing protein 1 homolog B (Q14684): 1 inhibitors Ribosomal biogenesis protein LAS1L (Q9Y4W2): 1 inhibitors Ribosomal protein eS27-like (Q71UM5): 2 inhibitors Ribosome biogenesis protein BRX1 homolog (Q8TDN6): 1 inhibitors Ribosome biogenesis protein WDR12 (Q9GZL7): 1 inhibitors Ribosome biogenesis regulatory protein homolog (Q15050): 1 inhibitors Ribosome maturation protein SBDS (Q9Y3A5): 1 inhibitors Ribosome-binding protein 1 (Q9P2E9): 2 inhibitors Rootletin (Q5TZA2): 1 inhibitors SAM domain-containing protein SAMSN-1 (Q9NSI8): 1 inhibitors SAP domain-containing ribonucleoprotein (P82979): 1 inhibitors SAP30-binding protein (Q9UHR5): 1 inhibitors SEC23-interacting protein (Q9Y6Y8): 1 inhibitors SERPINE1 mRNA-binding protein 1 (Q8NC51): 2 inhibitors SNW domain-containing protein 1 (Q13573): 1 inhibitors SPATS2-like protein (Q9NUQ6): 1 inhibitors SRA stem-loop-interacting RNA-binding protein, mitochondrial (Q9GZT3): 1 inhibitors SS18-like protein 2 (Q9UHA2): 1 inhibitors STE20-related kinase adapter protein alpha (Q7RTN6): 1 inhibitors STE20-related kinase adapter protein beta (Q9C0K7): 1 inhibitors STING ER exit protein (Q9H5V9): 1 inhibitors SUN domain-containing protein 2 (Q9UH99): 2 inhibitors SWI/SNF complex subunit SMARCC1 (Q92922): 2 inhibitors SWI/SNF complex subunit SMARCC2 (Q8TAQ2): 2 inhibitors SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 1 (P28370): 1 inhibitors SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 (O60264): 1 inhibitors SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (Q12824): 2 inhibitors SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1 (Q96GM5): 1 inhibitors SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 2 (Q92925): 1 inhibitors SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1 (Q969G3): 1 inhibitors Schlafen family member 11 (Q7Z7L1): 1 inhibitors Sclerostin (Q9BQB4): 9 inhibitors Sec1 family domain-containing protein 1 (Q8WVM8): 1 inhibitors Secretory carrier-associated membrane protein 2 (O15127): 1 inhibitors Secretory carrier-associated membrane protein 3 (O14828): 2 inhibitors Secretory phospholipase A2 receptor (Q13018): 1 inhibitors Selenocysteine lyase (Q96I15): 1 inhibitors Septin-2 (Q15019): 1 inhibitors Septin-6 (Q14141): 1 inhibitors Septin-7 (Q16181): 2 inhibitors Septin-8 (Q92599): 1 inhibitors Septin-9 (Q9UHD8): 2 inhibitors Serine hydrolase BPHL (Q86WA6): 1 inhibitors Serine palmitoyltransferase 3 (Q9NUV7): 3 inhibitors Serine palmitoyltransferase small subunit B (Q8NFR3): 1 inhibitors Serine-threonine kinase receptor-associated protein (Q9Y3F4): 2 inhibitors Serine/arginine repetitive matrix protein 1 (Q8IYB3): 1 inhibitors Serine/arginine repetitive matrix protein 2 (Q9UQ35): 1 inhibitors Serine/arginine-rich splicing factor 1 (Q07955): 3 inhibitors Serine/arginine-rich splicing factor 2 (Q01130): 3 inhibitors Serine/arginine-rich splicing factor 3 (P84103): 3 inhibitors Serine/arginine-rich splicing factor 7 (Q16629): 3 inhibitors Serine/arginine-rich splicing factor 9 (Q13242): 1 inhibitors Serine/threonine-protein kinase LMTK2 (Q8IWU2): 1 inhibitors Serine/threonine-protein kinase/endoribonuclease IRE 1 [547-977,D688N] (O754609[547-977,D688N]): 279 inhibitors Serine/threonine-protein phosphatase 1 regulatory subunit 10 (Q96QC0): 1 inhibitors Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform (Q14738): 1 inhibitors Serine/threonine-protein phosphatase 4 regulatory subunit 3A (Q6IN85): 1 inhibitors Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit C (Q8NB46): 1 inhibitors Serine/threonine-protein phosphatase 6 regulatory subunit 1 (Q9UPN7): 2 inhibitors Serine/threonine-protein phosphatase 6 regulatory subunit 3 (Q5H9R7): 1 inhibitors Serine/threonine-protein phosphatase PGAM5, mitochondrial (Q96HS1): 2 inhibitors Serine/threonine-protein phosphatase PP1-beta catalytic subunit (P62140): 1 inhibitors Serpin B10 (P48595): 1 inhibitors Serpin B12 (Q96P63): 1 inhibitors Serpin B6 (P35237): 1 inhibitors Serpin B8 (P50452): 1 inhibitors Serrate RNA effector molecule homolog (Q9BXP5): 2 inhibitors Sideroflexin-1 (Q9H9B4): 2 inhibitors Sideroflexin-3 (Q9BWM7): 1 inhibitors Signal peptidase complex catalytic subunit SEC11A (P67812): 3 inhibitors Signal peptidase complex subunit 2 (Q15005): 2 inhibitors Signal peptidase complex subunit 3 (P61009): 1 inhibitors Signal peptide peptidase (Q8TCT9): 2 inhibitors Signal recognition particle 14 kDa protein (P37108): 3 inhibitors Signal recognition particle 19 kDa protein (P09132): 1 inhibitors Signal recognition particle 9 kDa protein (P49458): 3 inhibitors Signal recognition particle receptor subunit alpha (P08240): 1 inhibitors Signal recognition particle receptor subunit beta (Q9Y5M8): 1 inhibitors Signal recognition particle subunit SRP54 (P61011): 1 inhibitors Signal recognition particle subunit SRP68 (Q9UHB9): 2 inhibitors Signal recognition particle subunit SRP72 (O76094): 3 inhibitors Sin3 histone deacetylase corepressor complex component SDS3 (Q9H7L9): 1 inhibitors Single-stranded DNA-binding protein, mitochondrial (Q04837): 2 inhibitors Sister chromatid cohesion protein PDS5 homolog A (Q29RF7): 3 inhibitors Sister chromatid cohesion protein PDS5 homolog B (Q9NTI5): 1 inhibitors Small glutamine-rich tetratricopeptide repeat-containing protein alpha (O43765): 4 inhibitors Small nuclear ribonucleoprotein E (P62304): 1 inhibitors Small nuclear ribonucleoprotein F (P62306): 1 inhibitors Small nuclear ribonucleoprotein Sm D1 (P62314): 1 inhibitors Small nuclear ribonucleoprotein Sm D2 (P62316): 3 inhibitors Small nuclear ribonucleoprotein Sm D3 (P62318): 1 inhibitors Small ribosomal subunit protein RACK1 (P63244): 1 inhibitors Small ribosomal subunit protein bS1m (Q9Y2Q9): 1 inhibitors Small ribosomal subunit protein eS1 (P61247): 2 inhibitors Small ribosomal subunit protein eS10 (P46783): 3 inhibitors Small ribosomal subunit protein eS12 (P25398): 2 inhibitors Small ribosomal subunit protein eS17 (P08708): 2 inhibitors Small ribosomal subunit protein eS19 (P39019): 3 inhibitors Small ribosomal subunit protein eS21 (P63220): 2 inhibitors Small ribosomal subunit protein eS24 (P62847): 2 inhibitors Small ribosomal subunit protein eS25 (P62851): 2 inhibitors Small ribosomal subunit protein eS28 (P62857): 2 inhibitors Small ribosomal subunit protein eS4, X isoform (P62701): 3 inhibitors Small ribosomal subunit protein eS6 (P62753): 3 inhibitors Small ribosomal subunit protein eS7 (P62081): 3 inhibitors Small ribosomal subunit protein eS8 (P62241): 2 inhibitors Small ribosomal subunit protein mS22 (P82650): 1 inhibitors Small ribosomal subunit protein mS23 (Q9Y3D9): 2 inhibitors Small ribosomal subunit protein mS27 (Q92552): 2 inhibitors Small ribosomal subunit protein mS29 (P51398): 1 inhibitors Small ribosomal subunit protein mS34 (P82930): 1 inhibitors Small ribosomal subunit protein mS35 (P82673): 1 inhibitors Small ribosomal subunit protein mS39 (Q96EY7): 1 inhibitors Small ribosomal subunit protein mS40 (Q9Y676): 1 inhibitors Small ribosomal subunit protein uS10 (P60866): 2 inhibitors Small ribosomal subunit protein uS11 (P62263): 1 inhibitors Small ribosomal subunit protein uS12 (P62266): 2 inhibitors Small ribosomal subunit protein uS13 (P62269): 2 inhibitors Small ribosomal subunit protein uS14 (P62273): 3 inhibitors Small ribosomal subunit protein uS15 (P62277): 3 inhibitors Small ribosomal subunit protein uS17 (P62280): 2 inhibitors Small ribosomal subunit protein uS17m (Q9Y2R5): 2 inhibitors Small ribosomal subunit protein uS19 (P62841): 2 inhibitors Small ribosomal subunit protein uS2m (Q9Y399): 1 inhibitors Small ribosomal subunit protein uS3 (P23396): 2 inhibitors Small ribosomal subunit protein uS3m (Q96EL2): 1 inhibitors Small ribosomal subunit protein uS4 (P46781): 2 inhibitors Small ribosomal subunit protein uS5 (P15880): 2 inhibitors Small ribosomal subunit protein uS7 (P46782): 3 inhibitors Small ribosomal subunit protein uS7m (Q9Y2R9): 2 inhibitors Small ribosomal subunit protein uS8 (P62244): 3 inhibitors Small ribosomal subunit protein uS9 (P62249): 3 inhibitors Small ribosomal subunit protein uS9m (P82933): 1 inhibitors Small subunit processome component 20 homolog (O75691): 2 inhibitors Small ubiquitin-related modifier 2 (P61956): 1 inhibitors Sodium-coupled neutral amino acid transporter 7 (Q9NVC3): 1 inhibitors Sodium-dependent multivitamin transporter (Q9Y289): 1 inhibitors Sodium/potassium-transporting ATPase subunit beta-1 (P05026): 2 inhibitors Sodium/potassium-transporting ATPase subunit beta-3 (P54709): 1 inhibitors Solute carrier family 25 member 3 (Q00325): 2 inhibitors Solute carrier family 35 member E1 (Q96K37): 2 inhibitors Solute carrier family 67 member A1 (Q96BI1): 1 inhibitors Sorbin and SH3 domain-containing protein 1 (Q9BX66): 1 inhibitors Sorcin (P30626): 1 inhibitors Sorting and assembly machinery component 50 homolog (Q9Y512): 2 inhibitors Sorting nexin-1 (Q13596): 1 inhibitors Sorting nexin-2 (O60749): 1 inhibitors Sorting nexin-3 (O60493): 1 inhibitors Sorting nexin-9 (Q9Y5X1): 1 inhibitors Spatacsin (Q96JI7): 1 inhibitors Spectrin alpha chain, non-erythrocytic 1 (Q13813): 3 inhibitors Spectrin beta chain, non-erythrocytic 1 (Q01082): 3 inhibitors Sperm-associated antigen 5 (Q96R06): 1 inhibitors Sphingomyelin phosphodiesterase 4 (Q9NXE4): 1 inhibitors Spliceosome RNA helicase DDX39B (Q13838): 2 inhibitors Spliceosome associated factor 3, U4/U6 recycling protein (Q15020): 1 inhibitors Spliceosome-associated protein CWC15 homolog (Q9P013): 1 inhibitors Spliceosome-associated protein CWC27 homolog (Q6UX04): 1 inhibitors Splicing factor 1 (Q15637): 2 inhibitors Splicing factor 3A subunit 1 (Q15459): 1 inhibitors Splicing factor 3A subunit 2 (Q15428): 1 inhibitors Splicing factor 3A subunit 3 (Q12874): 2 inhibitors Splicing factor 3B subunit 1 (O75533): 3 inhibitors Splicing factor 3B subunit 2 (Q13435): 2 inhibitors Splicing factor 3B subunit 4 (Q15427): 1 inhibitors Splicing factor 3B subunit 5 (Q9BWJ5): 1 inhibitors Splicing factor 3B subunit 6 (Q9Y3B4): 1 inhibitors Splicing factor U2AF 35 kDa subunit (Q01081): 3 inhibitors Splicing factor U2AF 65 kDa subunit (P26368): 2 inhibitors Splicing factor, proline- and glutamine-rich (P23246): 3 inhibitors Src substrate cortactin (Q14247): 2 inhibitors Stalled ribosome sensor GCN1 (Q92616): 3 inhibitors Staphylococcal nuclease domain-containing protein 1 (Q7KZF4): 2 inhibitors Stathmin (P16949): 2 inhibitors Stathmin-2 (Q93045): 2 inhibitors Sterol 24-C-methyltransferase (O74198): 2 inhibitors Stomatin (P27105): 1 inhibitors Stomatin-like protein 2, mitochondrial (Q9UJZ1): 2 inhibitors Stress-induced-phosphoprotein 1 (P31948): 5 inhibitors Structural maintenance of chromosomes flexible hinge domain-containing protein 1 (A6NHR9): 1 inhibitors Structural maintenance of chromosomes protein 1A (Q14683): 2 inhibitors Structural maintenance of chromosomes protein 2 (O95347): 2 inhibitors Structural maintenance of chromosomes protein 3 (Q9UQE7): 3 inhibitors Structural maintenance of chromosomes protein 4 (Q9NTJ3): 3 inhibitors Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial (Q9P2R7): 2 inhibitors Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial (P53597): 2 inhibitors Succinate--CoA ligase [GDP-forming] subunit beta, mitochondrial (Q96I99): 1 inhibitors Superkiller complex protein 3 (Q6PGP7): 1 inhibitors Superkiller complex protein 8 (Q9GZS3): 1 inhibitors Surfeit locus protein 4 (O15260): 3 inhibitors Survival of motor neuron-related-splicing factor 30 (O75940): 1 inhibitors Symplekin (Q92797): 2 inhibitors Synaptogyrin-2 (O43760): 2 inhibitors Synaptophysin-like protein 1 (Q16563): 2 inhibitors Synaptosomal-associated protein 23 (O00161): 2 inhibitors Synaptosomal-associated protein 29 (O95721): 1 inhibitors Syndecan-1 (P18827): 2 inhibitors Syndecan-4 (P31431): 1 inhibitors Syntaxin-18 (Q9P2W9): 1 inhibitors Syntaxin-binding protein 1 (P61764): 1 inhibitors T-complex protein 1 subunit alpha (P17987): 3 inhibitors T-complex protein 1 subunit beta (P78371): 3 inhibitors T-complex protein 1 subunit delta (P50991): 3 inhibitors T-complex protein 1 subunit epsilon (P48643): 2 inhibitors T-complex protein 1 subunit eta (Q99832): 3 inhibitors T-complex protein 1 subunit gamma (P49368): 2 inhibitors T-complex protein 1 subunit theta (P50990): 2 inhibitors T-complex protein 1 subunit zeta (P40227): 2 inhibitors TANK-binding kinase 1-binding protein 1 (A7MCY6): 2 inhibitors TATA box-binding protein-associated factor RNA polymerase I subunit B (Q53T94): 1 inhibitors TATA-binding protein-associated factor 2N (Q92804): 1 inhibitors TBC1 domain family member 15 (Q8TC07): 2 inhibitors TBC1 domain family member 5 (Q92609): 2 inhibitors TELO2-interacting protein 1 homolog (O43156): 2 inhibitors TELO2-interacting protein 2 (Q6NXR4): 1 inhibitors THO complex subunit 2 (Q8NI27): 2 inhibitors THO complex subunit 4 (Q86V81): 3 inhibitors THUMP domain-containing protein 1 (Q9NXG2): 2 inhibitors TIP41-like protein (O75663): 1 inhibitors TNF receptor-associated factor 2 (Q12933): 2 inhibitors TOX high mobility group box family member 4 (O94842): 1 inhibitors TRAF family member-associated NF-kappa-B activator (Q92844): 2 inhibitors TRAF-type zinc finger domain-containing protein 1 (O14545): 1 inhibitors TRAP220 (Q15648): 1 inhibitors Talin-1 (Q9Y490): 1 inhibitors Target of EGR1 protein 1 (Q96GM8): 1 inhibitors Tektin-1 (Q969V4): 1 inhibitors Telomere length regulation protein TEL2 homolog (Q9Y4R8): 2 inhibitors Telomere repeats-binding bouquet formation protein 1 (Q8NA31): 1 inhibitors Telomere-associated protein RIF1 (Q5UIP0): 2 inhibitors Tensin-4 (Q8IZW8): 1 inhibitors Terminal nucleotidyltransferase 4A (Q5XG87): 1 inhibitors Terminal nucleotidyltransferase 4B (Q8NDF8): 1 inhibitors Testin (Q9UGI8): 1 inhibitors Testis-expressed protein 10 (Q9NXF1): 1 inhibitors Testis-expressed protein 13A (Q9BXU3): 1 inhibitors Testis-expressed protein 264 (Q9Y6I9): 4 inhibitors Tetratricopeptide repeat protein 14 (Q96N46): 2 inhibitors Thimet oligopeptidase (P52888): 1 inhibitors Thiol S-methyltransferase TMT1A (Q9H8H3): 2 inhibitors Thioredoxin domain-containing protein 17 (Q9BRA2): 1 inhibitors Thioredoxin-dependent peroxide reductase, mitochondrial (P30048): 3 inhibitors Thioredoxin-like protein 1 (O43396): 1 inhibitors Thioredoxin-related transmembrane protein 1 (Q9H3N1): 2 inhibitors Threonine--tRNA ligase, mitochondrial (Q9BW92): 1 inhibitors Thymic stromal lymphopoietin (Q969D9): 52 inhibitors Thymosin beta-10 (P63313): 1 inhibitors Thymosin beta-4 (P62328): 1 inhibitors Thyroid hormone receptor-associated protein 3 (Q9Y2W1): 2 inhibitors Tissue factor pathway inhibitor 2 (P48307): 31 inhibitors Titin (Q8WZ42): 2 inhibitors Torsin-1A-interacting protein 1 (Q5JTV8): 1 inhibitors Trans-Golgi network integral membrane protein 2 (O43493): 1 inhibitors Transaldolase (P37837): 2 inhibitors Transcription and mRNA export factor ENY2 (Q9NPA8): 1 inhibitors Transcription elongation factor A protein 1 (P23193): 1 inhibitors Transcription elongation regulator 1 (O14776): 3 inhibitors Transcription factor 12 (Q99081): 1 inhibitors Transcription factor A, mitochondrial (Q00059): 2 inhibitors Transcription factor BTF3 (P20290): 1 inhibitors Transcription factor EB (P19484): 1 inhibitors Transcription initiation factor IIE subunit beta (P29084): 1 inhibitors Transcription initiation factor TFIID subunit 5 (Q15542): 1 inhibitors Transcription initiation factor TFIID subunit 9 (Q16594): 1 inhibitors Transcription intermediary factor 1-beta (Q13263): 3 inhibitors Transcriptional regulator protein Pur-beta (Q96QR8): 2 inhibitors Transcriptional repressor CTCF (P49711): 1 inhibitors Transcriptional repressor p66-alpha (Q86YP4): 3 inhibitors Transcriptional repressor p66-beta (Q8WXI9): 2 inhibitors Transducin beta-like protein 2 (Q9Y4P3): 1 inhibitors Transducin beta-like protein 3 (Q12788): 1 inhibitors Transferrin receptor protein 1 (P02786): 2 inhibitors Transformation/transcription domain-associated protein (Q9Y4A5): 1 inhibitors Transformer-2 protein homolog beta (P62995): 3 inhibitors Transgelin-2 (P37802): 2 inhibitors Translation initiation factor eIF2B subunit alpha (Q14232): 1 inhibitors Translation initiation factor eIF2B subunit beta (P49770): 1 inhibitors Translation initiation factor eIF2B subunit delta (Q9UI10): 2 inhibitors Translation initiation factor eIF2B subunit epsilon (Q13144): 2 inhibitors Translation initiation factor eIF2B subunit gamma (Q9NR50): 3 inhibitors Translationally-controlled tumor protein (P13693): 1 inhibitors Translin (Q15631): 2 inhibitors Translocating chain-associated membrane protein 1 (Q15629): 1 inhibitors Translocation protein SEC62 (Q99442): 1 inhibitors Translocation protein SEC63 homolog (Q9UGP8): 2 inhibitors Translocon-associated protein subunit alpha (P43307): 3 inhibitors Translocon-associated protein subunit delta (P51571): 1 inhibitors Translocon-associated protein subunit gamma (Q9UNL2): 2 inhibitors Transmembrane 9 superfamily member 2 (Q99805): 1 inhibitors Transmembrane 9 superfamily member 3 (Q9HD45): 2 inhibitors Transmembrane 9 superfamily member 4 (Q92544): 2 inhibitors Transmembrane emp24 domain-containing protein 10 (P49755): 1 inhibitors Transmembrane emp24 domain-containing protein 2 (Q15363): 1 inhibitors Transmembrane emp24 domain-containing protein 7 (Q9Y3B3): 1 inhibitors Transmembrane emp24 domain-containing protein 9 (Q9BVK6): 2 inhibitors Transmembrane protein 120A (Q9BXJ8): 1 inhibitors Transmembrane protein 126A (Q9H061): 1 inhibitors Transmembrane protein 14C (Q9P0S9): 1 inhibitors Transmembrane protein 161A (Q9NX61): 2 inhibitors Transmembrane protein 164 (Q5U3C3): 1 inhibitors Transmembrane protein 205 (Q6UW68): 1 inhibitors Transmembrane protein 33 (P57088): 3 inhibitors Transmembrane protein 41B (Q5BJD5): 1 inhibitors Transmembrane protein 43 (Q9BTV4): 2 inhibitors Transmembrane protein 70, mitochondrial (Q9BUB7): 1 inhibitors Transmembrane protein 94 (Q12767): 1 inhibitors Transport and Golgi organization protein 1 homolog (Q5JRA6): 2 inhibitors Transportin-1 (Q92973): 3 inhibitors Transportin-3 (Q9Y5L0): 2 inhibitors Treacle protein (Q13428): 2 inhibitors Trifunctional enzyme subunit alpha, mitochondrial (P40939): 2 inhibitors Trifunctional enzyme subunit beta, mitochondrial (P55084): 2 inhibitors Triokinase/FMN cyclase (Q3LXA3): 1 inhibitors Tripartite motif-containing protein 59 (Q8IWR1): 1 inhibitors Tripeptidyl-peptidase 1 (O14773): 2 inhibitors Tropomyosin alpha-3 chain (P06753): 3 inhibitors Tropomyosin alpha-4 chain (P67936): 1 inhibitors Tryptophan--tRNA ligase, cytoplasmic (P23381): 2 inhibitors Tubulin alpha-1B chain (P68363): 2 inhibitors Tubulin alpha-1C chain (Q9BQE3): 2 inhibitors Tubulin alpha-4A chain (P68366): 2 inhibitors Tubulin beta-4A chain (P04350): 1 inhibitors Tubulin beta-6 chain (Q9BUF5): 2 inhibitors Tubulin beta-8 chain (Q3ZCM7): 1 inhibitors Tubulin--tyrosine ligase-like protein 12 (Q14166): 1 inhibitors Tubulin-folding cofactor B (Q99426): 1 inhibitors Tubulin-specific chaperone A (O75347): 1 inhibitors Tubulin-specific chaperone D (Q9BTW9): 2 inhibitors Tudor-interacting repair regulator protein (Q9BRJ7): 1 inhibitors Tuftelin-interacting protein 11 (Q9UBB9): 1 inhibitors Tumor protein D54 (O43399): 1 inhibitors Twinfilin-2 (Q6IBS0): 1 inhibitors U1 small nuclear ribonucleoprotein 70 kDa (P08621): 1 inhibitors U1 small nuclear ribonucleoprotein A (P09012): 1 inhibitors U2 snRNP-associated SURP motif-containing protein (O15042): 3 inhibitors U3 small nucleolar RNA-associated protein 18 homolog (Q9Y5J1): 1 inhibitors U4/U6 small nuclear ribonucleoprotein Prp3 (O43395): 1 inhibitors U4/U6 small nuclear ribonucleoprotein Prp31 (Q8WWY3): 1 inhibitors U6 snRNA-associated Sm-like protein LSm8 (O95777): 1 inhibitors UBX domain-containing protein 1 (Q04323): 2 inhibitors UBX domain-containing protein 4 (Q92575): 1 inhibitors UDP-glucose:glycoprotein glucosyltransferase 1 (Q9NYU2): 3 inhibitors UTP--glucose-1-phosphate uridylyltransferase (Q16851): 1 inhibitors UV excision repair protein RAD23 homolog B (P54727): 2 inhibitors Ubiquilin-1 (Q9UMX0): 1 inhibitors Ubiquilin-2 (Q9UHD9): 1 inhibitors Ubiquitin conjugation factor E4 A (Q14139): 1 inhibitors Ubiquitin-associated and SH3 domain-containing protein B (Q8TF42): 2 inhibitors Ubiquitin-associated protein 2 (Q5T6F2): 2 inhibitors Ubiquitin-associated protein 2-like (Q14157): 3 inhibitors Ubiquitin-conjugating enzyme E2 G2 (P60604): 1 inhibitors Ubiquitin-conjugating enzyme E2 L3 (P68036): 2 inhibitors Ubiquitin-conjugating enzyme E2 variant 1 (Q13404): 1 inhibitors Ubiquitin-fold modifier 1 (P61960): 1 inhibitors Ubiquitin-like FUBI-ribosomal protein eS30 fusion protein (P62861): 2 inhibitors Ubiquitin-protein ligase E3A (Q05086): 1 inhibitors Ubiquitin-protein ligase E3C (Q15386): 2 inhibitors Ubiquitin-ribosomal protein eS31 fusion protein (P62979): 1 inhibitors Ubiquitin/ISG15-conjugating enzyme E2 L6 (O14933): 1 inhibitors Uncharacterized aarF domain-containing protein kinase 5 (Q3MIX3): 1 inhibitors Uncharacterized protein C18orf63 (Q68DL7): 1 inhibitors Uncharacterized protein FLJ45252 (Q6ZSR9): 2 inhibitors Unconventional myosin-If (O00160): 2 inhibitors Unconventional myosin-Ig (B0I1T2): 2 inhibitors Unhealthy ribosome biogenesis protein 2 homolog (Q14146): 2 inhibitors Uroporphyrinogen decarboxylase (P06132): 1 inhibitors Uveal autoantigen with coiled-coil domains and ankyrin repeats (Q9BZF9): 1 inhibitors V-type proton ATPase 16 kDa proteolipid subunit c (P27449): 1 inhibitors V-type proton ATPase catalytic subunit A (P38606): 1 inhibitors V-type proton ATPase subunit E 1 (P36543): 1 inhibitors V-type proton ATPase subunit G 1 (O75348): 2 inhibitors V-type proton ATPase subunit H (Q9UI12): 2 inhibitors Vacuolar ATPase assembly integral membrane protein VMA21 (Q3ZAQ7): 1 inhibitors Vacuolar protein sorting-associated protein 26A (O75436): 1 inhibitors Vacuolar protein sorting-associated protein 26B (Q4G0F5): 1 inhibitors Vacuolar protein sorting-associated protein 28 homolog (Q9UK41): 1 inhibitors Vacuolar protein sorting-associated protein 51 homolog (Q9UID3): 1 inhibitors Vacuole membrane protein 1 (Q96GC9): 2 inhibitors Vasodilator-stimulated phosphoprotein (P50552): 1 inhibitors Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (P49748): 2 inhibitors Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 2 (Q6Y1H2): 1 inhibitors Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 (Q9P035): 2 inhibitors Very-long-chain 3-oxoacyl-CoA reductase (Q53GQ0): 3 inhibitors Very-long-chain enoyl-CoA reductase (Q9NZ01): 3 inhibitors Vesicle transport protein GOT1B (Q9Y3E0): 1 inhibitors Vesicle transport protein USE1 (Q9NZ43): 1 inhibitors Vesicle-associated membrane protein 7 (P51809): 1 inhibitors Vesicle-associated membrane protein 8 (Q9BV40): 2 inhibitors Vesicle-associated membrane protein-associated protein A (Q9P0L0): 1 inhibitors Vesicle-associated membrane protein-associated protein B/C (O95292): 1 inhibitors Vesicle-trafficking protein SEC22b (O75396): 2 inhibitors Vesicular integral-membrane protein VIP36 (Q12907): 1 inhibitors Vigilin (Q00341): 1 inhibitors Villin-1 (P09327): 1 inhibitors Vinculin (P18206): 2 inhibitors Voltage-gated hydrogen channel 1 (Q96D96): 1 inhibitors Voltage-gated monoatomic cation channel TMEM109 (Q9BVC6): 2 inhibitors WASH complex subunit 4 (Q2M389): 1 inhibitors WASH complex subunit 5 (Q12768): 2 inhibitors WD repeat-containing protein 1 (O75083): 2 inhibitors WD repeat-containing protein 26 (Q9H7D7): 1 inhibitors WD repeat-containing protein 3 (Q9UNX4): 1 inhibitors WD repeat-containing protein 36 (Q8NI36): 1 inhibitors WD repeat-containing protein 82 (Q6UXN9): 2 inhibitors WW domain-binding protein 2 (Q969T9): 1 inhibitors Wings apart-like protein homolog (Q7Z5K2): 1 inhibitors Wolframin (O76024): 2 inhibitors X-ray repair cross-complementing protein 5 (P13010): 3 inhibitors X-ray repair cross-complementing protein 6 (P12956): 2 inhibitors Xaa-Arg dipeptidase (Q8IYS1): 1 inhibitors Y-box-binding protein 1 (P67809): 1 inhibitors Y-box-binding protein 3 (P16989): 1 inhibitors Zinc finger BED domain-containing protein 4 (O75132): 1 inhibitors Zinc finger C3HC-type protein 1 (Q86WB0): 1 inhibitors Zinc finger CCCH domain-containing protein 11A (O75152): 2 inhibitors Zinc finger CCCH domain-containing protein 18 (Q86VM9): 2 inhibitors Zinc finger CCCH-type antiviral protein 1 (Q7Z2W4): 2 inhibitors Zinc finger CCCH-type antiviral protein 1-like (Q96H79): 1 inhibitors Zinc finger CCHC domain-containing protein 8 (Q6NZY4): 1 inhibitors Zinc finger RNA-binding protein (Q96KR1): 1 inhibitors Zinc finger Ran-binding domain-containing protein 2 (O95218): 1 inhibitors Zinc finger X-chromosomal protein (P17010): 1 inhibitors Zinc finger protein 277 (Q9NRM2): 1 inhibitors Zinc finger protein 3 homolog (Q96NJ6): 1 inhibitors Zinc finger protein 618 (Q5T7W0): 1 inhibitors Zinc finger protein 787 (Q6DD87): 1 inhibitors Zinc finger protein Gfi-1 (Q99684): 1 inhibitors Zinc finger protein RFP (P14373): 1 inhibitors Zinc finger protein with KRAB and SCAN domains 2 (Q63HK3): 1 inhibitors Zinc transporter 6 (Q6NXT4): 1 inhibitors Zinc transporter 7 (Q8NEW0): 1 inhibitors Zinc transporter SLC39A7 (Q92504): 1 inhibitors Zinc transporter ZIP11 (Q8N1S5): 1 inhibitors Zinc transporter ZIP3 (Q9BRY0): 1 inhibitors Zona pellucida sperm-binding protein 1 (P60852): 2 inhibitors Zyxin (Q15942): 1 inhibitors c-Myc-binding protein (Q99417): 1 inhibitors eIF5-mimic protein 1 (Q9Y6E2): 1 inhibitors eIF5-mimic protein 2 (Q7L1Q6): 3 inhibitors kras g13d (P01116[G13D]): 608 inhibitors mRNA export factor RAE1 (P78406): 1 inhibitors mRNA turnover protein 4 homolog (Q9UKD2): 2 inhibitors mRNA-capping enzyme (O60942): 1 inhibitors rRNA methyltransferase 1, mitochondrial (Q6IN84): 1 inhibitors ribose-5-phosphate isomerase (Q8RU73): 7 inhibitors snRNA-activating protein complex subunit 4 (Q5SXM2): 1 inhibitors tRNA (cytosine(34)-C(5))-methyltransferase, mitochondrial (Q9H649): 1 inhibitors tRNA (guanine(26)-N(2))-dimethyltransferase (Q9NXH9): 1 inhibitors tRNA (guanine(27)-N(2))-dimethyltransferase (Q7Z2T5): 1 inhibitors tRNA N6-adenosine threonylcarbamoyltransferase (Q9NPF4): 2 inhibitors Number of new Entries: 1539 PubMed id or Patent id Title 10082200 Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor. 11259469 Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. 11706399 CI-1033, a pan-erbB tyrosine kinase inhibitor. 12193066 Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. 12384534 ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. 12403772 BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. 12432547 In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). 12719470 Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. 14500382 A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. 14613028 CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. 15050915 In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. 15173008 Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. 15323564 Selective Itk inhibitors block T-cell activation and murine lung inflammation. 15930265 In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. 16103100 The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. 16622124 Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. 16707462 Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. 16982756 KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. 17026809 Aurora kinase inhibitors: a new class of targeted drugs in cancer. 17145850 Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. 17267659 In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. 17291758 BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. 17291761 The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. 17495131 AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. 17575152 Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. 17575233 AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. 17942920 Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. 18089823 PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. 18188180 A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. 18256683 A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. 18408761 BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. 18723486 Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. 18790776 AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. 18973168 Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors. 19169685 SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. 19244237 Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design. 19284385 Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. 19295546 CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. 19383820 Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. 19383823 BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. 19459657 Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. 19567821 GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. 19690138 Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. 19740074 Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. 19996272 BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. 20033049 Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. 20068177 Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. 20167803 Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. 20234191 PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. 20237073 A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. 20439741 Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. 20614936 Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. 20701804 Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. 20729870 ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. 20832753 Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. 21159646 Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. 21168764 BTZO-1, a cardioprotective agent, reveals that macrophage migration inhibitory factor regulates ARE-mediated gene expression. 21363918 Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. 21402443 Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation. 21425998 Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. 21481795 Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. 21505060 Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. 2155222 KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. 21595651 In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP₂ receptor antagonist. 21691275 SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. 21789172 AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. 21964340 Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. 22084396 Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. 22198732 Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. 22319196 Species comparison and pharmacological characterization of human, monkey, rat, and mouse TRPA1 channels. 22319201 NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. 22389468 Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. 22566699 Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. 22750078 The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. 22829080 Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. 22842901 A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. 22906130 Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor. 22948716 Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. 23250418 Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. 23292653 Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. 23468529 Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. 23509247 Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. 23541634 Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects. 23614352 An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. 23935097 A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an extracellular signal-regulated kinase (ERK) inhibitor. 24006460 Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. 24102143 Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. 24171924 Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. 24239623 Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. 24419060 The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. 24553136 The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. 24900173 Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. 24919854 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. 25075558 Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). 25136132 (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. 25177796 Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. 25279926 Inhibition of demethylases by GSK-J1/J4. 25415869 Inhibitors of p21-activated kinases (PAKs). 25459880 RIP3 induces apoptosis independent of pronecrotic kinase activity. 25728001 A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). 25733882 PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. 25787766 Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. 25825497 LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2. 25915038 Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. 26013542 Role of G Protein-Coupled Receptor Kinases 2 and 3 in μ-Opioid Receptor Desensitization and Internalization. 26083237 Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. 26100443 Optimization of a novel series of N-phenylindoline-5-sulfonamide-based acyl CoA:monoacylglycerol acyltransferase-2 inhibitors: Mitigation of CYP3A4 time-dependent inhibition and phototoxic liabilities. 26147105 The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia. 26167872 Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. 26175415 A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. 26254279 Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. 26295308 The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma. 26364596 Molecular basis underlying resistance to Mps1/TTK inhibitors. 26407721 MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. 26641137 Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. 26832791 Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity. 26993378 HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity. 27071060 P21-Activated Kinase Inhibitors FRAX486 and IPA3: Inhibition of Prostate Stromal Cell Growth and Effects on Smooth Muscle Contraction in the Human Prostate. 27376689 Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition. 27535619 Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. 27552707 Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876. 27780853 The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. 27784673 Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. 27787897 Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models. 27903679 The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. 28232751 CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor. 28287083 Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. 28578312 A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. 28679043 Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target. 28719179 Inhibition of Human Class I vs Class III Phosphatidylinositol 3'-Kinases. 28741798 Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. 28813519 Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. 28953875 Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. 29051383 D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. 29065155 PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core. 29133594 Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling. 29223978 PRC2 Is Dispensable in Vivo for β-Catenin-Mediated Repression of Chondrogenesis in the Mouse Embryonic Cranial Mesenchyme. 29523590 Signaling function of PRC2 is essential for TCR-driven T cell responses. 29856759 Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. 29928781 NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. 29946150 Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. 30292171 A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress. 30413535 Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal. 30559935 Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. 30602670 Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876. 30683722 Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. 30886973 In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). 30996949 Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt. 31344028 GLUT4 expression and glucose transport in human induced pluripotent stem cell-derived cardiomyocytes. 31360115 Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers. 31400120 The MLL1 trimeric catalytic complex is a dynamic conformational ensemble stabilized by multiple weak interactions. 31434879 Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. 31482107 Are all cyclin-dependent kinases 4/6 inhibitors created equal? 31584233 Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity. 31848333 Discovery of a chemical probe for PRDM9. 31909200 A homogeneous bioluminescent immunoassay to probe cellular signaling pathway regulation. 32174193 Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening. 32477831 Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma. 33497606 Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2. 34154424 Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening. 36335744 CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. 36417820 Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy. 36787657 Recent advances on dual inhibitors targeting HIV reverse transcriptase associated polymerase and ribonuclease H. 36796299 Advances in the development of phosphodiesterase 7 inhibitors. 36857812 Discovery of novel 5-(2-hydroxyphenyl)-2-phthalide-3(3H)-pyrazolones as balanced multifunctional agents against Alzheimer's disease. 36893700 Oxazolidinone: A promising scaffold for the development of antibacterial drugs. 37209450 Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers. 37209451 Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer. 37210838 Recent advance of small-molecule drugs for clinical treatment of multiple myeloma. 37210839 Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy. 37216810 Discovery of highly potent and selective VEGFR2 kinase inhibitors for the treatment of rheumatoid arthritis. 37216812 Development of isoselenazolium chlorides as selective pyruvate kinase isoform M2 inhibitors. 37224761 Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies. 37224762 Synthesis and anti-inflammatory activity evaluation of NO-releasing furoxan/1,2,4-triazole hybrid derivatives. 37229832 Design, synthesis and biological evaluation of 4-(4-aminophenoxy)picolinamide derivatives as potential antitumor agents. 37235998 Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma. 37236000 Discovery, structural optimization, and anti-tumor bioactivity evaluations of betulinic acid derivatives as a new type of RORγ antagonists. 37244161 HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues. 37247506 Structure-affinity relationships of stereoisomers of norbenzomorphan-derived σ2R/TMEM97 modulators. 37247507 Synthesis and evaluation of piperazinotriazoles. Discovery of a potent and orally bioavailable neurokinin-3 receptor inhibitor. 37253309 Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2. 37257211 Discovery of new tetrahydroisoquinolines as potent and selective LSD1 inhibitors for the treatment of MLL-rearranged leukemia. 37257213 Molecular-level strategic goals and repressors in Leishmaniasis - Integrated data to accelerate target-based heterocyclic scaffolds. 37262997 Discovery of a high potent PIM kinase inhibitor for acute myeloid leukemia based on N-pyridinyl amide scaffold by optimizing the fragments toward to Lys67 and Asp128/Glu171. 37269667 Transient receptor potential ankyrin 1 (TRPA1) modulators: Recent update and future perspective. 37269670 Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo. 37285684 Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases. 37290182 Structure-based discovery of novel cruzain inhibitors with distinct trypanocidal activity profiles. 37295161 Identification of 5-[5-cyano-1-(pyridin-2-ylmethyl)-1H-indole-3-carboxamido] thiazole-4-carboxylic acid as a promising dual inhibitor of urate transporter 1 and xanthine oxidase. 37300915 Pharmacological activity and mechanism of pyrazines. 37302340 Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds. 37302342 Orally bioavailable styryl derivative of rohitukine-N-oxide inhibits CDK9/T1 and the growth of pancreatic cancer cells. 37307624 Elucidation of novel TRAP1-Selective inhibitors that regulate mitochondrial processes. 37315474 Discovery of 4'-trifluoromethylchalcones as novel, potent and selective hCYP1B1 inhibitors without concomitant AhR activation. 37321108 Design and synthesis of 6-arylpyridine-tethered sulfonamides as novel selective inhibitors of carbonic anhydrase IX with promising antitumor features toward the human colorectal cancer. 37321109 Development of diphenylmethylpiperazine hybrids of chloroquinoline and triazolopyrimidine using Petasis reaction as new cysteine proteases inhibitors for malaria therapeutics. 37329712 Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia. 37329713 Spiroindole-containing compounds bearing phosphonate group of potential Mpro-SARS-CoV-2 inhibitory properties. 37329714 New aryl and acylsulfonamides as state-dependent inhibitors of Nav1.3 voltage-gated sodium channel. 37336067 Exploring N-myristoyltransferase as a promising drug target against parasitic neglected tropical diseases. 37336069 Development and therapeutic potential of allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists for autoimmune diseases. 37348296 Design, synthesis and biological evaluation of 3-substituted-2-thioxothiazolidin-4-one (rhodanine) derivatives as antitubercular agents against Mycobacterium tuberculosis protein tyrosine phosphatase B. 37352796 Assessment of the structure-activity relationship and antileukemic activity of diacylpyramide compounds as human ClpP agonists. 37364511 Design, synthesis, antiviral evaluation, and In silico studies of acrylamides targeting nsP2 from Chikungunya virus. 37390508 Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation. 37390510 Design, synthesis, activity and molecular dynamics studies of 1,3,4-thiadiazole derivatives as selective allosteric inhibitors of SHP2 for the treatment of cancer. 37393789 SAR and lead optimization of (Z)-5-(4-hydroxy-3-methoxybenzylidene)-3-(2-morpholinoacetyl)thiazolidine-2,4-dione as a potential multi-target antidiabetic agent. 37393790 Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles. 37393791 Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023. 37393792 Discovery of tetrasubstituted thiophenes as Cisd2 activators: A potential novel therapeutic option in nonalcoholic fatty liver disease. 37399711 Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases. 37399712 Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy. 37402342 Purine containing carbonucleoside phosphonate analogues as novel chemotype for Plasmodium falciparum Inhibition. 37402343 The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases. 37406381 Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC. 37406382 Development of novel PEX5-PEX14 protein-protein interaction (PPI) inhibitors based on an oxopiperazine template. 37413878 Design, synthesis, and biological evaluation of novel penindolone derivatives as potential inhibitors of hemagglutinin-mediated membrane fusion. 37413879 Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists. 37413880 Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors. 37413881 Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review. 37413882 Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery. 37413883 N-aryltetrahydroisoquinoline derivatives as HA-CD44 interaction inhibitors: Design, synthesis, computational studies, and antitumor effect. 37413884 Reversal of subtype-selectivity and function by the introduction of a para-benzamidyl substituent to N-cyclopropylmethyl nornepenthone. 37421886 Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915. 37421888 Design, synthesis, and biological evaluation of a series of new anthraquinone derivatives as anti-ZIKV agents. 37421889 The role of natural anti-parasitic guided development of synthetic drugs for leishmaniasis. 37421890 Highly-tumor-targeted PAD4 inhibitors with PBA modification inhibit tumors in vivo by specifically inhibiting the PAD4-H3cit-NETs pathway in neutrophils. 37423124 Design, synthesis and evaluation of novel 1-phenyl-pyrrolo[1,2-b]isoquinolin-3-one derivatives as antagonists for the glycine binding site of the NMDA receptor. 37423125 Azaindole derivatives as potential kinase inhibitors and their SARs elucidation. 37423126 Discovery of 3-(1H-benzo[d]imidazole-2-yl)-1H-pyrazol-4 -amine derivatives as novel and potent syk inhibitors for the treatment of hematological malignancies. 37423127 Recent advances in Fragment-based strategies against tuberculosis. 37429083 Discovery of tetrahydroisoquinolineindole derivatives as first dual PRMT5 inhibitors/hnRNP E1 upregulators: Design, synthesis and biological evaluation. 37429084 Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)? 37437348 Discovery of novel thymidylate synthase (TS) inhibitors that influence cancer angiogenesis and metabolic reprogramming in NSCLC cells. 37437349 Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants. 37437350 2,4-Diaryl-pyrimido[1,2-a]benzimidazole derivatives as novel anticancer agents endowed with potent anti-leukemia activity: Synthesis, biological evaluation and kinase profiling. 37437351 An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms. 37437352 A dual nociceptin and mu opioid receptor agonist exhibited robust antinociceptive effect with decreased side effects. 37453330 Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies. 37454520 Immunosuppressive effects of new thiophene-based KV1.3 inhibitors. 37467618 Recent advance of small-molecule drugs for clinical treatment of osteoporosis: A review. 37473690 2-Substituted quinazolines: Partial agonistic and antagonistic ligands of the constitutive androstane receptor (CAR). 37478556 Coumarins as factor XIIa inhibitors: Potency and selectivity improvements using a fragment-based strategy. 37478557 Exploring the 1,3-benzoxazine chemotype for cannabinoid receptor 2 as a promising anti-cancer therapeutic. 37478559 Synthesis and antibacterial activities of baulamycin A inspired derivatives. 37478560 Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer. 37480712 Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges. 37482017 Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors. 37482018 Synthesis, cytotoxicity, antioxidant activity and molecular modeling of new NSAIDs-EBS derivatives. 37482020 Recent advances in triazoles as tyrosinase inhibitors. 37482021 Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors. 37482022 Discovery of new diaryl ether inhibitors against Mycobacterium tuberculosis targeting the minor portal of InhA. 37482023 Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: Design, synthesis, and biological assessments. 37487305 A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy. 37487307 Catechol-mimicking transition-state analogues as non-oxidizable inhibitors of tyrosinases. 37494773 Identification of Pyrido[3,4-d]pyrimidine derivatives as RIPK3-Mediated necroptosis inhibitors. 37499289 Development of novel celastrol-ligustrazine hybrids as potent peroxiredoxin 1 inhibitors against lung cancer. 37499291 Cell-active, irreversible covalent inhibitors that selectively target the catalytic lysine of EGFR by using fluorosulfate-based SuFEx chemistry. 37506545 The mystery of titan hunter: Rationalized striking of the MAPK pathway via Newly synthesized 6-Indolylpyridone-3-Carbonitrile derivatives. 37515920 Discovery of triazole-bridged aryl adamantane analogs as an intriguing class of multifunctional agents for treatment of Alzheimer's disease. 37517202 Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease. 37531744 RIPK2 inhibitors for disease therapy: Current status and perspectives. 37536208 5-Cyano substituted diarylpyridines as potent HIV-1 NNRTIs: Rational design, synthesis, and activity evaluation. 37536209 Neutral sphingomyelinase 2 inhibitors based on the pyrazolo[1,5-a]pyrimidin-3-amine scaffold. 37536210 An overview of phosphodiesterase 9 inhibitors: Insights from skeletal structure, pharmacophores, and therapeutic potential. 37542987 Current development of 1,2,3-triazole derived potential antimalarial scaffolds: Structure- activity relationship (SAR) and bioactive compounds. 37542989 Novel acridine-based LSD1 inhibitors enhance immune response in gastric cancer. 37542991 Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways. 37542993 Thiazole-based analogues as potential antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA) and their SAR elucidation. 37544183 Design, synthesis, and biological evaluation of 3, 5-disubsituted-1H-pyrazolo[3,4-b]pyridines as multiacting inhibitors against microtubule and kinases. 37544185 Targeting polyketide synthase 13 for the treatment of tuberculosis. 37556946 Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties. 37556947 Triazole hybrid compounds: A new frontier in malaria treatment. 37556948 Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer. 37562117 Structure activity relationships of 5-HT2B and 5-HT2C serotonin receptor antagonists: N6, C2 and 5'-Modified (N)-methanocarba-adenosine derivatives. 37567056 Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities. 37567057 Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy. 37567058 Synthesis, computational and experimental pharmacological studies for (thio)ether-triazine 5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer's disease. 37567059 Discovery and optimization of 2,3-diaryl-1,3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity. 37572539 Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia. 37573828 Small molecule inhibitors of NLRP3 inflammasome and GSK-3β in the management of traumatic brain injury: A review. 37573829 Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and elacridar: New potent P-gp modulators acting as MDR reversers. 37595546 Targeting autophagy with small-molecule activators for potential therapeutic purposes. 37597436 Natural products as potential lead compounds to develop new antiviral drugs over the past decade. 37597437 Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach. 37598483 Exploring positions 6 and 7 of a quinazoline-based scaffold leads to changes in selectivity and potency towards RIPK2/3 kinases. 37598484 Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19. 37607438 Hydrophobic tag-based protein degradation: Development, opportunity and challenge. 37607440 The application of PROTAC in HDAC. 37611534 Magic shotgun approach to anti-inflammatory pharmacotherapy: Synthesis of novel thienopyrimidine monomers/heterodimer as dual COX-2 and 15-LOX inhibitors endowed with potent antioxidant activity. 37619298 Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer. 37625288 SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of 4-butyl-polyhydroxybenzophenone compounds against NAFLD. 37633202 Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer. 37633203 Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur. 37639823 Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023. 37647727 Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer. 37651874 Synthesis of 1,3,5-triphenyl-1,2,4-triazole derivatives and their neuroprotection by anti-oxidative stress and anti-inflammation and protecting BBB. 37651875 Elemental exchange: Bioisosteric replacement of phosphorus by boron in drug design. 37651876 Micafungin: A promising inhibitor of UBE2M in cancer cell growth suppression. 37651878 Discovery of N-(2-oxoethyl) sulfanilamide-derived inhibitors of KAT6A (MOZ) against leukemia by an isostere strategy. 37651879 Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme. 37651880 Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs. 37657268 A review: FDA-approved fluorine-containing small molecules from 2015 to 2022. 37657271 Computational methods to analyze and predict the binding mode of inhibitors targeting both human and mushroom tyrosinase. 37657272 Hydrophobicity modulation via the substituents at positions 2 and 4 of 1,3,5-triazine to enhance therapeutic ability against Alzheimer's disease for potent serotonin 5-HT6R agents. 37657273 Synthesis of cannabidiol-based compounds as ACE2 inhibitors with potential application in the treatment of COVID-19. 37659195 Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review. 37659198 Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy. 37660484 Tetrahydro-β-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity. 37669595 MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation. 37672930 Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy. 37672931 Discovery of NLRP3 inhibitors using machine learning: Identification of a hit compound to treat NLRP3 activation-driven diseases. 37672932 Anti-influenza virus activities and mechanism of antrafenine analogs. 37678141 Discovery of novel benzofuran-based derivatives as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease: Design, synthesis, biological evaluation, molecular docking and 3D-QSAR investigation. 37678143 Discovery of a novel series of potent carbonic anhydrase inhibitors with selective affinity for μ Opioid receptor for Safer and long-lasting analgesia. 37683361 Discovery of anti-inflammatory natural flavonoids: Diverse scaffolds and promising leads for drug discovery. 37683362 Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor. 37683364 Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways. 37688938 Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D2 and D3 receptors. 37688939 Identification of 1,3,4-oxadiazolyl-containing β-carboline derivatives as novel α-glucosidase inhibitors with antidiabetic activity. 37690265 Recent advances in small molecule and peptide inhibitors of glucose-regulated protein 78 for cancer therapy. 37708796 The latest perspectives of small molecules FMS kinase inhibitors. 37708798 Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects. 37708799 Synthesis and mechanism of action of new purine derivatives against triple negative breast cancer. 37713804 Progress in the development of TRPV1 small-molecule antagonists: Novel Strategies for pain management. 37713805 Applications of oxetanes in drug discovery and medicinal chemistry. 37717380 Discovery of 1,2-diaryl-3-oxopyrazolidin-4-carboxamides as a new class of MurA enzyme inhibitors and characterization of their antibacterial activity. 37722288 Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives. 37729692 Synthesis and biological evaluation of fluoroquinolones containing a pyridoxine derivatives moiety. 37734258 Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties. 37748386 Exploring novel anticancer pyrazole benzenesulfonamides featuring tail approach strategy as carbonic anhydrase inhibitors. 37776573 Strategies for developing retinoic acid receptor alpha-selective antagonists as novel agents for male contraception. 37776574 Evaluation of novel pyrazol-4-yl pyridine derivatives possessing arylsulfonamide tethers as c-Jun N-terminal kinase (JNK) inhibitors in leukemia cells. 37778239 Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers. 37783102 Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation. 37788550 Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer. 37793326 Synthesis and clinical application of small-molecule inhibitors of Janus kinase. 37793328 Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2,4-diones: Design, synthesis and in vivo studies. 37797564 Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma. 37801824 Discovery and optimization of indirubin derivatives as novel ferroptosis inducers for the treatment of colon cancer. 37801827 Synthesis and application of small molecules approved for the treatment of lymphoma. 37804770 Development of chalcone-like derivatives and their biological and mechanistic investigations as novel influenza nuclear export inhibitors. 37826932 Exploring the structural-activity relationship of hexahydropyrazino[1,2-d]pyrido[3,2-b][1,4]oxazine derivatives as potent and orally-bioavailable PARP7 inhibitors. 37826933 Discovery of dihydropyridinone derivative as a covalent EZH2 degrader. 37826934 Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification. 37832229 Indirubin derivatives as bifunctional molecules inducing DNA damage and targeting PARP for the treatment of cancer. 37837671 Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer. 37839342 Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors. 37839344 Small molecules targeting molecular chaperones for tau regulation: Achievements and challenges. 37839347 Discovery of a novel BLT2 antagonist for the treatment of inflammatory airway diseases. 37857142 Covalent ligands of nuclear receptors. 37857145 Interleukin-1β converting enzyme (ICE): A comprehensive review on discovery and development of caspase-1 inhibitors. 37857146 ATP ion channel P2X7 receptor as a regulatory molecule in the progression of colorectal cancer. 37862815 Dual COX-2/15-LOX inhibitors: A new avenue in the prevention of cancer. 37862816 Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer. 37862818 Discovery of novel amidobenzimidazole derivatives as orally available small molecule modulators of stimulator of interferon genes for cancer immunotherapy. 37866334 Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia. 37866335 Synthetic non-toxic anti-biofilm agents as a strategy in combating bacterial resistance. 37866336 The location, physiology, pathology of hippocampus Melatonin MT2 receptor and MT2-selective modulators. 37871406 Multi-targeted anti-Alzheimer's agents: Synthesis, biological evaluation, and molecular modeling study of some pyrazolopyridine hybrids. 37871407 An updated review of chemical compounds with anti-Toxoplasma gondii activity. 37875056 Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency. 37883895 Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1. 37883896 Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reverse transcriptase. 37897926 Design, synthesis and preclinical evaluation of muscarine receptor antagonists via a scaffold-hopping approach. 37918035 Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors. 37922828 A potent and selective cis-amide inhibitor of ryanodine receptor 2 as a candidate for cardiac arrhythmia treatment. 37922829 Design and synthesis of certain 7-Aryl-2-Methyl-3-Substituted Pyrazolo{1,5-a}Pyrimidines as multikinase inhibitors. 37922830 Synthetic approaches and application of clinically approved small-molecule drugs to treat hepatitis. 37925763 Discovery of novel tumor-targeted near-infrared probes with 6-substituted pyrrolo[2,3-d]pyrimidines as targeting ligands. 37931330 Advances in nitric oxide regulators for the treatment of ischemic stroke. 37939444 Synthesis, biological evaluation and action mechanism of 7H-[1,2,4] triazolo [3,4-b] [1,3,4] thiadiazine-phenylhydrazone derivatives as α-glucosidase inhibitors. 37939861 Identification of benzothiazoles as novel PCSK9 inhibitors. 37939863 Discovery of a novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid derivative as a potent and selective heparanase-1 inhibitor utilizing an improved synthetic approach. 37939864 Design and synthesis of sirtinol analogs as human neutrophil elastase inhibitors. 37944387 Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration. 37944867 Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation. 37948954 Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer. 37948955 Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells. 37952596 Discovery of novel indole derivatives as potent and selective inhibitors of proMMP-9 activation. 37956762 Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2). 37976704 Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges. 37976705 Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors. 37976706 Synthetic product-based approach toward potential antileishmanial drug development. 37976707 Development of a specific and potent IGF2BP1 inhibitor: A promising therapeutic agent for IGF2BP1-expressing cancers. 37976708 Identification of selective 5-LOX and FLAP inhibitors as novel anti-inflammatory agents by ligand-based virtual screening. 37976710 Discovery of potent chromone-based autotaxin inhibitors inspired by cannabinoids. 37979441 5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib. 37981443 Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors. 37981444 Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection. 37984296 Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLC. 37984298 Facilitating the development of molecular glues: Opportunities from serendipity and rational design. 37984299 Discovery of triazole tethered thymol/carvacrol-coumarin hybrids as new class of α-glucosidase inhibitors with potent in vivo antihyperglycemic activities. 37989057 HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents. 37989059 Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment. 37992518 Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation. 37992521 Discovery of C-3 isoxazole substituted thiochromone S,S-dioxide derivatives as potent and selective inhibitors for monoamine oxidase B (MAO-B). 37995564 Serendipitous discovery of Class I HDAC inhibitors from rational design of molecular glue degraders targeting HDAC. 38000211 Advances in targeting Phosphodiesterase 1: From mechanisms to potential therapeutics. 38000213 Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7. 38000482 The potential of Rhein's aromatic amines for Parkinson's disease prevention and treatment: α-Synuclein aggregation inhibition and disaggregation of preformed fibers. 38007911 A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer. 38008339 Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors. 38008341 Azetidine ring, salicylic acid, and salicylic acid bioisosteres as determinants of the binding characteristics of novel potent compounds to Stat3. 38016297 Development of a new class of potent and highly selective G protein-coupled receptor kinase 5 inhibitors and structural insight from crystal structures of inhibitor complexes. 38029465 Synthesis and biological evaluation of indole derivatives containing thiazolidine-2,4-dione as α-glucosidase inhibitors with antidiabetic activity. 38029466 Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance. 38036273 Biological evaluation of indolactams for in vitro bryostatin 1-like activity. 38039787 Blood-stage antimalarial activity, favourable metabolic stability and in vivo toxicity of novel piperazine linked 7-chloroquinoline-triazole conjugates. 38039791 Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships. 38039793 Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer. 38039794 Benzothiozinone derivatives with anti-tubercular Activity-Further side chain investigation. 38043489 Exploring the potential of histone demethylase inhibition in multi-therapeutic approaches for cancer treatment. 38043490 Structure-based design of potent FABP4 inhibitors with high selectivity against FABP3. 38043491 The discovery of aryl-2-nitroethyl triamino pyrimidines as anti-Trypanosoma brucei agents. 38043492 Recent progress and applications of small molecule inhibitors of Keap1-Nrf2 axis for neurodegenerative diseases. 38043493 Discovery of 4-aminophenylacetamide derivatives as intestine-specific farnesoid X receptor antagonists for the potential treatment of nonalcoholic steatohepatitis. 38048696 Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection. 38048697 Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia. 38052155 Discovery of novel deoxyvasicinone derivatives with benzenesulfonamide substituents as multifunctional agents against Alzheimer's disease. 38056296 Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies. 38056297 Is it still worth renewing nucleoside anticancer drugs nowadays? 38056298 Targeting the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis to discover potent PDK inhibitors through structure-based virtual screening and pharmacological evaluation. 38056299 An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L. 38056300 Plant-derived strategies to fight against severe acute respiratory syndrome coronavirus 2. 38059836 Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy. 38061229 Design, synthesis and biological evaluation of biaryl amide derivatives against SARS-CoV-2 with dual-target mechanism. 38061230 Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo. 38065031 Structure-based design of SARS-CoV-2 papain-like protease inhibitors. 38070430 Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer. 38071792 Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors. 38071795 Investigating the anti-cancer potential of pyrimethamine analogues through a modern chemical biology lens. 38086189 Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment. 38086190 Small molecular CD73 inhibitors: Recent progress and future perspectives. 38091892 Design, synthesis and evaluation of novel UDCA-aminopyrimidine hybrids as ATX inhibitors for the treatment of hepatic and pulmonary fibrosis. 38096651 Novel orally bioavailable piperidine derivatives as extracellular arginase inhibitors developed by a ring expansion. 38101038 Click chemistry-aided drug discovery: A retrospective and prospective outlook. 38104378 Design, synthesis and bioactivity evaluation of novel fusion peptides and their CPT conjugates inducing effective anti-tumor responses on HER2 positive tumors. 38105611 Degradation of Polo-like Kinase 1 by the Novel Poly-Arginine N-Degron Pathway PROTAC Regulates Tumor Growth in Nonsmall Cell Lung Cancer. 38112492 Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds. 38117230 Lead Optimization of BIBR1591 To Improve Its Telomerase Inhibitory Activity: Design and Synthesis of Novel Four Chemical Series with In Silico, In Vitro, and In Vivo Preclinical Assessments. 38117239 Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl Alicyclic Amines That Improve Metabolic Stability and Retain an Atypical DAT Inhibitor Profile. 38117688 Exploiting the Carboxylate-Binding Pocket of β-Lactamase Enzymes Using a Focused DNA-Encoded Chemical Library. 38117948 Discovery of Potent and Selective Phosphatidylinositol 3-Phosphate 5-Kinase (PIKfyve) Inhibitors as Methuosis Inducers. 38117951 Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of Malignancies. 38118394 Smart glypican-3-targeting peptide-chlorin e6 conjugates for targeted photodynamic therapy of hepatocellular carcinoma. 38126712 Synthesis of Pyrazole-Based Macrocycles Leads to a Highly Selective Inhibitor for MST3. 38128234 Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy. 38128297 Sialyl LewisX glycomimetics bearing an extended anionic chain targeting E- and P- selectin binding sites. 38128906 Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment. 38134304 Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors. 38134745 DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. 38134746 Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy. 38134747 Curcumin hybrid molecules for the treatment of Alzheimer's disease: Structure and pharmacological activities. 38134748 Discovery of hydroxamate as a promising scaffold dually inhibiting metallo- and serine-β-lactamases. 38141285 Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from Flatland. 38141287 Dual-targeting compounds possessing enhanced anticancer activity via microtubule disruption and histone deacetylase inhibition. 38142509 Targeted regulated cell death with small molecule compounds in colorectal cancer: Current perspectives of targeted therapy and molecular mechanisms. 38142510 Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis. 38142511 Design, synthesis, and biological evaluation of HDAC6 inhibitors targeting L1 loop and serine 531 residue. 38142562 ω-(5-Phenyl-2H-tetrazol-2-yl)alkyl-substituted glycine amides and related compounds as inhibitors of the amine oxidase vascular adhesion protein-1 (VAP-1). 38146659 Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer. 38150670 Discovery of 2-Ethoxy-5-isobutyramido-N-1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects. 38150705 Design and Discovery of Novel NLRP3 Inhibitors and PET Imaging Radiotracers Based on a 1,2,3-Triazole-Bearing Scaffold. 38150963 Comprehensive and critical view on the anti-inflammatory and immunomodulatory role of natural phenolic antioxidants. 38150964 Resveratrol-derived inhibitors of the E3 ubiquitin ligase PELI1 inhibit the metastasis of triple-negative breast cancer. 38151460 Synthesis of α3β4 Nicotinic Acetylcholine Receptor Modulators Derived from Aristoquinoline That Reduce Reinstatement of Cocaine-Seeking Behavior. 38153295 Discovery of Novel Inhibitors of BRD4 for Treating Prostate Cancer: A Comprehensive Case Study for Considering Water Networks in Virtual Screening and Drug Design. 38154348 Thiazol-4(5H)-one analogs as potent tyrosinase inhibitors: Synthesis, tyrosinase inhibition, antimelanogenic effect, antioxidant activity, and in silico docking simulation. 38156615 Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases. 38156970 Molecular Pharmacology Profiling of Phenylfentanil and Its Analogues to Understand the Putative Involvement of an Adrenergic Mechanism in Fentanyl-Induced Respiratory Depression. 38157596 Design, synthesis and biological evaluation of carbamate derivatives incorporating multifunctional carrier scaffolds as pseudo-irreversible cholinesterase inhibitors for the treatment of Alzheimer's disease. 38157838 Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors. 38159286 From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases. 38159482 Structural modification of C2-substituents on 1,4-bis(arylsulfonamido)benzene or naphthalene-N,N'-diacetic acid derivatives as potent inhibitors of the Keap1-Nrf2 protein-protein interaction. 38159483 Target identification, and optimization of dioxygenated amide derivatives as potent antibacterial agents with FabH inhibitory activity. 38160619 Progress in the controllability technology of PROTAC. 38160620 Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses. 38164076 Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles. 38165765 Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist. 38166388 Discovery and Optimization of WDR5 Inhibitors via Cascade Deoxyribonucleic Acid-Encoded Library Selection Approach. 38166392 Identification of a Sonically Activated Degrader of Methionine Adenosyltransferase 2A by an in Silico Approach Assisted with the Hole-Electron Analysis. 38168630 Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity. 38169271 Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation. 38169272 Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy. 38170624 Discovery and SAR of JTE-151: A Novel RORγ Inhibitor for Clinical Development. 38170998 Structure-Guided Design, Synthesis, and Antivirulence Assessment of Covalent Staphylococcus aureus Sortase A Inhibitors. 38171145 Plasmodium falciparum topoisomerases: Emerging targets for anti-malarial therapy. 38171148 EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model. 38171149 Design, synthesis, and biological evaluation of novel discoidin domain receptor inhibitors for the treatment of lung adenocarcinoma and pulmonary fibrosis. 38171150 Discovery of 4-amino-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one derivatives as potential receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors. 38171251 Ferroptosis and its modulators: A raising target for cancer and Alzheimer's disease. 38171252 Novel mitochondrial and DNA damaging fluorescent Calix[4]arenes bearing isatin groups as aromatase inhibitors: Design, synthesis and anticancer activity. 38173250 Development of Antibacterial Peptides with Membrane Disruption and Folate Pathway Inhibitory Activities against Methicillin-Resistant Staphylococcus aureus. 38175809 Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia. 38175811 Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors. 38176026 Discovery of Natural Ah Receptor Antagonists from Salvia miltiorrhiza Bunge and Synthesis of Analogs for Tumor Immunotherapy. 38179950 Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn? 38180485 PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models. 38181380 Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b). 38183777 Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects. 38183778 Synthesis and clinical application of new drugs approved by FDA in 2023. 38185055 Benzopyran hydrazones with dual PPARα/γ or PPARα/δ agonism and an anti-inflammatory effect on human THP-1 macrophages. 38185056 Targeting aromatase to restrain oestrogen production and developing efficacious interventions against ER-positive cancer. 38185057 Discovery of N-alkyl-N-benzyl thiazoles as novel TRPC antagonists for the treatment of glioblastoma multiforme. 38185345 Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction. 38189253 Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia. 38190324 Structure-Activity Relationships and Discovery of (S)-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6H-pyrido[1,2-h][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer. 38194775 An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer. 38194776 Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms. 38194777 An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53. 38197882 Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D. 38198520 Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma. 38198596 Emerging Drug Targets for Antimalarial Drug Discovery: Validation and Insights into Molecular Mechanisms of Function. 38199162 Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders. 38199163 The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists. 38199164 N-(Heteroaryl)thiophene sulfonamides as angiotensin AT2 receptor ligands. 38199165 RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development. 38199166 Therapeutic potential of targeting polo-like kinase 4. 38199328 Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3. 38199330 Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer. 38206836 Discovery of Potent SOS1 PROTACs with Effective Antitumor Activities against NCI-H358 Tumor Cells In Vitro/In Vivo. 38207096 Unraveling the Puzzle of Therapeutic Peptides: A Promising Frontier in Huntington's Disease Treatment. 38207099 Discovery of Novel Pyridazine-Tethered Sulfonamides as Carbonic Anhydrase II Inhibitors for the Management of Glaucoma. 38211468 HDAC-targeting epigenetic modulators for cancer immunotherapy. 38211702 Design, synthesis and biological evaluation of 6-chloro-quinolin-2-one derivatives as novel FXIa inhibitors. 38214254 Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases. 38214909 Discovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points. 38214982 Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy. 38215587 Design, synthesis, and pharmacological evaluation of indole-piperidine amides as Blood-brain barrier permeable dual cholinesterase and β-secretase inhibitors. 38215588 Discovery of a novel lead characterized by a stilbene-extended scaffold against sepsis as soluble epoxide hydrolase inhibitors. 38215590 Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer. 38217503 Discovery of Novel Aminobutanoic Acid-Based ASCT2 Inhibitors for the Treatment of Non-Small-Cell Lung Cancer. 38217860 Dual Antagonism of α9α10 nAChR and GABAB Receptor-Coupled CaV2.2 Channels by an Analgesic αO-Conotoxin Analogue. 38218127 Phenoxytacrine derivatives: Low-toxicity neuroprotectants exerting affinity to ifenprodil-binding site and cholinesterase inhibition. 38219658 Chromone-based small molecules for multistep shutdown of arachidonate pathway: Simultaneous inhibition of COX-2, 15-LOX and mPGES-1 enzymes. 38219659 A further pocket or conformational plasticity by mapping COX-1 catalytic site through modified-mofezolac structure-inhibitory activity relationships and their antiplatelet behavior. 38219887 Therapeutic potential of Coumarin-polyphenolic acid hybrids in PD: Inhibition of α-Syn aggregation and disaggregation of preformed fibrils, leading to reduced neuronal inclusion formation. 38224650 HDAC/NAMPT dual inhibitors overcome initial drug-resistance in p53-null leukemia cells. 38227216 Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors. 38227770 Discovery, Optimization, and Evaluation of Novel Pyridin-2(1H)-one Analogues as Potent TRK Inhibitors for Cancer Treatment. 38227771 Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer. 38228254 Design and synthesis of unique morphinan-type molecules: Their application to the search for the unexplored binding domain between opioid receptors and morphinan ligands. 38230963 The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition. 38232131 Discovery of N-(1-(6-Oxo-1,6-dihydropyrimidine)-pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium tuberculosis. 38232463 Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization. 38232464 Drug discovery and optimization based on the co-crystal structure of natural product with target. 38232465 Development of potent and selective ULK1/2 inhibitors based on 7-azaindole scaffold with favorable in vivo properties. 38236416 Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced Mortality. 38237049 Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties. 38237257 Development of a tetrahydroindazolone-based HDAC6 inhibitor with in-vivo anti-arthritic activity. 38241614 Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis, and Biological Characterization. 38242072 Fluorinated captopril analogues inhibit metallo-β-lactamases and facilitate structure determination of NDM-1 binding pose. 38242331 Inhibition of dengue viruses by N-methylcytisine thio derivatives through targeting viral envelope protein and NS2B-NS3 protease. 38244254 Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): Updated progress and perspectives. 38244374 In vitro and in vivo anti-pigmentation effects of 2-mercaptobenzimidazoles as nanomolar tyrosinase inhibitors on mammalian cells and zebrafish embryos: Preparation of pigment-free zebrafish embryos. 38244940 Structure-based design and synthesis of sulfonylureas as novel NLRP3 inhibitors for Alzheimer's disease. 38246115 Development of UTX-143, a selective sodium-hydrogen exchange subtype 5 inhibitor, using amiloride as a lead compound. 38252624 Rebamipide and Derivatives are Potent, Selective Inhibitors of Histidine Phosphatase Activity of the Suppressor of T Cell Receptor Signaling Proteins. 38252989 3,5-Disubstituted-thiazolidine-2,4-dione hybrids as antidiabetic agents: Design, synthesis, in-vitro and In vivo evaluation. 38253001 Specific Inhibitors of Mitochondrial Deacylase Sirtuin 4 Endowed with Cellular Activity. 38253227 Synthesis and biological evaluation of novel 18F-labeled 2,4-diaminopyrimidine derivatives for detection of ghrelin receptor in the brain. 38261411 Multitargeting HDAC Inhibitors Containing a RAS/RAF Protein Interfering Unit. 38261767 SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery Process. 38262119 Design and synthesis of 4-amino-2',4'-dihydroxyindanone derivatives as potent inhibitors of tyrosinase and melanin biosynthesis in human melanoma cells. 38262120 Recent advances in the development of deubiquitinases inhibitors as antitumor agents. 38262305 Selective targeting of human TET1 by cyclic peptide inhibitors: Insights from biochemical profiling. 38265364 Tight-Binding Small-Molecule Carboxylesterase 2 Inhibitors Reduce Intracellular Irinotecan Activation. 38266245 Novel Carbonic Anhydrase Inhibitors with Dual-Tail Core Sulfonamide Show Potent and Lasting Effects for Glaucoma Therapy. 38266553 Hybrids of selective COX-2 inhibitors and active derivatives of edaravone as COX-2 selective NSAIDs with free radical scavenging activity: Design, synthesis and biological activities. 38266789 Direct-to-biology platform: From synthesis to biological evaluation of SHP2 allosteric inhibitors. 38267212 Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations. 38271867 Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors. 38277480 Peptide-Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics. 38277917 Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability. 38278079 Discovery of matrix metalloproteinase inhibitors as anti-skin photoaging agents. 38278080 Novel small molecule inhibitors targeting renal cell carcinoma: Status, challenges, future directions. 38280655 Novel xanthone derivatives as potent sirtuin 2 inhibitors. 38281455 Annual review of PROTAC degraders as anticancer agents in 2022. 38284169 Discovery and Characterization of a Bicyclic Peptide (Bicycle) Binder to Thymic Stromal Lymphopoietin. 38287228 Discovery of Artemisinins as Microsomal Prostaglandins Synthase-2 Inhibitors for the Treatment of Colorectal Cancer via Chemoproteomics. 38289623 Fragment-to-Lead Medicinal Chemistry Publications in 2022. 38290351 Discovery of new piperaquine hybrid analogs linked by triazolopyrimidine and pyrazolopyrimidine scaffolds with antiplasmodial and transmission blocking activities. 38290426 Perspectives on Nuclear Magnetic Resonance Spectroscopy in Drug Discovery Research. 38294952 Identification of Piperazinyl-Difluoro-indene Derivatives Containing Pyridyl Groups as Potent FGFR Inhibitors against FGFR Mutant Tumor: Design, Synthesis, and Biological Evaluation. 38295487 Discovery of thiophen-2-ylmethylene bis-dimedone derivatives as novel WRN inhibitors for treating cancers with microsatellite instability. 38295524 Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors. 38295686 Synthesis and biological evaluation of selective Pepstatin based trifluoromethylated inhibitors of Cathepsin D. 38295689 Targeting autophagy drug discovery: Targets, indications and development trends. 38295759 Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors. 38299539 Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500). 38300264 ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases. 38301029 Discovery of 2,3-Diaminoindole Derivatives as a Novel Class of NOD Antagonists. 38301128 Identifying Marine-Derived Tanzawaic Acid Derivatives as Novel Inhibitors against Osteoclastogenesis and Osteoporosis via Downregulation of NF-κB and NFATc1 Activation. 38301329 Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors. 38306388 Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390. 38306405 Development of Potent Mcl-1 Inhibitors: Structural Investigations on Macrocycles Originating from a DNA-Encoded Chemical Library Screen. 38306598 Exploring the Function of (+)-Naltrexone Precursors: Their Activity as TLR4 Antagonists and Potential in Treating Morphine Addiction. 38307441 Discovery of a novel series of selective macrocyclic PKCTheta inhibitors. 38307442 Identification of (4-chlorophenyl)(5-hydroxynaphtho[1,2-b]furan-3-yl)methanone as novel COX-2 inhibitor with analgesic profile. 38308949 Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase. 38308950 pH regulators and their inhibitors in tumor microenvironment. 38310752 Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance. 38310976 Exploring 2-methyl-substituted vitamin K3 derivatives with potent inhibitory activity against the 3CL protease of SARS-CoV-2. 38315032 Discovery of D25, a Potent and Selective MNK Inhibitor for Sepsis-Associated Acute Spleen Injury. 38316017 Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma. 38316368 Identification of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffolds as potent Lck inhibitors as anti-cancer agents. 38316747 A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor. 38320389 Synthesis and biological evaluation of 1H-pyrrolo[3,2-g]isoquinolines. 38320715 Identification of novel benzothiazole derivatives as inhibitors of NEDDylation pathway to inhibit the progression of gastric cancer. 38321747 Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases. 38323982 Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFRL858R/T790M/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers. 38325006 Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management. 38325007 Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment. 38325398 Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2. 38329974 Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response. 38330278 Discovery and Characterization of Selective, First-in-Class Inhibitors of Citron Kinase. 38330847 Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and α-synuclein fibrils. 38330850 Colony Stimulating Factor-1 Receptor: An emerging target for neuroinflammation PET imaging and AD therapy. 38330869 Tackling Influenza A virus by M2 ion channel blockers: Latest progress and limitations. 38335815 Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors. 38340508 MYC the oncogene from hell: Novel opportunities for cancer therapy. 38340509 Anticancer mechanism of coumarin-based derivatives. 38340642 Design, synthesis, and biological evaluation of phenylcyclopropylamine-entinostat conjugates that selectively target cancer cells. 38348661 BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor. 38348819 Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity. 38348878 Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy. 38349250 Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases. 38349664 Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one" Scaffold for the Treatment of B Cell Lymphoma. 38350360 Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody. 38354305 Design, Synthesis, and Activity Evaluation of Fluorine-Containing Scopolamine Analogues as Potential Antidepressants. 38354523 Novel inhibitors targeting the PGK1 metabolic enzyme in glycolysis exhibit effective antitumor activity against kidney renal clear cell carcinoma in vitro and in vivo. 38356330 Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates. 38359535 Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity. 38359536 Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions. 38359537 Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects. 38363069 Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma. 38364308 Glycan-Modified Peptides for Dual Inhibition of Human Immunodeficiency Virus Entry into Dendritic Cells and T Cells. 38364714 Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer. 38364716 Design, synthesis and biological evaluation of CDC20 inhibitors for treatment of triple-negative breast cancer. 38367219 Discovery of a Potent Nicotinamide Phosphoribosyltransferase Activator for Improving Aging-associated Dysfunctions. 38367489 Identification of the exosomal PD-L1 inhibitor to promote the PD-1 targeting therapy of gastric cancer. 38367493 Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors. 38367494 Novel estrogen receptor β/histone deacetylase dual-targeted near-infrared fluorescent probes as theranostic agents for imaging and treatment of prostate cancer. 38367495 Does size matter? - Comparing pyranoses with septanoses as ligands of the bacterial lectin FimH. 38368711 Pyrazolamide derivatives inhibit α-Synuclein aggregation, disaggregate preformed fibers, and reduce inclusion formation in neuron cells. 38373290 Rational Design of Benzobisheterocycle Metallo-β-Lactamase Inhibitors: A Tricyclic Scaffold Enhances Potency against Target Enzymes. 38373465 α-Amino bisphosphonate triazoles serve as GGDPS inhibitors. 38375763 Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors. 38377311 Design, Synthesis, and Bioevaluation of Novel Reversibly Photoswitchable PI3K Inhibitors Based on Phenylazopyridine Derivatives toward Light-Controlled Cancer Treatment. 38377560 Discovery of Novel N-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma. 38377825 Design, synthesis and biological evaluation of novel 1,2,4a,5-tetrahydro-4H-benzo[b][1,4]oxazino[4,3-d][1,4]oxazine-based AAK1 inhibitors with anti-viral property against SARS-CoV-2. 38377827 Design, synthesis, biological evaluation and in silico studies of novel quinoline derivatives as potential radioprotective molecules targeting the TLR2 and p53 pathways. 38382390 Structural modification based on the diclofenac scaffold: Achieving reduced colitis side effects through COX-2/NLRP3 selective inhibition. 38382391 Targeting insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) for the treatment of cancer. 38382679 Synthesis and kinetic evaluation of phosphomimetic inhibitors targeting type B ribose-5-phosphate isomerase from Mycobacterium tuberculosis. 38385264 Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis. 38385364 Hit-to-Lead Identification and Validation of a Triaromatic Pleuromutilin Antibiotic Candidate. 38385428 Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer. 38387069 Structure Guided Discovery of Novel Pan Metallo-β-Lactamase Inhibitors with Improved Gram-Negative Bacterial Cell Penetration. 38387074 Discovery of Pyrido[2,3-d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment. 38387335 Identification of 3-aryl-5-methyl-isoxazole-4-carboxamide derivatives and analogs as novel HIF-2α agonists through docking-based virtual screening and structural modification. 38387692 Re-exploration of tetrahydro-β-carboline scaffold: Discovery of selective histone deacetylase 6 inhibitors with neurite outgrowth-promoting and neuroprotective activities. 38393759 Discovery of Novel Steroid-Based Histamine H3 Receptor Antagonists/Inverse Agonists. 38393821 Allosteric Activation of α7 Nicotinic Acetylcholine Receptors by Novel 2-Arylamino-thiazole-5-carboxylic Acid Amide Derivatives for the Improvement of Cognitive Deficits in Mice. 38394929 Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity. 38401188 Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R/c-Kit Inhibitors with improved stability and BBB permeability. 38401190 Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells. 38408027 Mechanistic Investigation of Thiazole-Based Pyruvate Kinase M2 Inhibitor Causing Tumor Regression in Triple-Negative Breast Cancer. 38408347 Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors. 38408511 Development of 1,5-diarylpyrazoles as EGFR/JNK-2 dual inhibitors: design, synthesis, moleecular docking, and bioactivity evaluation. 38408513 Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights. 38412237 Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors. 38412693 Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs. 38413367 Design, Synthesis, and Biological Evaluation of Pierardine Derivatives as Novel Brain-Penetrant and In Vivo Potent NMDAR-GluN2B Antagonists for Ischemic Stroke Treatment. 38417155 Discovery and Structure-Activity Relationships of Novel ssDAF-12 Receptor Modulators. 38417632 The discovery of novel and potent indazole NLRP3 inhibitors enabled by DNA-encoded library screening. 38421819 Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements. 38422480 Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors. 38422567 Synthesis and biological evaluation of triazolones/oxadiazolones as novel urease inhibitors. 38422698 Fragment growth-based discovery of novel TNIK inhibitors for the treatment of colorectal cancer. 38422702 Small-molecule agents for treating skin diseases. 38423371 Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives. 38427954 Structure-Based Discovery of High-Affinity Small Molecule Ligands and Development of Tool Probes to Study the Role of Chitinase-3-Like Protein 1. 38428273 Discovery of a novel class of reversible monoacylglycerol lipase inhibitors for potential treatment of depression. 38428383 Structural Basis for Molecular Recognition of Cannabinoids by Inhibitory Cys-Loop Channels. 38430853 Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery. 38432056 Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease. 38432057 Insight into small-molecule inhibitors targeting extracellular nucleotide pyrophosphatase/phosphodiesterase1 for potential multiple human diseases. 38432058 Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4. 38432059 The mechanism of UNC-51-like kinase 1 and the applications of small molecule modulators in cancer treatment. 38436571 Dual Inhibitors of Brain Carbonic Anhydrases and Monoamine Oxidase-B Efficiently Protect against Amyloid-β-Induced Neuronal Toxicity, Oxidative Stress, and Mitochondrial Dysfunction. 38442261 Discovery of RORγ Allosteric Fluorescent Probes and Their Application: Fluorescence Polarization, Screening, and Bioimaging. 38442525 Design, synthesis and anti-necroptosis activity of fused heterocyclic MLKL inhibitors. 38451215 Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats. 38452725 The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364. 38452727 Design and biological evaluation of dual tubulin/HDAC inhibitors based on millepachine for treatment of prostate cancer. 38452728 Research progress of DDR1 inhibitors in the treatment of multiple human diseases. 38452730 Optimizing drug-like properties of selective butyrylcholinesterase inhibitors for cognitive improvement: Enhancing aqueous solubility by disrupting molecular plane. 38456618 Design, Synthesis, and Structure-Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition. 38457911 Casitas b cell lymphoma‑B (Cbl-b): A new therapeutic avenue for small-molecule immunotherapy. 38457912 Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers. 38458107 Biochemical and structural characterization of chlorhexidine as an ATP-assisted inhibitor against type 1 methionyl-tRNA synthetase from Gram-positive bacteria. 38460270 Structure-based discovery of potent CARM1 inhibitors for colorectal cancer therapy. 38460271 Novel thiazolidin-4-one benzenesulfonamide hybrids as PPARγ agonists: Design, synthesis and in vivo anti-diabetic evaluation. 38460487 Discovery of N-benzylbenzamide-based allosteric inhibitors of Aurora kinase A. 38462716 Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2). 38465588 Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity. 38466654 Design, Synthesis, and Biological Evaluation of 5-(5-Iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diamine (AF-353) Derivatives as Novel DHFR Inhibitors against Staphylococcus aureus. 38466661 Development of a Series of Pyrrolopyridone MAT2A Inhibitors. 38467640 The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-N-(6-methylpyrazolo[1,5-a]pyrimidin-3-yl)imidazo[1,2-a]pyrimidine-6-carboxamide (BIO-7488), a Potent, Selective, and CNS-Penetrant IRAK4 Inhibitor for the Treatment of Ischemic Stroke. 38470227 Discovery and Optimization of Selective Brain-Penetrant EBP Inhibitors that Enhance Oligodendrocyte Formation. 38471358 Sulfone-based human liver pyruvate kinase inhibitors - Design, synthesis and in vitro bioactivity. 38476002 Structure-Guided Elaboration of a Fragment-Like Hit into an Orally Efficacious Leukotriene A4 Hydrolase Inhibitor. 38477575 Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression. 38477709 Mechanism-Based Macrocyclic Inhibitors of Serine Proteases. 38477974 Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression. 38478885 Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs. 38479166 Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors. 38479168 Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases. 38482820 Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability. 38482828 Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity. 38484122 Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations. 38484677 Scaffold hopping derived novel benzoxazepinone receptor-interacting protein kinase 1 (RIP1) inhibitors as anti-necroptosis agents: Anti-inflammatory effect in systemic inflammatory response syndrome (SIRS) and epilepsy. 38484678 Ligand-based design and synthesis of new trityl histamine and trityl cysteamine derivatives as SIRT2 inhibitors for cancer therapy. 38485922 Cyclic Peptide Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury. 38488882 Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation. 38489246 Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model. 38490062 Targeting kelch-like (KLHL) proteins: achievements, challenges and perspectives. 38490063 Novel 6-hydroxybenzothiazol-2-carboxamides as potent and selective monoamine oxidase B inhibitors endowed with neuroprotective activity. 38492541 Inhibition of cancer cells by Quinoline-Based compounds: A review with mechanistic insights. 38493727 Novel pyrrole based CB2 agonists: New insights on CB2 receptor role in regulating neurotransmitters' tone. 38493730 Discovery of 3-hydroxymethyl-azetidine derivatives as potent polymerase theta inhibitors. 38498010 RNA-Small-Molecule Interaction: Challenging the "Undruggable" Tag. 38498304 Design and Synthesis of 3-(2H-Chromen-3-yl)-5-aryl-1,2,4-oxadiazole Derivatives as Novel Toll-like Receptor 2/1 Agonists That Inhibit Lung Cancer In Vitro and In Vivo. 38498998 Discovery of Conformationally Constrained ALK2 Inhibitors. 38500250 Structure-Guided Discovery of Potent and Selective CLK2 Inhibitors for the Treatment of Knee Osteoarthritis. 38502780 Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists. 38503166 Insights from structure-activity relationships and the binding mode of peptidic α-ketoamide inhibitors of the malaria drug target subtilisin-like SUB1. 38503167 Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer. 38508118 Synthesis and anti-liver fibrosis activity of imidazole and thiazole compounds containing amino acids. 38508119 Progress on synthesis and structure-activity relationships of lamellarins over the past decade. 38508120 Evaluation of novel 2-(quinoline-2-ylthio)acetamide derivatives linked to diphenyl-imidazole as α-glucosidase inhibitors: Insights from in silico, in vitro, and in vivo studies on their anti-diabetic properties. 38509003 Long-Residence Time Peptide Antagonist for the Vasopressin V2 Receptor to Treat Autosomal Dominant Polycystic Kidney Disease. 38511649 Discovery of DNL343: A Potent, Selective, and Brain-Penetrant eIF2B Activator Designed for the Treatment of Neurodegenerative Diseases. 38513340 Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities. 38517948 Discovery of Novel 11-Membered Templates as Squalene Synthase Inhibitors. 38518121 Discovery of Novel 5,6-Dihydro-4H-pyrido[2,3,4-de]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases. 38518523 Synthesis and biological evaluation of 1-phenyl-tetrahydro-β-carboline-based first dual PRMT5/EGFR inhibitors as potential anticancer agents. 38518525 Discovery of novel polyheterocyclic neuraminidase inhibitors with 1,3,4-oxadiazole thioetheramide as core backbone. 38518734 Fluorescent probes and degraders of the sterol transport protein Aster-A. 38518735 Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity. 38520762 Synergistic therapeutics: Co-targeting histone deacetylases and ribonucleotide reductase for enhanced cancer treatment. 38521175 Targeting ATP-binding site of WRN Helicase: Identification of novel inhibitors through pocket analysis and Molecular Dynamics-Enhanced virtual screening. 38521177 A PSMA-targeted doxorubicin small-molecule drug conjugate. 38522113 Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis. 38522114 Guanidine-to-piperidine switch affords high affinity small molecule NPFF ligands with preference for NPFF1-R and NPFF2-R subtypes. 38522589 Improved synthesis, molecular modeling and anti-inflammatory activity of new fluorinated dihydrofurano-naphthoquinone compounds. 38525852 Recent Advances on Small-Molecule Inhibitors of Lipocalin-like Proteins. 38526960 Drug Repurposing of ACT001 to Discover Novel Promising Sulfide Prodrugs with Improved Safety and Potent Activity for Neutrophil-Mediated Antifungal Immunotherapy. 38530741 Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator. 38530938 Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer. 38533580 Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor. 38537512 Synthesis, kinase inhibition and anti-leukemic activities of diversely substituted indolopyrazolocarbazoles. 38546542 Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for In Vivo Theranostics of Alzheimer's Disease. 38546708 5-Aminothiazoles Reveal a New Ligand-Binding Site on Prolyl Oligopeptidase Which is Important for Modulation of Its Protein-Protein Interaction-Derived Functions. 38547240 Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease. 38547733 Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities. 38547734 Discovery of pyrido[3,2-d]pyrimidin-6(5H)-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy. 38547735 Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation. 38552426 Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode. 38552597 Design, synthesis, and biological evaluation of aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT1A/5-HT7. 38554475 Design, synthesis and biological evaluation of matrine contains benzimidazole derivatives as dual TOPOI and PARP inhibitors for cancer therapy. 38555073 Design, synthesis and biological evaluation of tanshinone IIA derivatives as NLRP3 inflammasome inhibitors. 38556760 Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors. 38563549 Design, Synthesis, and Biological Evaluation of a Novel NIK Inhibitor with Anti-Inflammatory and Hepatoprotective Effects for Sepsis Treatment. 38564299 Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications. 38564512 Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma. 38564826 Targeting EGFR degradation by autophagosome degraders. 38569135 Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both In Vitro and In Vivo. 38569434 Drug development and potential targets for Cushing's syndrome. 38574002 Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia. 38574345 Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma. 38574638 Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH. 38577724 Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia. 38579492 Bioisoteres for carboxylic acids: From ionized isosteres to novel unionized replacements. 38579621 Structure-based discovery of small molecule inhibitors of FKBP51-Hsp90 protein-protein interaction. 38579622 Novel 6-alkyl-bridged 4-arylalkylpiperazin-1-yl derivatives of azepino[4,3-b]indol-1(2H)-one as potent BChE-selective inhibitors showing protective effects against neurodegenerative insults. 38580135 Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors. 38580317 Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death. 38581730 Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction. 38581732 Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer. 38582047 Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors. 38582133 Antascomicin B stabilizes FKBP51-Akt1 complexes as a molecular glue. 38583237 Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors. 38586950 Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors. 38587857 Discovery of Novel Heterotricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer Immunotherapy. 38588625 Advances in TRPV6 inhibitors for tumors by targeted therapies: Macromolecular proteins, synthetic small molecule compounds, and natural compounds. 38588626 Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer. 38592023 Discovery of 2-Amide-3-methylester Thiophenes that Target SARS-CoV-2 Mac1 and Repress Coronavirus Replication, Validating Mac1 as an Antiviral Target. 38592948 Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises. 38593344 Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy. 38593423 Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist. 38593588 Active site-directed probes targeting dipeptidyl peptidases 8 and 9. 38595098 Discovery of TNG908: A Selective, Brain Penetrant, MTA-Cooperative PRMT5 Inhibitor That Is Synthetically Lethal with MTAP-Deleted Cancers. 38597264 Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions. 38598312 Potentiating Activity of GmhA Inhibitors on Gram-Negative Bacteria. 38599294 The mechanism of covalent inhibition of LAR phosphatase by illudalic acid. 38599295 Structural modification of tanshinone IIA and their α-glucosidase inhibitory activity. 38604095 Discovery and optimization of 4-pyrazolyl-2-aminopyrimidine derivatives as potent spleen tyrosine kinase (SYK) inhibitors. 38604096 Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors. 38604131 Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles. 38604299 Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy. 38607318 Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader. 38608245 Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease. 38608962 Discovery andsynthesis of novel benzoylhydrazone neuraminidase inhibitors. 38613499 Structure-Guided Discovery and Preclinical Assessment of Novel (Thiophen-3-yl)aminopyrimidine Derivatives as Potent ERK1/2 Inhibitors. 38613773 Discovery of Novel Aryl Triazolone Dihydropyridines (ATDPs) Targeting Highly Conserved Residue W229 as Promising HIV-1 NNRTIs. 38614062 Tetrazole derivatives in the management of neurological disorders: Recent advances on synthesis and pharmacological aspects. 38614063 Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases. 38615409 Discovery of novel amide derivatives as potent quorum sensing inhibitors of Pseudomonas aeruginosa. 38619191 Design, Synthesis, and Pharmacological Evaluation of Spiro[carbazole-3,3'-pyrrolidine] Derivatives as cGAS Inhibitors for Treatment of Acute Lung Injury. 38620134 Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity. 38621319 Expanding the ligand spaces for E3 ligases for the design of protein degraders. 38621327 Modulators for palmitoylation of proteins and small molecules. 38626522 Exploration of isoxazole analogs: Synthesis, COX inhibition, anticancer screening, 3D multicellular tumor spheroids, and molecular modeling. 38626523 Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor. 38626524 Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer. 38626917 Synthesis and Structure-Activity Relationships for Glutamate Transporter Allosteric Modulators. 38630077 Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer. 38630165 Structural Elucidation and Antiviral Activity of Covalent Cathepsin L Inhibitors. 38630440 Design, Synthesis, and Biological Evaluation of β-Trifluoroethoxydimethyl Selenides as Potent Antiosteoporosis Agents. 38631541 In vitro inhibition of α-Synuclein aggregation and disaggregation of preformed fibers by polyphenol hybrids with 2-conjugated benzothiazole. 38634707 Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors. 38635563 Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist. 38636128 Development of benzimidazole-based compounds as novel capsid assembly modulators for the treatment of HBV infection. 38636130 Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships. 38636481 Brain-Permeable Immunoproteasome-Targeting Macrocyclic Peptide Epoxyketones for Alzheimer's Disease. 38640588 Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas. 38641151 Biological evaluation of sulfonate and sulfate analogues of lithocholic acid: A bioisosterism-guided approach towards the discovery of potential sialyltransferase inhibitors for antimetastatic study. 38642371 Discovery and Mechanistic Studies of Dual-Target Hits for Carbonic Anhydrase IX and VEGFR-2 as Potential Agents for Solid Tumors: X-ray, In Vitro, In Vivo, and In Silico Investigations of Coumarin-Based Thiazoles. 38643670 Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors. 38647397 Discovery of an Ortho-Substituted N-Cyclopropylmethyl-7α-phenyl-6,14-endoethano-tetrahydronorthebaine Derivative as a Selective and Potent Kappa Opioid Receptor Agonist with Subsided Sedative Effect. 38648167 Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease. 38648420 Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists. 38649304 Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity. 38651218 Artificial Intelligence-Assisted Optimization of Antipigmentation Tyrosinase Inhibitors: De Novo Molecular Generation Based on a Low Activity Lead Compound. 38651495 Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation. 38651522 Development of Prolinol Containing Inhibitors of Hypoxanthine-Guanine-Xanthine Phosphoribosyltransferase: Rational Structure-Based Drug Design. 38653067 Probing benzenesulfonamide-thiazolidinone hybrids as multitarget directed ligands for efficient control of type 2 diabetes mellitus through targeting the enzymes: α-glucosidase and carbonic anhydrase II. 38653068 Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease. 38656144 Druglike, 18F-labeled PET Tracers Targeting Fibroblast Activation Protein. 38657480 Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells. 38661655 Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer. 38663283 Design, synthesis, and biological evaluation of 3-phenyl substituted pyridine derivatives as potential dual inhibitors of XOR and URAT1. 38663285 Design, synthesis, and biological evaluation of some 2-(3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-yl)-N-phenylacetamide hybrids as MTDLs for Alzheimer's disease therapy. 38669059 Design, Synthesis, and Evaluation of Dihydropyrimidine Derivatives as Selective PDE1 Inhibitors for the Treatment of Liver Fibrosis. 38669736 1,2,3-Triazole-totarol conjugates as potent PIP5K1α lipid kinase inhibitors. 38669909 Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterization. 38669910 Quinazolines annelated at the N(3)-C(4) bond: Synthesis and biological activity. 38670537 Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor. 38670538 Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma. 38676656 Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation. 38677061 Discovery of the small molecular inhibitors against sclerostin loop3 as potential anti-osteoporosis agents by structural based virtual screening and molecular design. 38677560 Synthesis of a new 2-prenylated quinoline as potential drug for metabolic syndrome with pan-PPAR activity and anti-inflammatory effects. 38678823 High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders. 38678826 Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1. 38679872 Discovery of Urea Derivatives of Celastrol as Selective Peroxiredoxin 1 Inhibitors against Colorectal Cancer Cells. 38684226 Concurrent Optimizations of Efficacy and Blood-Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson's Disease Therapeutics. 38685143 Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics. 38686671 Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization. 38687204 Multitarget μ-Opioid Receptor Agonists─Neuropeptide FF Receptor Antagonists Induce Potent Antinociception with Reduced Adverse Side Effects. 38687638 Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader. 38687818 Illuminating Dark Chemical Matter Using the Cell Painting Assay. 38687956 Discovery of a New Anti-Inflammatory Agent from Anemoside B4 Derivatives and Its Therapeutic Effect on Colitis by Targeting Pyruvate Carboxylase. 38687966 A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19. 38688063 Discovery of novel diaryl substituted isoquinolin-1(2H)-one derivatives as hypoxia-inducible factor-1 signaling inhibitors for the treatment of rheumatoid arthritis. 38690856 Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer. 38691510 Novel Inhibitory Site Revealed by XAP044 Mode of Action on the Metabotropic Glutamate 7 Receptor Venus Flytrap Domain. 38691886 Structure-activity relationship in NOD2 agonistic muramyl dipeptides. 38691887 Design, synthesis, and biological evaluation of 5-(1H-indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors. 38691889 Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma. 38691891 Targeting the cysteine biosynthesis pathway in microorganisms: Mechanism, structure, and drug discovery. 38692522 Total synthesis/semi-synthesis of natural isopentenyl flavonoids with inhibitory activity on NLRP3 inflammasome. 38692523 Design, synthesis and structure-activity relationship of 1,8-naphthalimide derivatives as highly potent hCYP1B1 inhibitors. 38695063 Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2. 38695469 Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation. 38695666 Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1. 38699796 Triazoles in Medicinal Chemistry: Physicochemical Properties, Bioisosterism, and Application. 38701712 Perspectives and challenges in developing small molecules targeting purine nucleoside phosphorylase. 38701714 Lead optimization based design, synthesis, and pharmacological evaluation of quinazoline derivatives as multi-targeting agents for Alzheimer's disease treatment. 38704935 From lab to nature: Recent advancements in the journey of gastroprotective agents from medicinal chemistry to phytotherapy. 38704936 Exploration of novel isoxazole-fused quinone derivatives as anti-colorectal cancer agents through inhibiting STAT3 and elevating ROS level. 38704940 Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM). 38704942 Synthesis and Evaluation of diaryl ether modulators of the leukotriene A4 hydrolase aminopeptidase activity. 38704944 Discovery of 4-benzylpiperazinequinoline BChE inhibitor that suppresses neuroinflammation for the treatment of Alzheimer's disease. 38704960 Modulation of proteasome subunit selectivity of syringolins. 38706130 Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma. 38708937 Direct Inhibition of BK Channels by Cannabidiol, One of the Principal Therapeutic Cannabinoids Derived from Cannabis sativa. 38711345 Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update. 38712838 Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis. 38713163 Development of Inhibitors, Probes, and PROTAC Provides a Complete Toolbox to Study PARK7 in the Living Cell. 38713486 A CARM1 Inhibitor Potently Suppresses Breast Cancer Both In Vitro and In Vivo. 38714043 Recent discovery and development of AXL inhibitors as antitumor agents. 38714044 Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine. 38714262 Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor. 38716576 Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [177Lu]Lu-PSMA-617 in Healthy Organs. 38716896 Selenization of Small Molecule Drugs: A New Player on the Board. 38716967 Exploring the Structural Attributes of Yoda1 for the Development of New-Generation Piezo1 Agonist Yaddle1 as a Vaccine Adjuvant Targeting Optimal T Cell Activation. 38718622 Design, synthesis, and biological evaluation of novel sesquiterpene lactone derivatives as PKM2 activators with potent anti-ulcerative colitis activities. 38718625 Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor. 38718626 Discovery of potent small molecule ubiquitin-specific protease 10 inhibitors with anti-hepatocellular carcinoma activity through regulating YAP expression. 38722184 Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases. 38722799 Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase. 38723203 Identification of 1,3,4-Thiadiazolyl-Containing Thiazolidine-2,4-dione Derivatives as Novel PTP1B Inhibitors with Antidiabetic Activity. 38727100 Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases. 38728549 A β-Carboline Derivate PAD4 Inhibitor Reshapes Neutrophil Phenotype and Improves the Tumor Immune Microenvironment against Triple-Negative Breast Cancer. 38728572 Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches. 38728867 Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions. 38728868 Analogues of the pan-selectin antagonist rivipansel (GMI-1070). 38729623 Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility. 38733345 Impact of Combinatorial Histone Modifications on Acetyllysine Recognition by the ATAD2 and ATAD2B Bromodomains. 38733884 Recent advances in c-Met-based dual inhibitors in the treatment of cancers. 38734389 Design, synthesis of ceramide 1-phosphate analogs and their affinity for cytosolic phospholipase A2 as evidenced by surface plasmon resonance. 38735150 Inhibitory interactions of the 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one scaffold with Bunyavirales cap-snatching endonucleases expose relevant drug design features. 38739112 Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy. 38739840 Discovery of Oral AMP-Activated Protein Kinase Activators for Treating Hyperlipidemia. 38741265 Structure-Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist. 38744018 Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors. 38746878 Identification of Selective Imidazopyridine CSF1R Inhibitors. 38746884 Discovery of Novel Bicyclic Pyrazoles as Potent PIP5K1C Inhibitors. 38746889 Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment. 38746891 Novel Myeloperoxidase Inhibitors for Treating Multiple Diseases. 38746892 Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers. 38746894 Synthesis and Monoamine Oxidase Inhibitory Activity of Halogenated Flavones. 38746896 Structural Investigations of Phthalazinone Derivatives as Allosteric Inhibitors of Human DNA Methyltransferase 3A. 38746900 Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders. 38746901 Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases. 38746902 Novel CD73 Inhibitors for Treating Cancer. 38746903 A Tiny Pocket Packs a Punch: Leveraging Pyridones for the Discovery of CNS-Penetrant Aza-indazole IRAK4 Inhibitors. 38748070 Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches. 38748608 Explorations of Agonist Selectivity for the α9* nAChR with Novel Substituted Carbamoyl/Amido/Heteroaryl Dialkylpiperazinium Salts and Their Therapeutic Implications in Pain and Inflammation. 38748820 Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model. 38748913 Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy. 38749268 Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer. 38749341 Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors. 38749342 Design, synthesis and evaluation of novel prostate-specific membrane antigen-targeted aryl [18F]fluorosulfate PET tracers. 38749343 Lead compound profiling for small molecule inhibitors of the REV1-CT/RIR Translesion synthesis Protein-Protein interaction. 38751194 Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity. 38753594 Macrocyclic Azapeptide Nitriles: Structure-Based Discovery of Potent SARS-CoV-2 Main Protease Inhibitors as Antiviral Drugs. 38753759 WLB-87848, a Selective σ1 Receptor Agonist, with an Unusually Positioned NH Group as Positive Ionizable Moiety and Showing Neuroprotective Activity. 38754045 Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis. 38754142 Macrocyclization strategy for improving candidate profiles in medicinal chemistry. 38754562 α-Fluorination of tropane compounds and its impact on physicochemical and ADME properties. 38754564 Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia. 38758695 An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth. 38759454 Current therapy in amyotrophic lateral sclerosis (ALS): A review on past and future therapeutic strategies. 38759457 Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine derivatives as Mnk1/2 inhibitors. 38759932 Design and synthesis of novel thiazole-derivatives as potent ALK5 inhibitors. 38761584 An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy. 38761789 Piezo1 and its inhibitors: Overview and perspectives. 38762915 Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships. 38762916 Discovery of meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19. 38762918 Design, synthesis, molecular modeling, in vitro and in vivo biological evaluation of potent anthranilamide derivatives as dual P-glycoprotein and CYP3A4 inhibitors. 38764175 Structure-Based Optimization of Novel Sterol 24-C-Methyltransferase Inhibitors for the Treatment of Candida albicans Infections. 38768084 Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases. 38770784 Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. 38772136 Novel 4-triazole phenyl amide (4-TPA) molecules: Potent promoters of α-synuclein fibril disassembly. 38776379 Design of Selective PARP-1 Inhibitors and Antitumor Studies. 38776401 Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-Resistant Neisseria gonorrhoeae. 38776567 Discovery of first-in-class highly selective TRPV1 antagonists with dual analgesic and hypoglycemic effects. 38776806 Leveraging a rationally designed veliparib-based anilide eliciting anti-leukemic effects for the design of pH-responsive polymer nanoformulation. 38776807 Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer. 38780468 Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε. 38781491 Metabolomic Analysis and Antiviral Screening of a Marine Algae Library Yield Jobosic Acid (2,5-Dimethyltetradecanoic Acid) as a Selective Inhibitor of SARS-CoV-2. 38781921 The role of the methoxy group in approved drugs. 38782078 Replacement of the hydroxamic acid group in the selective HDAC8 inhibitor PCI-34051. 38782404 In Silico Assisted Identification, Synthesis, and In Vitro Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 Channel. 38784451 Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy. 38784454 A colorimetric assay adapted to fragment screening revealing aurones and chalcones as new arginase inhibitors. 38784455 Carltonine-derived compounds for targeted butyrylcholinesterase inhibition. 38784456 Substituted 4-methylcoumarin inhibitors of SLC26A3 (DRA) for treatment of constipation and hyperoxaluria. 38784462 PDE-stable 2'3'-cGAMP analogues, containing 5'-S-phosphorothioester linkage, as STING agonists. 38784463 4-Trifluoromethyl bithiazoles as broad-spectrum antimicrobial agents for virus-related bacterial infections or co-infections. 38784464 Helical sulfonyl-γ-AApeptides for the inhibition of HIV-1 fusion and HIF-1α signaling. 38784469 Imidazopyrimidine: from a relatively exotic scaffold to an evolving structural motif in drug discovery. 38784473 Evaluation of ketoclomazone and its analogues as inhibitors of 1-deoxy-d-xylulose 5-phosphate synthases and other thiamine diphosphate (ThDP)-dependent enzymes. 38784474 Coumarin-furo[2,3-d]pyrimidone hybrid molecules targeting human liver cancer cells: synthesis, anticancer effect, EGFR inhibition and molecular docking studies. 38784476 Computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy. 38787793 Structure-Based Design of a Potent and Selective YTHDC1 Ligand. 38787938 Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants. 38788241 Discovery of 3-((4-Benzylpyridin-2-yl)amino)benzamides as Potent GPR52 G Protein-Biased Agonists. 38788299 Application and challenges of nitrogen heterocycles in PROTAC linker. 38788300 Comprehensive analysis of resorcinyl-imidazole Hsp90 inhibitor design. 38795518 Exploring fluorine-substituted piperidines as potential therapeutics for diabetes mellitus and Alzheimer's diseases. 38795520 Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents. 38799223 SETDB1 as a cancer target: challenges and perspectives in drug design. 38801798 Amide bioisosteric replacement in the design and synthesis of quorum sensing modulators. 38804039 Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer. 38805213 Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases. 38805667 Discovery of ITI-333, a Novel Orally Bioavailable Molecule Targeting Multiple Receptors for the Treatment of Pain and Other Disorders. 38805937 Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy. 38805939 Small molecules that regulate the N6-methyladenosine RNA modification as potential anti-cancer agents. 38807539 Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure. 38809766 Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability. 38809993 Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer. 38810170 Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression. 38810335 A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: Design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments. 38814086 Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management Treatments. 38814877 Design, Synthesis, and Structure-Activity Relationships of Novel Peptide Derivatives of the Severe Acute Respiratory Syndrome-Coronavirus-2 Spike-Protein that Potently Inhibit Nicotinic Acetylcholine Receptors. 38815872 Identification of highly potent and selective HTRA1 inhibitors. 38817193 X-ray Structure-Guided Discovery of a Potent Benzimidazole Glutaminyl Cyclase Inhibitor That Shows Activity in a Parkinson's Disease Mouse Model. 38818879 Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy. 38820338 Discovery of Potent and Selective Covalent Inhibitors of HER2WT and HER2YVMA. 38820854 Structure-based design of multitargeting ChEs-MAO B inhibitors based on phenyl ring bioisosteres: AChE/BChE selectivity switch and drug-like characterization. 38823264 Identification of 3-(9H-carbazol-9-yl)-2-(1,3-dioxoisoindolin-2-yl)propanoic acids as promising DNMT1 inhibitors. 38823265 Dual-target inhibitors of colchicine binding site for cancer treatment. 38823727 Synthesis and evaluation of 3-hydroxyquinolin-2(1H)-one derivatives as inhibitors of tyrosinase. 38829718 Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia. 38830007 Discovery and Optimization of Tetrahydroisoquinoline Derivatives To Enhance Lysosome Biogenesis as Preclinical Candidates for the Treatment of Alzheimer's Disease. 38830427 The recent discovery of a promising pharmacological scaffold derived from carvacrol: A review. 38833750 A consensus reverse docking approach for identification of a competitive inhibitor of acetyltransferase enhanced intracellular survival protein from Mycobacterium tuberculosis. 38837951 Overcoming Secondary Mutations of Type II Kinase Inhibitors. 38838545 Discovery of novel benzimidazole derivatives as selective and reversible monoamine oxidase B inhibitors for Parkinson's disease treatment. 38838546 Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship. 38838547 Research progress on GPX4 targeted compounds. 38838548 Design, synthesis and antiproliferative activity of raloxifene/histone deacetylase inhibitor hybrids in breast cancer. 38838918 Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities. 38843586 Derivatives of D(-) glutamine-based MMP-2 inhibitors as an effective remedy for the management of chronic myeloid leukemia-Part-I: Synthesis, biological screening and in silico binding interaction analysis. 38843875 Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity. 38844173 Design and synthesis of novel fluorene derivatives as inhibitors of pyruvate dehydrogenase kinase. 38845345 Structural Modification and Biological Evaluation of 2,8-Disubstituted Adenine and Its Nucleosides as A2A Adenosine Receptor Antagonists: Exploring the Roles of Ribose at Adenosine Receptors. 38845361 Discovery and Optimization of Novel SaFabI Inhibitors as Specific Therapeutic Agents for MRSA Infection. 38847373 Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy. 38847803 Structure-Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD+-Dependent Lysine Deacylase Sirtuin 2. 38848667 Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer's Disease. 38850857 Design, synthesis, biological evaluation, and in silico studies of novel pyridopyridine derivatives as anticancer candidates targeting FMS kinase. 38851000 Identification of sulfonylpyrimidines as novel selective aldosterone synthase (CYP11B2) inhibitors. 38851056 Psammaplin A analogues with modified disulfide bond targeting histone deacetylases: Synthesis and biological evaluation. 38851358 [1,2,4]Triazolo[1,5-a]pyrimidine derivatives: Structure-activity relationship study leading to highly selective ENPP1 inhibitors. 38852337 New insights into butyrylcholinesterase: Pharmaceutical applications, selective inhibitors and multitarget-directed ligands. 38852338 Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors. 38852339 Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity. 38855903 Identification and Validation of PKR as a Direct Target for the Novel Sulfonamide-Substituted Tetrahydroquinoline Nonselective Inhibitor of the NLRP3 Inflammasome. 38857067 Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine. 38857566 Advances in dual-targeting inhibitors of HDAC6 for cancer treatment. 38861808 Discovery of 7-alkoxybenzofurans as PDE4 inhibitors with hepatoprotective activity in D-GalN/LPS-induced hepatic sepsis. 38863440 Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4. 38865743 A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties. 38865744 Exploration of 1-(indolin-1-yl)-2-(thiazol-2-yl)ethan-1-one derivatives as novel anti-HBV agent with potential TLR7-agonistic effect. 38869493 Fentanyl-Type Antagonist of the μ-Opioid Receptor: Important Role of Axial Chirality in the Active Conformation. 38870714 Efficient synthesis of indole-chalcones based glycohybrids and their anticancer activity. 38870715 Bioisosteric heterocyclic analogues of natural bioactive flavonoids by scaffold-hopping approaches: State-of-the-art and perspectives in medicinal chemistry. 38870831 Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD Immunotherapy. 38870832 An insight into sustainable and green chemistry approaches for the synthesis of quinoline derivatives as anticancer agents. 38871484 Design, Synthesis, and Biological Evaluation of 1,2,4-Oxadiazole Derivatives Containing an Aryl Carboxylic Acid Moiety as Potent Sarbecovirus Papain-like Protease Inhibitors. 38874515 Discovery of N-Substituted Acetamide Derivatives as Promising P2Y14R Antagonists Using Molecular Hybridization Based on Crystallographic Overlay. 38875808 Novel thiosemicarbazide-based β-carboline derivatives as α-glucosidase inhibitors: Synthesis and biological evaluation. 38875810 Synthesis and biological evaluation of multimodal monoaminergic arylpiperazine derivatives with potential antidepressant profile. 38876176 Discovery of a potent, orally available furopyridine derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor. 38876177 Discovery of a potent orally available pyrazolopyridone derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor. 38878516 Discovery of new anti-diabetic potential agents based on paracetamol incorporating sulfa-drugs: Design, synthesis, α-amylase, and α-glucosidase inhibitors with molecular docking simulation. 38878517 Design and synthesis of 6-C-alkyl-DMDP type nanomolar inhibitors of β-galactosidase and β-glucosidase based on broussonetine S and related derivatives. 38878518 Discovery of pyridazinone derivatives bearing tetrahydroimidazo[1,2-a]pyrazine scaffold as potent inhibitors of transient receptor potential canonical 5 to ameliorate hypertension-induced renal injury in rats. 38879970 Development and therapeutic perspectives of CXCR4 antagonists for disease therapy. 38879996 Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC). 38885173 Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer. 38885438 Potent, Selective Agonists for the Cannabinoid-like Orphan G Protein-Coupled Receptor GPR18: A Promising Drug Target for Cancer and Immunity. 38885550 Discovery of novel CXCR4 inhibitors for the treatment of inflammation by virtual screening and biological evaluation. 38888047 Discovery and Development of NLRP3 Inhibitors Targeting the LRR Domain to Disrupt NLRP3-NEK7 Interaction for the Treatment of Rheumatoid Arthritis. 38888140 Discovery of a Novel ASM Direct Inhibitor with a 1,5-Diphenyl-pyrazole Scaffold and Its Antidepressant Mechanism of Action. 38888292 Design, Synthesis, and Activity Evaluation of Novel Benzazole Bifunctional Antifungal Inhibitors with an LDH Carrier. 38888621 Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M4 Muscarinic Acetylcholine Receptor. 38889052 Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy. 38889244 Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML. 38889606 Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidin-7(8H)-one derivatives as potent USP1 inhibitors. 38889608 Novel carbazole-oxadiazole derivatives as anti-α-glucosidase and anti-α-amylase agents: Design, synthesis, molecular docking, and biological evaluation. 38889609 The U.S. FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective. 38894895 Identification and Evaluation of Reversible Covalent Binders to Cys55 of Bfl-1 from a DNA-Encoded Chemical Library Screen. 38894896 Insight on Some Newly Synthesized Trisubstituted Imidazolinones as VEGFR-2 Inhibitors. 38894901 Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer. 38894904 Imidazopyridine Compounds as ERK5 Inhibitors for Treating Cancer. 38894905 SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme. 38894907 The Inhibitors of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT-1) Protease as Potential Treatment of ABC-DLBCL and Similar Diseases. 38894909 Nonsymmetrically Substituted 1,1'-Biphenyl-Based Small Molecule Inhibitors of the PD-1/PD-L1 Interaction. 38894910 Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer. 38894911 Structural Modifications of Covalent Cathepsin S Inhibitors: Impact on Affinity, Selectivity, and Permeability. 38894912 Structure-Based Rational Design of Constrained Peptides as TIM-3 Inhibitors. 38894914 Lysosomal Degradation of Extracellular Targets: Innovations and Implications. 38894918 Lead Identification of Novel Naphthyridine Derivatives as Potent SOS1 Inhibitors. 38894921 Benzodioxane Carboxamide Derivatives As Novel Monoamine Oxidase B Inhibitors with Antineuroinflammatory Activity. 38894924 Optimization of a Novel DEL Hit That Binds in the Cbl-b SH2 Domain and Blocks Substrate Binding. 38894925 Novel 2,4-Dichloro-5-sulfamoylbenzoic Acid Oxime Esters: First Studies as Potential Human Carbonic Anhydrase Inhibitors. 38894930 2-Aminopyridines as Potent and Selective Nav1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model. 38894932 Novel HSD17B13 Inhibitors for Treating Liver Diseases. 38894933 Potent, Selective, and Orally Bioavailable Quinazoline-Based STK17A/B Dual Inhibitors. 38896548 G Protein-Coupled Estrogen Receptor-Mediated Anti-Inflammatory and Mucosal Healing Activity of a Trimethylpyridinol Analogue in Inflammatory Bowel Disease. 38896992 Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study. 38897928 Structure-Based Design and Synthesis of Covalent Inhibitors for Deubiquitinase and Acetyltransferase ChlaDUB1 of Chlamydia trachomatis. 38901105 Extensive targeting of chemical space at the prime side of ketoamide inhibitors of rhomboid proteases by branched substituents empowers their selectivity and potency. 38901106 Dual 5-HT6/SERT ligands for mitigating neuropsychiatric symptoms of dementia exerting neuroprotection against amyloid-β toxicity, memory preservation, and antidepressant-like properties. 38903944 Design, synthesis and antibacterial activity evaluation of ebselen derivatives in NDM-1 producing bacteria. 38905482 Rational Molecular Editing: A New Paradigm in Drug Discovery. 38905539 Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma. 38905805 Discovery of novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors for the efficient treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo. 38906067 Optimization of α-amido boronic acids via cryo-electron microscopy analysis: Discovery of a novel highly selective immunoproteasome subunit LMP7 (β5i)/LMP2 (β1i) dual inhibitor. 38906068 Exploring the interaction of N-(benzothiazol-2-yl)pyrrolamide DNA gyrase inhibitors with the GyrB ATP-binding site lipophilic floor: A medicinal chemistry and QTAIM study. 38906336 Structure-activity relationship of dual inhibitors containing maleimide and imidazole motifs against glutaminyl cyclase and glycogen synthase kinase-3β. 38907711 Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation. 38908102 Novel dihydropyrimidines as promising EGFR & HER2 inhibitors: Insights from experimental and computational studies. 38908103 Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor. 38908104 Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation. 38911148 Small molecule targeted therapies for endometrial cancer: progress, challenges, and opportunities. 38911150 Integrating a quinone substructure into histone deacetylase inhibitors to cope with Alzheimer's disease and cancer. 38911152 Discovery of aurones bearing two amine functionalities as SHIP2 inhibitors with insulin-sensitizing effect in rat myotubes. 38911155 Amine-containing donepezil analogues as potent acetylcholinesterase inhibitors with increased polarity. 38911158 Design, synthesis, and biological evaluation of 1,2,4-oxadiazole-based derivatives as multitarget anti-Alzheimer agents. 38911163 Benzenesulfonamide decorated dihydropyrimidin(thi)ones: carbonic anhydrase profiling and antiproliferative activity. 38911168 Heterocyclic compounds as xanthine oxidase inhibitors for the management of hyperuricemia: synthetic strategies, structure-activity relationship and molecular docking studies (2018-2024). 38911170 Potential of covalently linked tamoxifen hybrids for cancer treatment: recent update. 38911171 Unveiling sultam in drug discovery: spotlight on the underexplored scaffold. 38911172 Identification of SARS-CoV-2 Mpro inhibitors through deep reinforcement learning for de novo drug design and computational chemistry approaches. 38911173 Design, synthesis, molecular docking and anti-proliferative activity of novel phenothiazine containing imidazo[1,2-a]pyridine derivatives against MARK4 protein. 38912577 Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy through the Activation of Antigen Presentation of cDC1 Cells. 38913493 Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment. 38913497 Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation. 38913699 Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment. 38913701 Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury. 38913996 Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1. 38914346 Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment. 38916990 Design of a Lead-Like Cysteine-Targeting Covalent Library and the Identification of Hits to Cys55 of Bfl-1. 38917049 Development of a Potent and Selective G2A (GPR132) Agonist. 38917622 Macrocarpal B blocks the binding between the phospholipase A2 receptor and its antibodies. 38917665 Modulation of endogenous opioid signaling by inhibitors of puromycin-sensitive aminopeptidase. 38917956 Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives. 38919032 Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma. 38920289 Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma. 38925013 Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer. 38925014 Lipid-conjugated nucleoside monophosphate and monophosphonate prodrugs: A versatile drug delivery paradigm. 38925015 Multimechanism biological profiling of tetrahydro-β-carboline analogues as selective HDAC6 inhibitors for the treatment of Alzheimer's disease. 38925524 Machine learning-based QSAR and LB-PaCS-MD guided design of SARS-CoV-2 main protease inhibitors. 38932616 Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase. 38936149 5-HT6 receptor neutral antagonists protect astrocytes: A lesson from 2-phenylpyrrole derivatives. 38941718 Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses. 38941887 Skin- and airway-deliverable TRPA1 inhibitor. 38942126 Design and synthesis of novel and potent allosteric HIV-1 integrase inhibitors with a spirocyclic moiety. 38942127 Stereochemical inversion at a 1,4-cyclohexyl PROTAC linker fine-tunes conformation and binding affinity. 38943602 Discovery of Oxidized p-Terphenyls as Phosphodiesterase 4 Inhibitors from Marine-Derived Fungi. 38943626 Development of Degraders of Cyclin-Dependent Kinases 4 and 6 Based on Rational Drug Design. 38943875 Synthesis of thiazolidine-2,4-dione tethered 1,2,3-triazoles as α-amylase inhibitors: In vitro approach coupled with QSAR, molecular docking, molecular dynamics and ADMET studies. 38944933 PepExplainer: An explainable deep learning model for selection-based macrocyclic peptide bioactivity prediction and optimization. 38944934 Synthesis and antibacterial medicinal evaluation of carbothioamido hydrazonyl thiazolylquinolone with multitargeting antimicrobial potential to combat increasingly global resistance. 38946306 Discovery of GPR84 Fluorogenic Probes Based on a Novel Antagonist for GPR84 Bioimaging. 38949959 Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8. 38953866 Structure-Guided Design of Potent Coronavirus Inhibitors with a 2-Pyrrolidone Scaffold: Biochemical, Crystallographic, and Virological Studies. 38954961 An overview of RAF kinases and their inhibitors (2019-2023). 38955347 New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives. 38958057 Small Molecule Targeting PPM1A Activates Autophagy for Mycobacterium tuberculosis Host-Directed Therapy. 38959401 Lipid Trolling to Optimize A3 Adenosine Receptor-Positive Allosteric Modulators (PAMs). 38959455 More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5-a]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication. 38959726 Binding sites and design strategies for small molecule GLP-1R agonists. 38959727 Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction. 38959730 Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009-2024). 38960379 NN1213 - A Potent, Long-Acting, and Selective Analog of Human Amylin. 38961616 A Diterpenoid of the Medicinal Plant Andrographis paniculata Targets Cutaneous TRPV3 Channel and Relieves Itch. 38961727 Targeting Relevant HDACs to Support the Survival of Cone Photoreceptors in Inherited Retinal Diseases: Identification of a Potent Pharmacological Tool with In Vitro and In Vivo Efficacy. 38964169 Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer. 38964259 Design and synthesis of 7-membered lactam fused hydroxypyridinones as potent metal binding pharmacophores (MBPs) for inhibiting influenza virus PAN endonuclease. 38964519 Synthesis and activity of benzimidazole N-Acylhydrazones against Trypanosoma cruzi, Leishmania amazonensis and Leishmania infantum. 38967785 New Strategies for Responding to SARS-CoV-2: The Present and Future of Dual-Target Drugs. 38968440 Discovery of MT-1207: A Novel, Potent Multitarget Inhibitor as a Promising Clinical Candidate for the Treatment of Hypertension. 38971049 Synthesis and evaluation of neuroactive steroids with novel pharmacophore at C-21 let identify a compound with advantageous PK profile and higher EC50 and Emax as PAM on GABAA receptor. 38971050 Synthesis and evaluation of 3,4,5-trisubstituted triazoles as G protein-biased kappa opioid receptor agonists. 38972081 Design, synthesis and structure-activity relationships of novel non-ketolides: 9-Oxime clarithromycin featured with seven-to thirteen-atom-length diamine linkers at 3-OH. 38977106 Synthesis, biosimulation and pharmacological evaluation of benzimidazole derivatives with antihypertensive multitarget effect. 38981216 Structure-activity relationships of middle-size cyclic peptides, KRAS inhibitors derived from an mRNA display. 38981336 Structure-based mapping of the histone-binding pocket of KDM4D using functionalized tetrazole and pyridine core compounds. 38986343 Discovery of N'-benzyl-3-chloro-N-((1S,3R,4R)-3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl)benzenesulfonamide as a novel selective KOR ligand. 38988222 Designing Small Molecule PI3Kγ Inhibitors: A Review of Structure-Based Methods and Computational Approaches. 38991154 Targeting Myeloperoxidase Ameliorates Gouty Arthritis: A Virtual Screening Success Story. 38995734 Amphiphilic Heparinoids as Potent Antiviral Agents against SARS-CoV-2. 38996194 Discovery of Novel Diaryl-Substituted Fused Heterocycles Targeting Katanin and Tubulin with Potent Antitumor and Antimultidrug Resistance Efficacy. 38996365 The Development of a Highly Potent and Selective Human Toll-like Receptor 2 Agonist: Synthesis and Biological Evaluation of CaLGL-1 and Its Derivatives. 38996544 Targeting prolidase. A survey of the literature data to depict a structure-activity relationship frame and to address future studies for drug development. 38996652 Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs. 38996937 N-methylmorpholine incorporation into the structure of biphenyl leads to the bioactive inhibitor of PD-1/PD-L1 interaction. 38996938 Plakevulin A induces apoptosis and suppresses IL-6-induced STAT3 activation in HL60 cells. 38996940 2-(Piperidin-3-yl)phthalimides reduce classical markers of cellular inflammation in LPS-challenged RAW 264.7 cells and also demonstrate potentially relevant sigma and serotonin receptor affinity in membrane preparations. 39002182 Design, synthesis, and anti-melanogenic efficacy of 2-mercaptobenzoxazoles with nanomolar tyrosinase activity inhibition. 39002183 Chiral pyrrolidines as multipotent agents in Alzheimer and neurodegenerative diseases. 39004018 Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7). 39004019 Novel compounds with dual inhibition activity against SARS-CoV-2 critical enzymes RdRp and human TMPRSS2. 39004050 Synthesis and biological evaluation of O4'-benzyl-hispidol derivatives and analogs as dual monoamine oxidase-B inhibitors and anti-neuroinflammatory agents. 39004318 Discovery of the first selective, small-molecule GFRα2/3 inhibitors through DNA-encoded library technology. 39005064 Electrophile Determines Cellular Phenotypes among XPO1-Targeting Small Molecules. 39007759 Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers. 39008565 Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors. 39010658 Structure-Based Design and Discovery of a Potent and Cell-Active LC3A/B Covalent Inhibitor. 39011823 ERAP Inhibitors in Autoimmunity and Immuno-Oncology: Medicinal Chemistry Insights. 39013072 Molecular Transformers: Adaptive Multitarget Ligands for Esterase-Induced Transition from Analgesics to Anesthetics. 39013357 Novel neuroprotective 5,6-dihydropyrido[2',1':2,3]imidazo[4,5-c]quinoline derivatives acting through cholinesterase inhibition and CB2 signaling modulation. 39013358 The synthesis of 1,2,3-triazoles as binders of D-dopachrome tautomerase (D-DT) for the development of dual-targeting inhibitors. 39015262 Synthesis and Evaluation of 1,3-Disubstituted Imidazolidine-2,4,5-triones as Inhibitors of Pyruvate Carboxylase. 39015266 Novel AHR Agonists for Treating Psoriasis and Atopic Dermatitis. 39015272 Design Principle of Heparanase Inhibitors: A Combined In Vitro and In Silico Study. 39015277 Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases. 39015278 Optimization of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors, Leading to the Potent DS08701581. 39015280 Toward Precision Oncology: The Role of TPD in Targeting CDK2 and Beyond. 39018526 Discovery of GS-7682, a Novel 4'-Cyano-Modified C-Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys. 39018923 Farnesyl pyrophosphate synthase inhibitors with antiosteoporosis efficacy in ovariectomized rats: A mixed binding approach beyond bisphosphonates. 39018924 1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer. 39023313 Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2. 39024966 Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line. 39026395 Deuterium Editing of Small Molecules: A Case Study on Antitumor Activity of 1,4-Benzodiazepine-2,5-dione Derivatives. 39026631 Discovery of new 1,3-diphenylurea appended aryl pyridine derivatives as apoptosis inducers through c-MET and VEGFR-2 inhibition: design, synthesis, in vivo and in silico studies. 39026636 Synthesis of a new series of 4-pyrazolylquinolinones with apoptotic antiproliferative effects as dual EGFR/BRAFV600E inhibitors. 39026639 N-Sulfonylphenoxazines as neuronal calcium ion channel blockers. 39026645 Molecular understanding of the therapeutic potential of melanin inhibiting natural products. 39026648 Synthesis and in vitro evaluation of novel amino-phenylmethylene-imidazolone 5-HT2A receptor antagonists. 39026650 Design, synthesis, and anticancer assessment of structural analogues of (E)-1-((3,4,5-trimethoxybenzylidene)amino)-4-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]quinoxaline-2-carbonitrile (6b), an imidazo[1,2-a]quinoxaline-based non-covalent EGFR inhibitor. 39026651 Novel flexible biphenyl PfDHFR inhibitors with improved antimalarial activity. 39026652 Inhibition of DXR in the MEP pathway with lipophilic N-alkoxyaryl FR900098 analogs. 39026653 Rational design of small-sized peptidomimetic inhibitors disrupting protein-protein interaction. 39026656 Design and synthesis of chromene-1,2,3-triazole benzene sulfonamide hybrids as potent carbonic anhydrase-IX inhibitors against prostate cancer. 39026657 Impact of atropisomerism on a non-steroidal glucocorticoid receptor agonist. 39028865 Rational In Silico Design of Selective TMPRSS6 Peptidomimetic Inhibitors via Exploitation of the S2 Subpocket. 39028937 Back-Pocket Optimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent EPHA2/GAK Kinase Inhibitors. 39029338 Synthesis and evaluation of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate analogs as competitive partial agonists of butyrophilin 3A1. 39031090 Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects. 39032403 Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors. 39032404 7-Amino-3-phenyl-2-methyl-pyrazolopyrimidine derivatives inhibit human rhinovirus replication. 39033612 Discovery of novel indazole derivatives as second-generation TRK inhibitors. 39036880 Design, Synthesis, and Evaluation of the Selective and Orally Active LSD1 Inhibitor with the Potential of Treating Heart Failure. 39037114 Discovery of Novel Pyrimidine-Based Derivatives as Nav1.2 Inhibitors with Efficacy in Mouse Models of Epilepsy. 39038276 Natural Product-Inspired Dopamine Receptor Ligands. 39038808 A Comprehensive In Vitro Characterization of a New Class of Indole-Based Compounds Developed as Selective Haspin Inhibitors. 39041067 Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer. 39041662 Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease. 39042910 New Class of Hsp90 C-Terminal Domain Inhibitors with Anti-tumor Properties against Triple-Negative Breast Cancer. 39042991 Discovery and optimization of thiazole-based quorum sensing inhibitors as potent blockers of Pseudomonas aeruginosa pathogenicity. 39047608 Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia. 39047611 Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy. 39051153 Structure of Designer Antibody-like Peptides Binding to the Human C5a with Potential to Modulate the C5a Receptor Signaling. 39051441 Undobolins A-L, Ophiobolin-Type Sesterterpenoids from Aspergillus undulatus. 39051854 Peptidic Boronic Acid Plasmodium falciparum SUB1 Inhibitors with Improved Selectivity over Human Proteasome. 39053006 Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies. 39053189 Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sites. 39053191 Design, synthesis and biological evaluation of novel SIRT3 inhibitors targeting both NAD+ and substrate binding sites for the treatment of acute myeloid leukemia. 39053192 Exploring monocyclic core: Discovery of pyrrol-2-one derivatives as a new series of potent MCHR1 antagonists with in vivo efficacy. 39053193 Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria. 39054645 Bipyridine Derivatives as NOP2/Sun RNA Methyltransferase 3 Inhibitors for the Treatment of Colorectal Cancer. 39058542 Discovery and Optimization of Hsp110 and sGC Dual-Target Regulators for the Treatment of Pulmonary Arterial Hypertension. 39066713 Design, Synthesis and Antitumor Activity of a Novel Class of SHP2 Allosteric Inhibitors with a Furanyl Amide-Based Scaffold. 39067437 Biological and structural investigation of tetrahydro-β-carboline-based selective HDAC6 inhibitors with improved stability. 39067439 Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors. 39068862 Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads. 39068863 N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease. 39072488 Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate. 39073853 Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor. 39077892 Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer. 39078366 Genomic Discovery and Structure-Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors. 39078401 Structural and Physicochemical Features of Oral PROTACs. 39079310 Synthesis of furanotriterpenoids from betulin and evaluation of Tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitory properties of new semi-synthetic triterpenoids. 39080842 Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity. 39081058 Structural Optimization of Oxaprozin for Selective Inverse Nurr1 Agonism. 39082690 Halogen Bonding Hot Spots as a Constraint in Virtual Screening: A Case Study of 5-HT7R. 39082833 Discovery of Novel Azaphenothiazine Derivatives to Suppress Endometrial Cancer by Targeting GRP75 to Impair Its Interaction with IP3R and Mitochondrial Ca2+ Homeostasis. 39083980 Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma. 39084610 Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy. 39088797 Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy. 39088801 Discovery of Novel, Selective, and Nonbasic Agonists for the Kappa-Opioid Receptor Determined by Salvinorin A-Based Virtual Screening. 39089001 Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis. 39089002 Structure-based screening, optimization and biological evaluation of novel chrysin-based derivatives as selective PPARγ modulators for the treatment of T2DM and hepatic steatosis. 39089850 Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors. 39092855 Hydrazides as Inhibitors of Histone Deacetylases. 39094274 FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives. 39094277 Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer. 39096294 Identification and Characterization of a Blood-Brain Barrier Penetrant Inositol Hexakisphosphate Kinase (IP6K) Inhibitor. 39096818 GPX4 allosteric activators inhibit ferroptosis and exert myocardial protection in doxorubicin-induced myocardial injury mouse model. 39098133 Discovery of novel N2-indazole derivatives as phosphodiesterase 4 inhibitors for the treatment of inflammatory bowel disease. 39101748 Bioisosteres at C9 of 2-Deoxy-2,3-didehydro-N-acetyl Neuraminic Acid Identify Selective Inhibitors of NEU3. 39102360 Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity. 39102466 Discovery of Novel Imidazo[1,2-a]pyridine-Based HDAC6 Inhibitors as an Anticarcinogen with a Cardioprotective Effect. 39102502 Atropisomerism Observed in Galactose-Based Monosaccharide Inhibitors of Galectin-3 Comprising 2-Methyl-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione. 39102508 Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors. 39102524 Discovery of Triazolopyrimidine Derivatives as Selective P2X3 Receptor Antagonists Binding to an Unprecedented Allosteric Site as Evidenced by Cryo-Electron Microscopy. 39105778 Development of VU6036864: A Triazolopyridine-Based High-Quality Antagonist Tool Compound of the M5 Muscarinic Acetylcholine Receptor. 39106326 Structural Insights into Protein-Inhibitor Interactions in Human Tryptophan Dioxygenase. 39106658 Thioamides in medicinal chemistry and as small molecule therapeutic agents. 39108024 Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout. 39109492 Discovery of 4-(Arylethynyl)piperidine Derivatives as Potent Nonsaccharide O-GlcNAcase Inhibitors for the Treatment of Alzheimer's Disease. 39110625 Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. 39110628 Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer. 39111015 Design, synthesis, and optimization of novel PD-L1 inhibitors and the identification of a highly potent and orally bioavailable PD-L1 inhibitor. 39114932 Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC). 39115219 A First-in-Class Pyrazole-isoxazole Enhanced Antifungal Activity of Voriconazole: Synergy Studies in an Azole-Resistant Candida albicans Strain, Computational Investigation and in Vivo Validation in a Galleria mellonella Fungal Infection Model. 39119945 Exploring 2-Sulfonylpyrimidine Warheads as Acrylamide Surrogates for Targeted Covalent Inhibition: A BTK Story. 39121336 Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1H-indole-1-yl Moiety Binding to the P1-P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells. 39129245 Discovering New Metallo-Deubiquitinase CSN5 Inhibitors by a Non-Catalytic Activity Assay Platform. 39132814 Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9. 39132828 Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug Design. 39133077 Domoic Acid as a Lead for the Discovery of the First Selective Ligand for Kainate Receptor Subtype 5 (GluK5). 39133975 Discovery of pyrrolo[2,3-d]pyrimidin-4-one derivative YCH3124 as a potent USP7 inhibitor for cancer therapy. 39134060 Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4. 39136241 Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme. 39136313 Development of Brain Penetrant Pyridazine Pantothenate Kinase Activators. 39136667 Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors. 39137033 Dual 5-HT2A and 5-HT2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis. 39137258 Synthesis and Biological Evaluation of Novel Psidium Meroterpenoid Derivatives against Cisplatin-Induced Acute Kidney Injury. 39137389 Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). 39137454 A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect. 39140037 Development of Novel Bacterial Topoisomerase Inhibitors Assisted by Computational Screening. 39140038 Galectin-8N-Selective 4-Halophenylphthalazinone-Galactals Double π-Stack in a Unique Pocket. 39140039 Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases. 39140040 Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2. 39140041 Discovery of Broad-Spectrum Herpes Antiviral Oxazolidinone Amide Derivatives and Their Structure-Activity Relationships. 39140043 Innovative Therapeutic Approaches Targeting K-Ras: Analysis of Macrocyclic Compounds, Peptidomimetics, and Pyridopyrimidine Inhibitors. 39140047 Ligand-Based Pharmacophoric Design and Anti-inflammatory Evaluation of Triazole Linked Semisynthetic Labdane Conjugates. 39140049 Chemical Probes to Investigate Central Nervous System Disorders: Design, Synthesis and Mechanism of Action of a Potent Human Serine Racemase Inhibitor. 39140054 Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease. 39140055 Fragment-Based Screen of SARS-CoV-2 Papain-like Protease (PLpro). 39140057 Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes. 39140058 Design and Assessment of First-Generation Heterobifunctional PPARα/STING Modulators. 39140060 Treatment of Metabolic Disorders Using Novel DGAT2 Inhibitors: Pyrazolopyridine and Triazolopyridine Derivatives. 39140061 Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections. 39140065 Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases. 39140066 Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors. 39140071 Small Molecules Blocking the Assembly of TCAB1 and Telomerase Complexes: Lead Discovery and Biological Activity. 39140772 Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor. 39142023 Acroamine A, a 2-Amino Adenine Alkaloid from the Marine Soft Coral Acrozoanthus australiae and Its Semisynthetic Derivatives That Inhibit cAMP-Dependent Protein Kinase A Catalytic Subunit Alpha. 39142150 Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents. 39143914 Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies. 39145486 Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. 39145509 Allosteric Activation of Protein Phosphatase 5 with Small Molecules. 39146284 Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity. 39149093 Exploiting spirooxindoles for dual DNA targeting/CDK2 inhibition and simultaneous mitigation of oxidative stress towards selective NSCLC therapy; synthesis, evaluation, and molecular modelling studies. 39149096 Design, synthesis and biological evaluation of arylsulfonamides as ADAMTS7 inhibitors. 39149102 Discovery of novel coumarin triazolyl and phenoxyphenyl triazolyl derivatives targeting amyloid beta aggregation-mediated oxidative stress and neuroinflammation for enhanced neuroprotection. 39149103 Antitubercular evaluation of dihydropyridine-triazole conjugates: design, synthesis, in vitro screening, SAR and in silico ADME predictions. 39149105 Targeted suppression of oral squamous cell carcinoma by pyrimidine-tethered quinoxaline derivatives. 39149109 Phenylstyrylpyrimidine derivatives as potential multipotent therapeutics for Alzheimer's disease. 39149111 New pyrazole-pyridazine hybrids as selective COX-2 inhibitors: design, synthesis, molecular docking, in silico studies and investigation of their anti-inflammatory potential by evaluation of TNF-α, IL-6, PGE-2 and NO in LPS-induced RAW264.7 macrophages. 39149114 Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review. 39149790 Small Molecular Inhibitors That Target ATM for Drug Discovery: Current Research and Potential Prospective. 39150226 Methyl-Transferase-Like Protein 16 (METTL16): The Intriguing Journey of a Key Epitranscriptomic Player Becoming an Emerging Biological Target. 39151060 Evo312: An Evodiamine Analog and Novel PKCβI Inhibitor with Potent Antitumor Activity in Gemcitabine-Resistant Pancreatic Cancer. 39151117 Design, Synthesis, and Biological Activity of Novel Quinone Derivatives as Potent STAT3 Inhibitors for Psoriasis Treatment. 39153334 Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization. 39159426 Discovery of a Covalent Inhibitor of Pro-Caspase-1 Zymogen Blocking NLRP3 Inflammasome Activation and Pyroptosis. 39159497 Rational Design of a Novel 6H-Benzo[c]chromen Series as Selective PI3Kα Inhibitors. 39161321 Investigating Active Site Binding of Ligands to High and Low Activity Carbonic Anhydrase Enzymes Using Native Mass Spectrometry. 39163191 Discovery of Pyrazolo[1,5-a]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors. 39163586 Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation. 39163619 Structure-Based Drug Design of 2-Amino-[1,1'-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1-Amplified Breast Cancer. 39163776 Discovery of novel 2-substituted 2, 3-dihydroquinazolin-4(1H)-one derivatives as tubulin polymerization inhibitors for anticancer therapy: The in vitro and in vivo biological evaluation. 39163780 Indole-core inhibitors of influenza a neuraminidase: iterative medicinal chemistry and molecular modeling. 39166848 Design, Synthesis, and Biological Evaluation of 5-Amino-4-fluoro-1H-benzo[d]imidazole-6-carboxamide Derivatives as Novel and Potential MEK/RAF Complex Inhibitors Based on the "Clamp" Strategy. 39167895 Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization. 39169676 Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis. 39171975 The Missing Link(er): A Roadmap to Macrocyclization in Drug Discovery. 39172943 Discovery of Dehydrogenated Imipridone Derivatives as Activators of Human Caseinolytic Protease P. 39178382 Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies. 39178726 Regulation of protein phosphorylation by PTPN2 and its small-molecule inhibitors/degraders as a potential disease treatment strategy. 39180479 Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis. 39185622 Discovery of Novel Neo-Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ. 39185935 Cellular, Structural Basis, and Recent Progress for Targeting Murine Double Minute X (MDMX) in Tumors. 39189384 Exploring Degradation of Intrinsically Disordered Protein Yes-Associated Protein Induced by Proteolysis TArgeting Chimeras. 39190548 Selective Aurora A-TPX2 Interaction Inhibitors Have In Vivo Efficacy as Targeted Antimitotic Agents. 39191393 A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma. 39191400 Nonlipogenic ABCA1 Inducers (NLAI) for Alzheimer's Disease Validated in a Mouse Model Expressing Human APOE3/APOE4. 39196854 Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer. 39207927 Harnessing Nitric Oxide-Donating Benzofuroxans for Targeted Inhibition of Carbonic Anhydrase IX in Cancer. 39208364 Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2H,4H)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer. 39208742 Discovery of novel dihydropyrrolidone-thiadiazole compound crosstalk between the YycG/F two-component regulatory pathway and cell membrane homeostasis to combat methicillin-resistant Staphylococcus aureus. 39208743 Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo. 39208744 Development of peptoid-based heteroaryl-decorated histone deacetylase (HDAC) inhibitors with dual-stage antiplasmodial activity. 39216381 Design, synthesis and biological evaluation of N-salicyloyl tryptamine derivatives as multifunctional neuroprotectants for the treatment of ischemic stroke. 39221504 Structure-Based Design and Development of Phosphine Oxides as a Novel Chemotype for Antibiotics that Dysregulate Bacterial ClpP Proteases. 39221768 Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH. 39225755 Structural Optimization and Structure-Activity Relationship of 1H-Pyrazole-4-carboxylic Acid Derivatives as DNA 6mA Demethylase ALKBH1 Inhibitors and Their Antigastric Cancer Activity. 39226127 Natural Product-Inspired Discovery of Naphthoquinone-Furo-Piperidine Derivatives as Novel STAT3 Inhibitors for the Treatment of Triple-Negative Breast Cancer. 39229678 Undescribed Amaryllidaceae Alkaloids from Zephyranthes citrina and Their Cytotoxicity. 39229909 Re-Evaluating PIN1 as a Therapeutic Target in Oncology Using Neutral Inhibitors and PROTACs. 39230932 Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2. 39230973 Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis. 39231262 Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors. 39235978 Structure Activity of β-Amidomethyl Vinyl Sulfones as Covalent Inhibitors of Chikungunya nsP2 Cysteine Protease with Antialphavirus Activity. 39236094 Development of Tailless Homologue Receptor (TLX) Agonist Chemical Tools. 39240657 Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 Release. 39241669 NRF2 inhibitors: Recent progress, future design and therapeutic potential. 39250434 Structure, Function, and Activity of Small Molecule and Peptide Inhibitors of Protein Arginine Methyltransferase 1. 39250602 The "Doorstop Pocket" In Thioredoxin Reductases─An Unexpected Druggable Regulator of the Catalytic Machinery. 39253767 A Lysosome-Targeting hNEU1 Inhibitor Treats Myocardial Infarction: A Potential Therapeutic Breakthrough. 39254660 Structure-Activity Relationship of Inositol Thiophosphate Analogs as Allosteric Activators of Clostridioides difficile Toxin B. 39256214 Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases. 39256986 Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects. 39258574 Tuning RXR Modulators for PGC1α Recruitment. 39258897 Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia. 39259669 Preclinical Evaluation of Dihydropyrazole-Cored Positron Emission Tomography (PET) Ligands for Imaging of Receptor-Interacting Serine/Threonine Protein Kinase 1 (RIPK1) in the Brain. 39259672 Inhibition of the EphA2-Sam/Ship2-Sam Association through Peptide Ligands: Studying the Combined Effect of Charge and Aromatic Character. 39264152 Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity. 39264726 Discovery of 2-Aryl-4-aminoquinazolin-Based LSD1 Inhibitors to Activate Immune Response in Gastric Cancer. 39269610 Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen. 39269788 Targeting Thyroid-Stimulating Hormone Receptor: A Perspective on Small-Molecule Modulators and Their Therapeutic Potential. 39270448 Anticancer potential of active alkaloids and synthetic analogs derived from marine invertebrates. 39276584 Discovery, synthesis and biological evaluation of novel isoquinoline derivatives as potent indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase dual inhibitors. 39283654 Enhanced Recognition Memory through Dual Modulation of Brain Carbonic Anhydrases and Cholinesterases. 39291000 Advancements in Targeted Therapeutics: Integrating Metabolic Modulation, Immune Engineering, and Biologic Formulation Technologies. 39291008 Asymmetric Dirhodium-Catalyzed Modification of Immunomodulatory Imide Drugs and Their Biological Assessment. 39291010 Side Chain Investigation of Imidazopyridazine as a Hinge Binder for Targeting Actionable Mutations of RET Kinase. 39291011 Highly Selective Novel Heme Oxygenase-1 Hits Found by DNA-Encoded Library Machine Learning beyond the DEL Chemical Space. 39291012 Quinolinonyl Derivatives as Dual Inhibitors of the HIV-1 Integrase Catalytic Site and Integrase-RNA interactions. 39291015 Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine. 39291017 Virtual Screening and Molecular Docking: Discovering Novel METTL3 Inhibitors. 39291021 Synthesis and Optimization of Small Molecule Inhibitors of Prostate Specific Antigen. 39291023 Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) as Treatment for Inflammatory Diseases. 39291024 Study of Chalcogen Aspirin Derivatives with Carbonic Anhydrase Inhibitory Properties for Treating Inflammatory Pain. 39291025 Inhibitors of the Cyclic GMP-AMP Synthase (cGAS) as Potential Treatment for Autoimmune and Inflammatory Diseases. 39291027 Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases. 39291029 Novel Azepino[4,5-b]indolone as cGAS Inhibitors for Treating Immune-Mediated Diseases. 39291031 Nicotinic Acid Derivatives As Novel Noncompetitive α-Amylase and α-Glucosidase Inhibitors for Type 2 Diabetes Treatment. 39291036 Benign-by-Design SAHA Analogues for Human and Animal Vector-Borne Parasitic Diseases. 39291659 Structure-Based Optimization of a Series of Covalent, Cell Active Bfl-1 Inhibitors. 39303516 Discovery of novel substituted pyridine carboxamide derivatives as potent allosteric SHP2 inhibitors. 39353237 Design, synthesis and biological evaluation of indazole derivatives as VEGFR-2 kinase inhibitors with anti-angiogenic properties. 39356741 Discovery of CZL-046 with an (S)-3-Fluoropyrrolidin-2-one Scaffold as a p300 Bromodomain Inhibitor for the Treatment of Multiple Myeloma. 39357030 Discovery of Imidazo[1,2-a]pyrazine Derivatives as Potent ENPP1 Inhibitors. 39361006 Discovery of Orally Active Phenylquinoline-Based Soluble Epoxide Hydrolase Inhibitors with Anti-Inflammatory and Analgesic Activity. 39361813 An Adenosine Analogue Library Reveals Insights into Active Sites of Protein Arginine Methyltransferases and Enables the Discovery of a Selective PRMT4 Inhibitor. 39389791 Discovery of Benzo[d]oxazoles as Novel Dual Small-Molecule Inhibitors Targeting PD-1/PD-L1 and VISTA Pathway. 39420956 Structure-Activity Relationship of Truncated 4'-Selenonucleosides: A3 Adenosine Receptor Activity and Binding Selectivity. 9354447 Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. 9774334 Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. US12324807 Combination therapy for PI3K-associated disease or disorder US12324812 Glucopyranosyl derivatives and their uses US12325696 Indazole derivative, preparation method therefor, and pharmaceutical application thereof US12325697 CBL-B modulators and uses thereof US12325701 YKL-40 inhibitors and their therapeutic US12325725 Cyclin-dependent kinase degraders and methods of use US12331033 Inhibitors of SARM1 US12331038 Hexone glucokinase inhibitor and use thereof US12331044 Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection US12331046 CTPS1 inhibitors and uses thereof US12331054 Perk inhibiting imidazolopyrazine compounds US12338218 Crystal form of benzimidazole-2-one compound, solvate thereof, crystal form of solvate thereof, and preparation method thereof US12338220 Antiviral pyrazolopiridinone compounds US12338237 Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same US12338238 Inhibitors of SARM1 US12338251 Substituted macrocycles useful as kinase inhibitors US12338253 Nitrogen-containing polycyclic fused ring compound, pharmaceutical composition thereof, preparation method therefor and use thereof US12343350 Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) US12344588 Sulfonamide compounds and use thereof US12344595 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors US12344597 Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis US12344603 Pyrido-pyrimidinone and pteridinone compounds and methods of use US12344612 Bicyclic ketone compounds and methods of use thereof US12344614 Benzodiazepine derivatives as GABA a GAMMA1 PAM US12344616 Factor XIa inhibitors US12344620 BRD4 inhibitor compound in solid form and preparation method therefor and use thereof US12350272 Pyridopyrimidinone derivatives for use as AXL inhibitors US12351556 Pyridin-2(1H)one derivatives, their preparation and their use for the treatment of pain US12351571 Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases US12351572 Substituted 1,2,4-triazoles as TYK2 inhibitors US12351576 FGFR inhibitor, preparation method therefor and application thereof US12351585 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof US12351590 Pyrrolopyrimidine compound and use thereof US12351648 Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome US20250177391 INHIBITORS OF DDR1 AND DDR2 FOR THE TREATMENT OF ARTHRITIS US20250177394 COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER US20250177582 HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS US20250179023 HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF US20250179028 ACRYLAMIDE COMPOUNDS US20250179047 5-[7-(3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBONYL)-1,2,3,4 TETRAHYDROISOQUINOLIN-6-YL]-1H-PYRROLE-3-CARBOXAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS US20250179055 Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof US20250179060 PREPARATION METHOD OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND US20250179065 HDAC6 INHIBITORS AND USES THEREOF US20250179079 HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS US20250179094 TGF-B INHIBITOR COMPOUND AND USE THEREOF US20250186391 ORAL COMPLEMENT FACTOR D INHIBITORS US20250186410 DUAL INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY US20250186425 PPARG INVERSE AGONISTS AND USES THEREOF US20250186444 METHIONINE ADENOSYLTRANSFERASE 2A HETEROCYCLIC INHIBITOR US20250186450 COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS US20250186562 TARGET SUBSTRATE PROTEIN DEGRADATION PLATFORM US20250188030 Biphenyl and Phenylpyridine Compounds US20250188037 N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES US20250188057 NON-AROMATIC CYCLIC-PYRIMIDINE ANALOGS AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS US20250188059 NOVEL COMPOUND AND USE THEREOF FOR INHIBITING CHECKPOINT KINASE 2 US20250188067 SALT AND CRYSTAL FORM OF DIPEPTIDYL PEPTIDASE INHIBITOR COMPOUND US20250188075 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS US20250188078 SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE US20250188079 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) US20250188094 PYRAZOLE MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF US20250188095 DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLYL METHYL KETONE DERIVATIVE AND USE THEREOF US20250188102 TRIAZINE COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF US20250195475 CDK2 INHIBITOR AND PREPARATION METHOD AND USE THEREOF US20250195508 COMPOUNDS AND COMPOSITIONS FOR ANITMALARIAL THERAPEUTIC AND PROPHYLACTIC USE US20250195518 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF US20250195521 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS US20250195530 POLQ INHIBITORS US20250195699 Radiolabeled Mu Opioid Antagonist and Methods of Making and Using the Same US20250197363 THIADIAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, INCLUDING SAME US20250197368 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS US20250197369 NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME US20250197375 PYRIMIDINES AND METHODS OF THEIR USE US20250197382 KIF18A INHIBITOR US20250197390 FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF US20250197392 CRYSTALLINE FORMS OF AN INHIBITOR OF THE MENIN/MLL INTERACTION US20250197396 COMPOUNDS FOR INHIBITING INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOF US20250197403 HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS US20250197405 HETEROAROMATIC COMPOUNDS AS PKMYT1 INHIBITORS AND USE THEREOF US20250197406 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS FOR USING SAME US20250197407 TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS US20250197424 QUINOLINE COMPOUND AND USE THEREOF US20250197425 2,6,9-TRISUBSTITUTED PURINES US20250197428 INHIBITORS OF KIF18A AND USES THEREOF US20250205203 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF US20250205270 ANTIBODY-DRUG CONJUGATE PRECURSORS COMPRISING A CYCLIC DINUCLEOTIDE US20250206717 COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF US20250206740 PIPERIDINYL-METHYLPURINE PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS US20250206759 FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND US20250206761 HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER US20250213546 TREATING CANCER WITH SMALL MOLECULES THAT INHIBIT ACSS-2 US20250213561 SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY US20250213569 METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY US20250213571 TYK2 INHIBITORS AND USES THEREOF US20250213705 PSMA TARGETING LIGANDS AND METHODS OF USE US20250213735 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF US20250214932 T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIRONONANE CORE AND METHODS OF USE THEREOF US20250214942 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE US20250214965 COMPOUND AS KIF18A INHIBITOR US20250214967 FAK DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS US20250214978 AT2R AGONIST US20250214980 MULTICYCLIC COMPOUNDS US20250214986 P2X3 INHIBITOR COMPOUND, SALT THEREOF, POLYMORPH THEREOF AND USE THEREOF US20250214991 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS US20250214997 METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF US20250214999 HETEROCYCLIC GLP-1 AGONISTS US20250215008 PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR